var title_f38_39_39536="Stool sample 3 with answer";
var content_f38_39_39536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ascaris lumbricoides ovum in stool",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wet mount of stool (x400) showing the ovum of Ascaris lumbricoides.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39536=[""].join("\n");
var outline_f38_39_39536=null;
var title_f38_39_39537="Pelvic AP compression fracture type I";
var content_f38_39_39537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50783&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Pelvic AP compression fracture: Type I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two images of a Type I AP compression fracture: (A) Schematic; (B) Plain radiograph with outlet view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39537=[""].join("\n");
var outline_f38_39_39537=null;
var title_f38_39_39538="Knife handles";
var content_f38_39_39538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Knife handles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Knife handles are manufactured in varying lengths and grips for different surgical tasks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39538=[""].join("\n");
var outline_f38_39_39538=null;
var title_f38_39_39539="Ferric gluconate: Patient drug information";
var content_f38_39_39539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ferric gluconate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     see \"Ferric gluconate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/37/13909?source=see_link\">",
"     see \"Ferric gluconate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrlecit&reg;;",
"     </li>",
"     <li>",
"      Nulecit&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrlecit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ferric gluconate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3576463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11190 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39539=[""].join("\n");
var outline_f38_39_39539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170704\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855041\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019319\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019321\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019320\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019325\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019326\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019328\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019323\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019330\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=related_link\">",
"      Ferric gluconate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/37/13909?source=related_link\">",
"      Ferric gluconate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_39_39540="U-S theca lutein cysts";
var content_f38_39_39540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound theca lutein cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 562px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIyAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6mkIAJPQcmvPbv4w+CrO9ntZ9UCzwOUddvRhXoNx/qJP901+aHxBH/Fca5/19yfzoA+6v+F1+Bv8AoLj/AL5pP+F2eBv+guP++a/PWigD9Cv+F2eBv+gv/wCO0f8AC7PA3/QX/wDHa/PWigD9Cv8Ahdngb/oLD/vmlHxs8Df9BYf981+elFAH6F/8Lr8Df9BYf980n/C7PA3/AEFh/wB81+etFAH6Ff8AC7PA3/QX/wDHaP8Ahdngb/oL/wDjtfnrRQB+hf8AwuzwN/0Fh/3zR/wuzwN/0Fh/3zX56UUAfoV/wuzwN/0Fh/3zR/wuzwN/0Fh/3zX560UAfoV/wuzwN/0Fh/3zR/wuzwN/0F//AB2vz1pRQB+hP/C7PA3/AEF//HaP+F2eBv8AoL/+O1+e1FAH6E/8Ls8Df9Bf/wAdo/4XZ4G/6C//AI7X57UUWA/Qn/hdngb/AKCw/wC+aP8Ahdngb/oL/wDjtfntRTsB+hP/AAuzwN/0F/8Ax2j/AIXZ4G/6Cw/75r89aKQH6F/8Lr8Df9Bcf980H42eBv8AoLj/AL5r89KKAP0K/wCF2eBv+gv/AOO0f8Ls8Df9Bf8A8dr89aKAP0K/4XZ4G/6C/wD47R/wuzwN/wBBf/x2vz1ooA/Qv/hdngb/AKCw/wC+aT/hdngb/oLj/vmvz1ooA/Qr/hdngb/oLf8AjtH/AAuzwN/0Fh/3z/8AXr89aKAP0K/4XZ4G/wCgsP8Avn/69H/C7PA3/QWH/fP/ANevz1ooA/Qr/hdngb/oLD/vn/69H/C7PA3/AEFh/wB8/wD16/PWigD9Cv8Ahdngb/oLD/vn/wCvR/wuzwN/0Fh/3z/9evz1ooA/Qr/hdngb/oLD/vn/AOvR/wALs8Df9BYf98//AF6/PWigD9Cv+F2eBv8AoLD/AL5/+vR/wuzwN/0Fh/3z/wDXr89aKAP0K/4XZ4G/6Cw/75/+vR/wuzwN/wBBYf8AfP8A9evz1ooA/Qr/AIXZ4G/6Cw/75/8Ar0f8Ls8Df9BYf98//Xr89aKAP0K/4XZ4G/6Cw/75/wDr0f8AC7PA3/QWH/fP/wBevz1ooA/Qr/hdngb/AKCw/wC+f/r0f8Ls8Df9BYf98/8A16/PWigD9Cv+F2eBv+gsP++f/r0f8Ls8Df8AQWH/AHz/APXr89aKAP0K/wCF2eBv+gsP++f/AK9H/C7PA3/QWH/fP/16/PWigD9Cv+F2eBv+gsP++f8A69H/AAuzwN/0Fh/3z/8AXr89aKAP0K/4XZ4G/wCgsP8Avn/69WtK+L3g3VNStrCz1QPc3DiONduNzHtX5112XwdAPxS8MAjI+3R/zoA/SKiiigCO4/1En+6a/NH4hf8AI8a7/wBfcn86/S64/wBRJ/umvzQ+IX/I8a5/19yfzoA56iiigAooooAKKKKACiiigAooooAKKKKACiiigApyjNNp8fGaa8wQbaTFejeA/hL4h8Y23n2Iht4W+605wG+ldmn7MPi9hk3umj/gZrJ4mkna6K5GjwgLxzSEADOc1694y+BHiLwhoNxq2oXlg0EIyVRiSa8iIyCR+OauNRVPh1JasMFOKjGc0mDXSfDubRbfxjpcnimN5dGWUGdFGcimBzjJt9c9waTFfQnxk8NeHPGGvWz/AA4S1iSOIfaZF+WKQ4+Xb64HWvOn+GGqrC0pvbBmTgxiTJoA4DA9aQCusPgfUTL5Zmtg57bqkn8A6lAoMlxajPbfQByGPSggDrXb2fw31a7fbHPa7iMgb+ta9h8F/El6heKSzC+74oA8xxjrRj869Yj+BHi6WYR26W0xPUo+QK0P+Gc/GY5Y2SjsTJ1oA8WxS8Y5r1O9+CHii03GdrRQvU7+lY1x8M9XglEclxZg/wC/QBwg6+1Ljk12b/D7UgcLc2bY9HqSP4b6o/S6sgfQyUAcORinKua7gfDPV2BK3FmQO++ltvhxqsjMsdzZE9D89AHDFDuxjP05pVQEfrX1R8DvAHhzQLXUZPGzabc3MqYj3NuCjHb3r55+Idja6d4x1SDTI3j04TH7OHGPloA5thzxTaceaTBxmgBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK7L4N/wDJUvDH/X9H/OuNrsvg3/yVLwx/1/R/zoA/SKiiigCO4/1En+6a/ND4hf8AI8a5/wBfcn86/S+4/wBRJ/umvzQ+IX/I8a5/19yfzoA56iiigAooooAKKKKACiiigAooooAKKKKACiiigApy9DTaegypFNOwH2lHeXel/s9W2oaGgS8W2GNq5Oa8Eh+LHxCaS2je5uI0MgXcYSAcmvRPhL8cNA0XwXFoviW2kZoBtXam4MPer/i741+DdV0Gez0zT1inYgq5iAxj8K8aFKVGUueF7nS22krnQfHi8uP+FLWP2uTddTxgyH+8a+NQcCvdPib8TNO8S+DLDS4GfzYIgrZHU14WemPSuvARlTi7q1ya6SsgPQEmtDStOe6k3upEK9feqcAUTL5o+Wthrp7eVJIeUHRB3rt8jB9jttGvXsLdIrSRYh0CgYrbt55kmZ3lBDcn6153ZXr3MhDJtJ5+ldBBdB9sZcgg5NAHXJFA6PMeZh3zSWcdu0DyXbEs33QTWJbXyxghAT2JoMkcm397j0GaAO+8GXlpE7veJ8y8LzXW6J4wtrVpY4Id2DwCa8otbuNCihwG9c1opfWto/mowYkc80Aexv8AFY2kIS3sgJMfNtx+dT+LPHmoN4ftp7WPy5X53/8A1q8Lt9dt0uJHd87jyK29T8XwSWNvlPkh6KaANrWfHF/qOmvaTY8w8swGK5OTVIXuAA2SqfNu5zWPqXidWknu0jwGXAWuSttSllufMlUruNAHZQ38aNLJEvybsEGqk93ItyJUfKntWH9skDShQcdqgN2/lqYwS4PIoA7O0uxcghXZZPQGpCUiiILMs5PZutc/bfaPswkiRlc9TTJLmaCUb23Z6+1AGhcXs+5kmclR05rG8Qxf2zZKk4USp9xx1NWo4zcTM5c9OhqrCF8yT7Qdp7CgDzu5ge2maOZSCOM1CTgY7V0+sCKeORWX94D8rVzJXGQc8UAMooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArsvg3/yVLwx/1/R/zrja7L4N/wDJUvDH/X9H/OgD9IqKKKAI7j/USf7pr80PiF/yPGuf9fcn86/S+4/1En+6a/ND4hf8jxrn/X3J/OgDnqKKKACiiigAooooAKKKKACiiigAooooAKKKKACno2OtMooAmLKcZ/OkAHao6fjgbuAemKEApGR6fhSHtxzXUX/ii2uvBdtoa6ZFHPDIHN2PvMPSuYTbkbjx60A9S3ChuZFV1ChOprTYwW7xzjlV4we9Q2nlyRM68Y45qW1RL65WOX5UTke9HW4GvpBhmZpCu3d0Fb8Nisf78p8pqgmmosazxOAF4xWpAtw0aAyAxjtQBUmX/SCqDapFFpYF2Oc9cA1etilzK4mG3bwDV/T7N1yQ42E8UAQ3fhieGBLiOQsSOmafaeGLi8O0yMshGcGrzXUq3PlSTfKtdHpST6hPCti48x+N1AGBZeBjOjCFy0qH5q1oPh3LqFi8rzBFj7E11aQ6poN60EkXyOOWx1NP0uw1TxGl5JanyYoTggN96gDz9fB4n22gX94DjPanD4fvgwyEBgflrvbTQbyBpZJ3YXEf3RjrWPew6j57TzSEMPuqDQBx8vhP7HdL9oOIwfmqtd6VCmpBbRA0RH3q1pr24laR7nJAbaQetVzIsMTRJIAznIJ7CgCK8uI7GwMYUGQ8Yrn7i38+NZMFJM5INal80chEZkDMP4qozTRIgEr7iDjjvQA278v7OgiO1x1IrFv9+Ay8tnmuiWa2hiaQhSAPumsWe4iZ2YLhM8UAY80kQJWRcHHU1zOoxsJSwxsPTFdHeb7icnZhOgNV10e3LEPMct+lAHNGN1xuUjPqKbivRtR12xk8GL4fXTo1uI5d/wBsP3iPSvPJUZGIPQcfWgBnakpe1JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdl8G/+SpeGP+v6P+dcbXZfBv8A5Kl4Y/6/o/50AfpFRRRQBHcf6iT/AHTX5ofEL/keNc/6+5P51+l9x/qJP901+aHxC/5HjXP+vuT+dAHPUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFPCZFIVwOaAG0uTS7cdakhgaTJBGBQBEMnmnAbiAASas2kG9mUoxweorYttKRAsvQjoDQBR0uJZH2vuUDt2qa5SRb+MwA7O+KvSowII2qDxwK1UWBbWNUG5+7UAUJr6ZIspkBeCKt2etOLbagJf3qzHBHOPLaMjjOcdapTWDjJiwoHt1oA0f7QkkVAiDd/EasWt/OxeON9yrzzWYpaKFuxYYzTLYm3kVh37+tAGvNdPPwDiToa1vD+qX2m3UaWxJK/MprLso8q0jjcT0xWpZIscimQ7SOQfagDuNR8a6jcWafakG8Hv1qn4e8Y39nqDhW8tDz5Y6NUUsVhcWsc0d0qkHkN61mXkgt79Z1eNlXoQBQB1+oeINZ1bUIzbiRFIw3oax9RXV4pi6PI8gPIap9M8YxltnlDzIxwwHBrQ1Tx2ZNFyttGbndjIUCgDjZtA12+uHn2ugY5KnvVZ9FvA7G5DDAxmuth1fWtYtd9jF5sqjG1eKrzf20Ifs+qWvkyydMmgDhLjSLiOQFJMqaSGyHlv5hyQfyrsJNNuGiKRqAR1bNZ509beNhcEEnuDQByksDku4RmUcZq0mm+ZZ7mA3notTPdGIS2sK7tx4ap7C7SzkAuRucdqAKdno3mMqSZA71HdaXZx3LBpgCBwKuSagZ7p/JfBJ6Y6Uy/uY/L2+UHk7npQBgSaJLO7NH+8QVQ1GztmhMcuI5EHbvXa2us2tvaGPaFcjBFclrKrczM0YGD0oA4xuCR2FN71uT2Y2rEwG4ng1kTQtDKyNwQaAIaKft7k4HY0jLjFADaKKKACiiigAooooAKKKKACiiigAooooAK7L4N/wDJUvDH/X9H/OuNrsvg3/yVLwx/1/R/zoA/SKiiigCO4/1En+6a/ND4hf8AI8a5/wBfcn86/S+4/wBRJ/umvzQ+IX/I8a5/19yfzoA56iiigAooooAKKKKACiiigAooooAKKKKACiiigDoPCvhbV/E888OhWb3UsCeZIEGdq+tYkqNG5DDBUkEehFaeg69qugSyy6NfTWTzJsd4m27l9KzW3PISTkk7iT3oA1I4o7yBVZREwHB9azzbyIzJuwRUrXRe22HAZehFaOk2ZmyZWDA96ADRzcQjGU2HnNdLDYrexIDJtc9KpW+nRhtwJbb/AAiumsobK4tlBJhlXpQBl/2aqMsBUs3rV2XQLlIgY1AQ+lOec2ExeZg69FarFvql48R8r5gx4FABoci2jtb3aqzsMKfSn3OkzNcrlUeLrwafc6dPbmO5uI+H7+laFteCKJgnzhR8zUAYEmjIC0jnoeF7VXGiTXDbx8qr2rpJNQs7qNNiGML1JPWr3h57bUrt0eVUhTv0zQBl+HfDuo3lx5dmA2P71STWMttrBttUxGc44rdn1GTTNS26ZcIEHUg1taT4h0S8lc6zbebMP+WnrQBy8ulW7W0wR22qeGPSuWlL+eYwGZc4yK9juvFXh2a2ksksAgxx0yfevMJbuFJr1I4jgsCnHTFAEsGk3Vj5U+UKyHoTW1daMxkEbFVaRc5XoKyLXUZL23XEcjMhyQa02uLuVRMYnj2jHPQigDR8Jaknhl5dl0GODkVmeNvFT6m0U8MpV1P3q5u5gvL+6ZLWBg/Q+9areCdTWzje7QRo3rQBRtfE7wyYnJLH171R1HVHmd2QkFv4RWhf+ERbxea0wdh0GelVPsUVv5c0pGR2oAzIjIrqwVyx56UXDSXc4TJ3DrjrWtqN6kbJ9mVSWH5Vl2MxtJ5Jmw8hoAvWRt47hVmGzA5Y96p67IhlLRHaq9Md6yNWv3csSPnJzxVKW6nkjRiOFoArXd5JPchIkbPerQR4wGbP0NV4wJJvtAYq47U6dm4d5ee4oAJyZGDFDgdxUtnpEer3EcEO77ZMdkQ9TViDUYfI27QW/nVq0v1tr2GRQIpFO5HH8BoAwPFnhnVPCmpnT9ctnt7kAMqnow9awm6V6Z4okuvFCefqFxJeXiDCTMSePSvPLy2ltJjFcrtYe3WgCrSU7pkdQabQAUUUUAFFFFABRRRQAUUUUAFFFFABXZfBv/kqXhj/AK/o/wCdcbXZfBv/AJKl4Y/6/o/50AfpFRRRQBHcf6iT/dNfmh8Qv+R41z/r7k/nX6X3H+ok/wB01+aHxC/5HjXP+vuT+dAHPUUUUAFFFFABRRRQAUUUUAFFFLQAlFLg+lGKAEopaSgB28/hRknqelNpynB6UAPCZXdkfStPT5HaMeUdoXrzWTkc1atJ0ijcHO5u9AHT2l5PbIXjXd65rb07WLaWBhJHukPXtiuI0/UmiVklbKGiO5LOzQvsQdQaAOpvL6K4G09AelWrPUvsZVyvyKOK523khaIln5qwsxms2VCCo6GgDpm8S3WsRSRH5EUfLRo7N5JV3JLHlfWsayuVt7byyBuIzUVpqEkMrTDOF7UAb0ip9vETfu0PamSxyW7yLbSsEHORxWG2o/aLwyzPt9KkGpyoj7gStAGrMylEDSHex5JNaD3MdvDFGrgs3U1xl7f+aI2GcDuKeZisKO0mT6UAegjTlmMdx9pAYDoPSrsV9plpIqtFvcfeyOtcRDrflwp5QLPjvUf9pN54lcjdmgDv7jWrNEf7LAInI6Yp914zL6UIDaBtoxuxiuT1K6VoUnDL05x3qSC/t7rTlRWAYdqANXTdXmhka5hZVJ52ntVjWPF2pX8ccQ3MF7dBXJmZRK3zbQPXvV+LWIlgwAnHegBTc3s8xEspUf3c1BdHeCHIyPesm41N57pjGw2dyKx5r25N58mWiJ5bsKAN0Tgy+WgyRVC6niV8CQqxGcVWFzGzFklAI6kVn3sii7QzAsSe1AFq/miS23FvmqKzlP2bdIeT2qDVRvniWIKU4xn1qxNCWjQsQgA5AoAr3U7I6+Tg5qvcwTEgtJy3VRViZ4II/wB2RJLn7vpVeS6YOshTI7+1AFiw09hIHViMc81tJZfaWHzYPqKxbG7aeYgybFPQVtm7FgFz/F0NAHYWc9rpOnAy7WkxwfSuN8RXaa1IFEYDdFYCrkMUuoEMdwQ+vSty3srK3h3SBRjqaAPLbyzltJfLmUqeoPY1V7+1el+IILfVLQQwIMjpIBXnl3bvazvFIOR0oArkYpKXH50lABRRRQAUUUUAFFFFABRRRQAV2Xwb/wCSpeGP+v6P+dcbXZfBv/kqXhj/AK/o/wCdAH6RUUUUAR3H+ok/3TX5ofEL/keNc/6+5P51+l9x/qJP901+aHxC/wCR41z/AK+5P50Ac9RRRQAUUUUAFFFFABRRRQAU5ThhxSdvejtQBe0qGG41S1t7yXybaSRVkk67QTya2vF+j6XpevGDSL37ZZAZEuMZrmCaXcQCB0oAdPt8xtn3aipcnGKSgAooqSNN4PtQAgAxTKUjBxS4FACcY96sQAhlCkYbrUHQcUc9s0AXZm8qdSnOeoFWluLkMscK4U9eKgsXjSFmf5nHQGpm1MsgEcfzdDxQBLJqDW5AcbpBTG1KSeVA6COI9aY86w43w7nYZyaqXMzyoN8YVexoA0nt7e4ud0MpAA9e9T4uQojxuQ8E1gLIyKVBwexFaUN1eW8YLcp2zQBeGnRxy483r/CallijjhBlbpWGty814JZXxjtmtAIJiJppMxDqoNAGjEYpAjx8Y61WeZLm+ZAeF9O9X/tlrHYMkcPUccVk2iPATcMgCNnFAGmLtZEMYJJXtSWt2YZtpThu/pVe2vYArNHHlicE4qsXkkujETtVuhoAnu7h5pWIbAB2gCobV5bUyI7lgfWla1FvdKysWAHP1qZ7ZPLeVn3M3QUAMt59kuAOGqzNcJawk+XnPas5WeK5QMnyVa1K4SQCJOH7UAVAjvlyoVW6LUSt5fmCTDepPamwzSw3aiXlSDioHEckhy7Ek9BQBZgm8m1LgbxnK5qUie+kikEbLGOp7VFau9vMEmjzEOQDW7HqaNbmKKPansKAMu6tI43EiDJPWrccMRtipi+93q1bGJo/mRsnuatMESPn7uORQBztxpcls6zQOCD2qrdXRa4jM2SUPSrl5qSLOVRDtX1qiMTLJcSAZH3RQB0dtrc4WNBGFjq5eXDSx5D/ACmuINxPsxk7aurczT24jhJLd/agDpbe+Pk+Ugx710PhfwppXiN7hdcvRZIkRMcndn7CuGszIiiOSQZ6mtRLyaaRYUQlB1NAHK6xZmw1G4tidwjchX/vDsap9B65r1GHwvFrFvIZW2uFyGNedatYvp95JA+DtOA3rQBRop2MHmkIwaAEooooAKKKKACiiigArsvg3/yVLwx/1/R/zrja7L4N/wDJUvDH/X9H/OgD9IqKKKAI7j/USf7pr80PiF/yPGuf9fcn86/S+4/1En+6a/ND4hf8jxrn/X3J/OgDnqKKKACiiigAooooAKXBxQKd1+npQAig9a09P0me4jE7IRFnv3rq/hh4Sh1fU47nWAU09Dkr3avY/HHw4S10ldU8PL5thjmIDlaAPmjUbcwTkYwtQJGHUkEZFddrVmJ2ddm2RDgiuVnhdZCAhGKAIApLYHJoZSrYYYNOBZHB6MKdNKZTufg0ARYpyHAPvSAZPApQGLbcc0AJnmm091KHaRzTKAFBoBJpKUHBoAcg5JFS29yYN2ADn1qEHH40h6e1AFtHa4kDSsAF5q3eG2ljjkD4C8FPWsvA25B5oUgEEjp2oA1rA2YkbzRkHpVe/uBPP5aNiIdKoHqSOK0LBbNoSLgkOeh9KAGaYkP2wLdHCetdUXsbVAwi3RHqa51NHkmbNs29etTJePDugu0wV4UetAHTtqGlrpcjBUJ7e1cykr3almOy3BOBVeS1RLdnuG2ljuUA1SDSIACcIe1AFuRjAW+yurAnJpBI9whbkOvequyPPD7ffNWZWEVuscLbnc8kUAW9NiuBcr9ob92yk5NNnuY7eWUCTcf4aZL9oS0UEZqGKynn2pHFkt3oAvW/nTW4klwT2qG4ga4lXyCBIOtPXTdUgPkgFQaPsNzbzr5jYc9aAJG0/wC4HYtIKiGjsJtySBVBzzWrMSoUYy+OtVVvxJcrbnt1oApTvuvFhVt/vWxaW7IAFUEntimWWnQJeSSMNwHOa3tJeEq5AHFAEhvLYWX2doVST1xWPqED+QTE+R24qe8+SfzMb19KlNyLiACKEIvpQByyWE06P9oXb3BxWc0brJ5SEt6Cu5nhkaEbcHjOBWH9kdJWk27GPUntQBkfZLkYjI4f9K2LeGOyt/LTDzOMH2qnczmEN5bh2FLoM8JvPOu25HQUAbuhaA0Za6uckN0BrT2RwS4Qr71n6rrsk22KFCkY4zio4FMgyC27uxoA259XLRG3tn2AdTWNqFnDfwbGBaU9G96vW2mi5kVIiB/ePrXY6b4YNzGFhiAHQk96APEL6wnsZzFcIVPYkcGqpBz0r6V8QeEtKufDJ0+dRJfYykwHKH0r571vS7jSNQktbxSHU8N6igDNx60lOOelNoAKKKKACiiigArsvg3/AMlS8Mf9f0f8642uy+Df/JUvDH/X9H/OgD9IqKKKAI7j/USf7pr80PiF/wAjxrn/AF9yfzr9L7j/AFEn+6a/ND4hf8jxrn/X3J/OgDnqKKXFACUU5ULD5QTjrgdKCMfSgBtKvFBGKKAHBeMnivTNGvtO1rwTY6FPo0Fs9rI0j6kExJKCeBmuE0rT2uZVeVSIh+telaMYBbpAUATtgUAdHpEEcIj+xsCijhO4rv8ATPHTWNi1pdw4hYbSpHBridM0ySFRPbMSfSutubW01DSzHdRCO5C8PigDyD4h/Z/7Rku7HCrIckCuHumaaIMg+Yd66vxJG9pqE0LqWQE4JrDtDEwkUp9KAMS+hBhWU4D9xTNPNsrE3GCPepdZjKSBgTiszbkcA/lQBsvYed/pFjtbH8FV7uGaRA5iMcg7CptKvvIGzy2U+taiyJcSDLgtQBzDkbMSAiQVBXR6rpS7tyuCx7CsGaF4mIcEUARUUtA60AFFFGOKACigDijFAEsmwKoTO7vTVOG6Dn1pEYK3IzSqQc5HPagC5bXE9t/q5goNR3g3yBvP3k9yelRpPsGGUMKhz14oA0YXfCiQLKqnvVvVzDLBE4QIV6gVjRSMjZU81Ymu2lj2SD8aALS3tmVQNAOODxTZBbC6Qx8DqKzVUklRyaXuNx6UAb0uoosDxzBd/bFUrTUp7Y+YGGB0FUEZQ5JGRjjNNPr1PpQBsP4gu5bhZGPHSql9eztc7mfJ6iqJHIqa3Ie4UMN2eKAL1ndz3E/zOAAKsCeKKRZI0SSTO0kULpUixmaBef7tXdP0JpmS4YEbv4B60AaulWs7HaVDeYM4Aro7Wwi0y1b7RA2W7kVueFNLis447m6T7nrWr4mvbK8jRgqhFHagDzWW2NxOSmFjz3qpqEAjmHkSnI7Doa6J9PMsjzW5/dDtWbcm3gQl03P7UAZ4N0ib3KLxwKxtQupLvMI3hu5Fa7wvfSfuwy45qe3tmtY33RqSf4jQBzRhW3szCsW6Vv4jWcltPBJlUDN9OldPJCm5pC2T9OlVrOD7TOxQliO2KAHaRDKF8y9G5T0UV3fh/wAKX/iBVS1iKIewHNVvCHgvXPEF6sdjHujyO1e76Tq1j8NLFbe+txLqAXk4zzQB5jbeCptHmZL9jGqc+hNbFjeSzQtFp8blV4DV09ppGsfErUTdsjWtg55YjHFWvHFna/D3T4raxKvIw5YjnNAHDXs11p20SrvkfqfSs7xtqulaz4NTQbjS4V1FDuS/Vfn+hNVLzxOskchyPPbua5ctNPI0i8sTkk0Aea31nJZzPDMuCp4OPvCqxHPTFenzaKviEmF+JgMI4GK8/wBb0u50i/ezulwy9D2NAGc3WkpT1oIoASiiigArsvg3/wAlS8Mf9f0f8642uy+Df/JUvDH/AF/R/wA6AP0iooooAjuP9RJ/umvzQ+IX/I8a5/19yfzr9L7j/USf7pr80PiF/wAjxrn/AF9yfzoA56rFnby3UyQ26F5XOABVep4JpIJI5IXKOvIYcYoA9u+C3ww1S/u9RXVtNZIHgOyRxxkA145r9g+l6ze2Mv34JWTH416H4K+NvizwzIkcc6XVsvBR1ySPrU+n+EPEHxl1rWvEOl20UCKcuOAC2OgoA8m9Se1aWlaZLdkS7cxA80p0i5t9RntLqPZLbuUkT3HWuu0YAQqIkwnQrQAtqB5SwrGAg9q17VkhVR91qgjgLMSvBFWbe1EswE3BoA7PwpLdG5i2jzYcjNfQGq+E7HU/DMdzbx+VOse7jua8D8KrJplyjId6N2r6F8Da/b3dr9lunVDjAVu9AHy38RNGmW5kdACEODXAi2YKdq4NfY/xL+HMOo6fcXmlZFyoLFOxFfLl9pVzayygphkPzKRQByGpaZLPBz8vvVX7DssRsZSy9a3Lu+dgYjGRjjpWHfKTCQSyA96ACykaSFvOhGBxkVk3UoWZvIJBzVqwuhbZiL7w1On09nmDRjBPPPegCtZX7wT7pSXHoau3DC/U+UvNU7ywuInDTRkKe9bGkwBJ4/KGRQBzc8TwuVkXBqKu512zjmTc0QDgY4rmJdNkAJCkCgDP5JAFX109ltWnl+72qK5jhRB5bfvO9I19K1r5BPy0AV1OGzjNK7bmzjFNPbFNoAU9aKSigB1NoooAUU6NTI4UdTTRUttgSBmOAKAJJY5LWQbyNxqFlJclfm7mr1nbm/uTvf5R0roLPQgFyhGDxQByTEsv3MY71LZN5chJj3g+td3a+GmeMgBTmtS18BXLwiQoFX1oA84Wzaa6+7iOuj0XRLaaUFSQ3auht/DBtrsLOQVJrtoPCFnBZG6iuED4ztzQByUWkww4R5OTWnF9nsnBhj8wR+1I+lyTIZEcMQfWtK3s7WHTlkLF5VPzCgDPutSmuZgCpjhI+70qutu15chORGP1rY1xI7q2jMKbMDrXPy6gIU8qFwZB3oAbqTXenSPGh/ckVy5v5PNIVNxz3rXvtQeaMLMS2DjNXtO0pL6NCiYPrigDDS4vXcCOMKx9KvjT7ucqsj4B6iustfD8kMnmErhV4zVK4uUsZTNOue2BQBzmowRQReRCmXxyaveEtJnmuI4LeDc8pwWA6VXnv01DUh5UexTxXr3gDTLTTLf7bdXSLkfKvfNAHW6BDc+BNGLQvAbqVeh6iud0fQ7vxf4g8/UJw58zcyse1P0zTL/xb4ndbN5Dag8sxyMV6vpmh6d4OtHeSZWu5RgEn7tAHQ3N9pfhbRkWR44Y40wFHc4r5v8AiLqc/inVZZYcsgJxnoBWn4/1GOa6ZHu2uDnJAPArkxPM6bLMYDcHigDjrnTmSQ7l3EelKRIy7YY9gH3jXdyWtrYWObl1MzDoetcnrMwijJjICmgCFdWi02Hy4VDSN1PcVga0kWt27m4/1i8o3fNRmHe/mMxNQ3l9FANm2gDibqGS3lKSjnsfWoDXaWekT+J9Rt7Cyi3XM7hI+2CfWpPif8ONZ+H11bRawEZJ1ykiHgnuKAOGopfpSUAFdl8G/wDkqXhj/r+j/nXG12Xwb/5Kl4Y/6/o/50AfpFRRRQBHcf6iT/dNfmh8Qv8AkeNc/wCvuT+dfpfcf6iT/dNfmh8Qv+R51z/r7k/nQBz1O3HGKbRQA9XIrt/h9498R+EIbyLQZzFa3QxInYH1rh1xuGeldFpt5btGIsBcdaANKSOe7uWvZJS00rb5GP8AETWrBC0cQkjbH94VRSV49uwBk9K07JlmBB4z0FADYpmEoGSMmu88M2NreSRrcttJ71x32c7fmGMHg12/hu2ZbZGkG49iKAO4n0e2htALNw0g6Yrc8OWkNzYutwzRXS/dPTmsTwzaR3GrW/7xwMgMO1e0x+GLAAMQcbeSKAK/hDVmltDb6jMrSp8oJPUV5R8cPDNnFm90sqHfmRV6V3moeGmuhK2lTspj96oS6BearoU8ZAkuI8gqRyaAPnjRLDTJQY76MBj/ABEd65/xnpdvYuRCgliPcdq7bxboV7YXJhe3MJOe1c8PPtLKSC7iEobuw5oA8wudMJxKilVHPFSW9+0kqq6EBOMkVv3Vw2TGkfy56VDvgePb5Sq69eOtAGdqWrLOBbhdx7GqdvJcQSL5jhfTFaEumLJIJVGPpWRqUQgvV3yEj0zQA+91m484qDkD1q7bX8dxaNk4fHSs9Z7Ey/vEPpmqk6obnbaP8rUAV5z+/Y+/amMeas3FpJbkGdSAe9VW68dKAAY70qDcaQetH0oAc6babQcnqaKAEooooAmt4fNLc4wKjIIyPShWI+6cUlAEkM8kLAxsRWjFrd5GODxWTUm/cqq3QUAdTpPie6C+WfvZ4NdJB4t1DK2zu2w15vZBmuFEZwc111pp1088chVsDHOKAOiupLp9knmnBq3JqU0Fn8rsxI55rM1aWSKFRHywHSqttqBNky3A+boBQBo6dqF2oLRyd/uk1f0nU7oX5VIfMBPIPSs2ygja180kqeuK6PwvNDGxcxkqeN1AD9Zmu9vzbI0bgqD0rEfRYXIa3lLu3JrpNY02a5Yy+XIIj603SNLtbRTLLPhv7pNAEOiaXp6xmC/jOf72K2Yf7Os5DDZ5Z+2RxWTd61a2s53qGQd6zDrUeoXmbJQqr3oA1dclkszvmkO0/wAIridQ1L7VcCKEFiT0rfMc2rXJW4YhR3PSoLjRI7e5C2JEkx7igDPtl+wjdcx5J6H0r0vwy9rLpIWMPNcS8BewrmbLRLy8iFtcRbnbjdiuu0/Srnwxa8AF2HHHSgD0rR9Rj8NeFhHpwA1GT73HSsS4F9q4km1O9/eY4UNXAwHV76/CJKY2c9Wr0jQ/Dd1b20UkxaTP3pG6UAcJe2cOnzlrgeaXOPmPStmCysl0ozWoBlxkZ7V2+q+D7LU4V2SgY5ZzXn3jHVrPw/AdN0lfOnPylutAHB6wJpL4+YzO/Ze1Z99o8rRiS5k2+1WkluorkyXKFpH5AA6Vlard3M0rJuYgdR6UAUbu5itIyvBUd6xLWRNTuCwGEHen6oA/7vnJ6k1Y0iOCKLapAx3oGWbe+k0a8gutPYxXMLh1YeoqX4h+LNZ8ePDNrc277OuEQdM+tZl/H5s24N8v1qo8yu32eDlzwTQScq6bHZW6imGuou9HXyCD/rOu6ualiMTlG60DI67L4N/8lS8Mf9f0f8648j2rsfg5x8UvDH/X9H/OgD9IaKKKAI7j/USf7pr80fiF/wAjzrn/AF9yfzr9Lrj/AFEn+6a/N7xRb2118TtSgvpxb20l+6ySn+EZPNAHI1IqnI3ghCetdF470nSNH8SvaeHdSTU7AIpWdTkEkcis+G8g8nyZ0x6mgCO4hWNEeMboz3FT6fYbm84Hg9qltowFIhy0J9a2NKjUfKBigCS1chNsq9OBWpawyqu/advalFspwRitCzulhUxyDMZ6n0oA1NDls7rFtc4U9ya7nSLGKzUQrJujb7przb7A5f7Ta/Oue1d14Zu5o/KMkRf2NAHpPgrY14bdCokHRq9X0meclra9jwy/db+9Xk3h+e0s9RjvGgfd3UdK9R/4SHT3tVnZyp7A9RQBqWttFbO4iGCxyaq39o0T/arMYlB+ZR0arVnOZ4xIR8rDKn2qwuDzQB598V9HS/8ADEl6qBLxFzkCvlPWNUkUFJCWcHHSvui7tYbuF4bhA8bjBBr5s+J/gqwtNVuWsVC4y2ygDw+SOObDr9TVSZoYz0571oSB4LuSIx7RnjNVjbw3eVlIRx39aAK5GbYlcke1Ylwtujguhdj613ul6QjW7LFIGHvWDremKu5uAV9O9AHIy6ZM8m4KArcjmn/2Nchd0RyR6VpmBpbR9spVl6DNQx3d3bWW+NNxB5zQBlXTXSER3IJxVI9a7C01exkhU38Q8w9SRWHrctlJITZjAoAyscZpKU9KSgAooooAKKKKACiiigAp3TFNpwOPrQBoaRcx20wZoiz54Nel6ZrjNZiJrfGRwcVx/g3TIrp/NmddufumvQfssNtEWDxlQOBQBlTJK+Mpu3GpJ/DqyxCYzbM9h61D/aMguCuFWM/xGoZdTeKXyo381D6UAdJ4d022jgKX5ZvTArY07+xNOuJTeqwjHzIorBsb2+2o6W5ZMccVOTFLI0up/JIBwlAG1rfimXURHbWUSw23QH2qvqGmW0lijLd/v8ZwK5m6dpg0dudo/hNXNHglghL3DrKewoAx9Ys44oiZ5SSe1XvCOlxzWkh+ZQOQcVPNYx3shedgqqehr1D4ZaKviKBrCBYIo0HL45oA4XS7e5kdra3U7CceZjpXY6L4Qs7JS17cCWSXoR2Ndnc+GrbQXbT1nikeQcleopdI8O2/2yOG/uBFDnIdzyaAOcsrV9Fu9wZZdxxGnU10Wo6bbjTvt2rXS/aTysK84p/jaPTdPUJooe6vcbdx5A+lLo/g4xeHpNR1+8+ZxuCE8/SgDI0iOykvIL3UI9luh4wOteia7q1ve6IRbSJbWQHXvXkuoXKLZtHbyPJCrfKKoXHiISWy28oIHcHpQB1kXiVJIHs7Qs5HAevO/FdvNFfrKiCWUnOBzU8GpQLchYpFi9cVryvHLGDYASyEfM79qAOak1GKKMC6gAnYY+lYWqvBDE/loGduScVp3kX2e9Z7hxO3t2rG1SWOWYKg2p/eNAHJS2M19cHA2oOpqOSAx/ubU8fxMa6S8uIIofJgUkt1NYwtJJHOzIU0AY08EvMayE+9TabYC2lEjMWY1oXUAtUOBk1FpyTXLhVU8nigB2oGR28uMday7vSUljKnicd66Ge2aCQtKdpAqkitMx2/nQBxF1bvbSFJhz611fwb4+Kfhj/r9jrsfDPhHQNaW8TxJqi6cI4y8UhONzY6VzHwttha/F/w9Ep3RrqCBH/vDPBoA/ReiiigCO4P7mQf7Jr80fiF/wAjzrn/AF9yfzr9Lrj/AFEn+6a/NH4g/wDI8a6P+nuT+dAGFlQBtB3etLI+9fm+99KfayhJAGUEVqzw2soXopNAEWjzSRrgjKelbdvclJAwXisaFVtZQv8AAe9bdmVbBQg0AaQlcqGj5z2qa3ldeZEyp6io48D5kOW7itS0aOUYcDd6UAbOixMjJNbvmMnlD2r0BdPnFtFc2qhs9QO1ef6VbzfaAEztzXq2ipN9gVSwHsaANPRbATywyfadko/gIyDXp2lLa3tm1reRRJL06DmvNbG2eK5jkWVQO6k10uqXUUtov2It9pQZJHagDtVlXSLXbdt/o6/dfHSpbLVLa7ZRbEup6MBxXL6At1rmk3EN9cuYQMEGt/w1YQ6bYC1hdmUHgntQBsk1wHxW8PLqGkSX1sSl3EP4Rnd7V3bruwCMgVBdQSynCONh6qaAPhvXbSd5nZ1KyA8jGKyrLTi0qySHp1Br6X+JPgiS+aSaws1imXJLIOtfPeqQzWd68cyssinBNAHVaTY2ctkfLYo+K57VtGkSV3OHUcjnrVaz1i4ifytwKetOvbq5lOYizDvQByWoqXmISMoR1xWVcWU0TGQS/IfvJXdwvZgf6Yg3etY+q2lo8heF/k9KAOZfTDeQhrccr1rHuIWt5CjH5h7V2ttFLbf6oZQ1XvrK3updsw2ykcYoA4w0laGoadJZu2VJXPFUT+tADaKKKACiiigBaSlFLgd6AEwacAOAenehUZzhFJq3badczOFWNlB7kUAb/h3V7S0j8gxEue+a7ODVITYnzICc+9cjpnh0RujSPyeprvI9KEVkoCmVMc4FAHM6pcR3QAiTYo6gGnaDpU91LutlLL3zW2mixzLmGBxJnpius0Xwnr9zGn9mafKo/iYrgGgCK0Etvp7RbB5gFc8ZWVJjex5c5xmvV9P+HviKC0eaeCPpk7j0rH/szRFjlXUZQbkfwigDgtHspG/eEbYjyS3atnQYoBqkkJVpQeFwM8109lpmn6ygs7IMNvUgV2nw58O2Wn6vI0lskpiGcsKAOetvBTRQfbtXtjHa9QOma6/wroZu49+lQnTbMfemL/eFdm9i3ixCLmUxWMT48lO9bM+j2h0n7LBGFiRcKF70AYrSaLocAKBLufGGdiGJpbX+xbiRGK+dcS8rF/drHg8NW1zK6G6W1lXou6sDX/Emn+ECVtWW4uxwzjmgC78VZ7XRHt2twkbtywAzivPLzXr7VQsdpMzA8DceKl1TU7rxS6/uGkDnguOlVp/DzaSMyXABYcID0oAyrtv7NmAu7tSx5YAcCue1i9t7l28l8NSazp1xqEziAmRwfWq2naSbG4EmpqSpHC0AbHhDwZea4/mKWEYOS+a7bUNFh0mwMMkhVsYyp5NUvC2t3drEYtPAVT09hVmW8hS6abUpvNkPIAOcGgDjZ9JnBeUgpEOdzHrXOajD5hJaQbV7Cuw8T60kyFFBRPWuKiCXc52NkD1oAm0m1F+cKmETqxFMvpUM5trQAheGatGW+XT7F0ChWYY4pnhTSbjXrkW9hbPJIx+ZsUAY/wDZMlywCkturs9A8PW9lab5NpmI/KrviDwvd+GoQ8xw+OFNctBdajdTbPmVG4OPSgCl4ntojdNHExdieQo4rK8lokAVfmFdVqs1rp9uIlUGY9W71ioDIhd12p60AYrQT3soWYARj1ro/AUds/xH8MRbAXivEIZa57Ub0KDtOAPStX4TzZ+JPh4/3rtOv40AffFFFFAEdx/qJMddpr81/Hmw+M9eR/v/AGyQg/jX6UXGfJk/3TX5rePtp8Za8G+99skIP40Ac2QQ2P1q3CVbak+cH7rCqir8wDcA9614dPZFV925W6e1AE0WntE4Msm9T0q3BHJazc/cPSpIgY4wCdw9amY71Ur1FAFuBwG3LWlZzB8jbhh3rOsxkqCOSa20iEUsZZMKe9AG1o1+9u2WUtivSvDd+tzbb43BPdT1rz7To4tytwU711Iso0tRcafL5b9xmgDtLS3W+Enlz7ZF7E9DUsUj20Dq0oS5X7rHofrXGwX1zCVkzgjqQetbNhcPev8Avf3iN1GeaAOy8K6jfSwuuVjGfmIHBFenae8Js0KMp45IryO236bZST24ZlI5B7Vv+Brr+0mzazMGU/Oh6UAegyXMSRmQt8g60+GZJ03QtkVCpidzCU5xz6VNHEkK7Y1wPagB7AMpU85GDXhXj3wKJrm9u4YgQSSRivdMZI9qqapGjafODGHO08UAfHx8MRQRPJLGwOeKfa2FuImTG1vSvZ5oNKuNPuYb5QkwY7eK4q48Oywagt1FF5lr6igDzO+0+Asyyr364rHbS7cXIEbF07jNd58RMQwjyIRGxH0rzOG9kjlwTtb19aANZraBblEL7V9zV6Tw8moXMUdkyvKT1riNTvbgTbnPB6HNN0PxDeWN5vimbepyOaAPY5vgnr99p+5bfeWXINeX698NNU0ed472F0dT3B5r0LRfjf4nsoFiWQuqjgEZp2ofFKTX5/8AiaxJu7nFAHiF/olxBIFjhc/hUJ0W+CZMLflX0VoWreEJbhWvoEY+mK7qLSfB+rmM29qqx9+KAPjRtOuV6xNn6Uj2NxHgtGcV91S/CDwbfWyyhliVh14H8657XPgLokts76dqMa7RnBIoA+NILdpZCp+Uj1rattKWa3CDBbuRXoviD4eWulXzCScNjjIpuk+H7eEs2cKOcmgDj9OslsyEaLOe5FdMsUIgG2Pn1p17EhnIjAwK0bC3T7ETI6gjmgDJS68oGMxAqehIrqfDGpRpCYJsEt0zXOXbm7cQRxqqj+OooRPYXSM/zDtg0AehWFydLuzeHy3xyEIrttF+LV28qRCKGCNeoAxmvGnaa7mQRK5JrRk0oq8XmuUbvigD3XUfig11ELayVGd/lYgetUtT8A6NcaS2q6jciG4kXcqA9TXl1pBJBdRrZxtv4+ZuM10UmoX630UepS7wBwu7gUAN8O6Xd6deldNBk3HsDnFewWOi3N3ow8lfIuiPnPQ1l+FfEmj6b5UUsSmeQ/fAyB+NdHqfivT9Ovl8uRX3jJ56UARHQdV0zRyumXG65b7wNW9EuZ9D0QyeILmNZjkhWOKz7v4m6DaBvOmw4HAHevF/H3i648cawkGlb0hX5VGSM0Aani3V7zWdelOjTEF8r8p6CuYl8PTR3HlXczSXDHcd1W9OgufBkyT35DyOOhOabqfiKPUb4XCYRqALmu6zdadoiW1lEiSIPvAc1w1rqOraxOEmZyxOM1013eW97HtnlUEeh61Z8Kizj1DdsHlpySaAO28H6HpGlaYJ9YmVbkjIBPWvNviTrFtHfMLNVdexq7438RW95qAihfhOBg1zkWlPq0w2IzjucUAN8P6hNJhEJDHuK6CLSvKkN5eS5B5Ck1NoHhtJL9bWzUmT+LA5rqNZ8JSwQATlhgZAoA4HUbWPUCV4VKhg0BY4nNojOR3ArVi0y4l1JLeOJ9gPPFev+DLS3tgtsmnFxjlmXqaAPEtH8JrqNyx1F2R+iRnPNe5+FbDTfA3h4NbwA6lMOh61sR+FrS11JtTuYVafpDEOmauN4eW6le+1iUKQMhf4VFAHlXiZZNXvG/tGQea5yB2ArMutJht7YxWcYYbfmkIrc1tNMTWJZFlzbKcbs9awvFPii3NmYNOQLGoxu9aAOC16C1tpfnId65XXtRZbbYi49hWpeTGV2mnbPOcVz+o3ETEuRuXtQBzc0kj/ADSAg+ldR8KpC3xN8M46fbE/rXMX06gl5flX+EVr/Ca6MnxQ8LqBgfbY/wCtAH6K0UUUAR3H+pk/3TX5teObUzeM9fYnGLyQfrX6Szn91J/umvzd8aXDReONeGN0TXkmfzoA5eRiflfnbwMVs6NdI6eS/pxVK7tgz+bb/Oh6gdqTTBsmJPUdaAN5Y2jJUnKnpSeVNGC+flqe1ZJUIqxb27ocg709KALWjSIQol69q6uHbKVilUbD0Nc7HZgFZFBHfFbVjNHOBGz7StAG/a6MMjZIQvUVprLHZx7JSTj0qTQ1g8gb5QdvvUWvW63iZspFLL1FAGnbXtpPb+XCD75ra8MRWolLST+Ww6AmuD0liZ1hcGGYH863gEe58q4fyn/hbOM0Aeg3xvL2A28LIkWOG9aj8I/bPD2ohiodGPOBVTwyYboray3uyRfuZPWu1iFvp00UetR7Q33ZQcg0Ab//AAkHl3EZktmWOTHzYrcLNt80HCkZxVKQWjWIB2vERlGAzUGhXzSyvavhgnQ57UAaNvf20zbI5lLjqueaskA8Hof1ridc02H+1vtxme1mU/Kv8LVPZeJ5YZRBeQ7/AO66nOaAF1vwhDeXBeNAAxy1aQ8OWq6YtpHlQB1NalldpdIWQMPqMVOeAxPUUAeP+PPh+11p837oysoyrqOg9K+b9d8MXEMrqInBU9x0r7htNThu/OVAwMRwwZetczrml6XqjM1pZhrl8q2UwKAPz/8AEMdxaXOyVjgdAapw3oQjMYDdzX018TvhNO0clzFZlt3Pyjp+leC634Nu7DKpFIzjqCDQBDba/DFFtKDd61Ys721uwXfAasJdInVW89TGw7GoAJLN8qCc9eKAOzigtn/exSsGHvXU6FrGoWpQRyEp2ry+yv5CQhVgxNdlo+rPaRASLuPbigD1RvFGoywpFLP+79qkj1K+e4WK2vZHiPX5q88g1V7uXEilRXTaZctYr50ZDADmgB/ito2wkjnzM5NcxJeSg+UjHAFXr/Wkvb8M6AAdTVWSNZrxpLF1Y4+7QBHDZPJGXditb2maLbT2heW4OB71X00ajcZtvsxIPXArR0ezuLC9CXULeUTyp4oAzp9LEsgisTuJOBXpXhb4PajNZw3N4yNvG4KfSkmstLFut1Cwt5UGdo5zW3onxF1CW2j0+zO+QfKGPFAGdrOif8IzeLE1iHYjjArl71GvdViE1q1uu7liMCvbLPU9LtLdJvE2PtPUbvmrkPHXiXSNQvbeOwtlCA8vjG78KANyLTfDp0+2K3SSzKvKoeawL/TbW4vzvtpGiA+XA5q5a6RfO8MmgxIcjLZ5rrrO4tbbTmu78xLfW4y8RxzQB5hfWE9rA0pg8i2Q5DMOa5jXNQ+1w7rdssOMitr4h/Ey219fsNnCEIO0gVi+GdKtxdo185ETcn2oA5/TdPea9R7gmUMcHPavSxYaHottb3CzKJupCnkVQ8RXWhWA8nQh5lywwTXm2rSXxn2lmZyckE0AeleKr/Rr2JJbqYkgYAJrz6XThd3Ba1l2QeuarxyR3LrHcxuzqOR2ouYJpJE+yF0iHUCgDUtLKysGUyu07HtnNXL2V2IW1jMYPGAOtdB4D8HTa1MrBW3L3YcV6ZN4c0bw08Ml5Gt1cnkRjsaAPIbH4c3FxZnUr8tEjcgnvXofg7wbcJpZNmyMzjqRXpmny2Ov6eBLEu1f+WfTFTXs9ro9kTagAgcKtAHH6b4bh8Ho2oXUyNcuep7V0VnaW+o2xubuRSrDPJrynxZrd1rmpqt7MI4Yz8qK1X7DX7exQG4mZkUcJnrQB2HhvQPM1ue6dEFqhwnHWur1W8g0q2LJEplP3EUcmvPbD4mlmESWQSJRwc1jeJPiLJcF/JjVdvQmgDqf+Ene0vvtGqffb7kWfu1Q8YeLrV7PbdXY2tyIojyfrXgGt6/qV/qUk8szbR05qC41Ge7hRmz8vcmgDvdUh/tVftKnybUcqnqK841+8drgw23EaGt5NWmNgIy/GMYzXNapNEjeXEMyP1NAGJf3RxsY81z2oaiiKY4uZv7tb17bYjIP3zWFNZRW6sfvzt3oAwJJHkkzcEsw6JXU/CEs3xV8Mbhg/bY+PSsj7NFbKzyMN7dz2ra+ErIfix4YMf8Az+x8+vNAH6N0UUUAR3HMEg/2TX5r+NphB4710MuUN3ICPxr9KLj/AFEn+6a/Nfxugl8da5Gf4ryTn05NAGbCFWXdaPlW+8hpBayR3YYfcJpi2b2sgaUkD+EjvWxGySRDzR8w6EUAOhDFwVGAPStfT7jypBleKxR9qjfdCA0fpVm1uJTJyoz9KAOwa4imtiYsBh1BqHSZIDOVmGG6ZqnAXlh3LHyOuKmhKMuJl2n16UAdJBP9gkIX95E3f0pXhu3b7Vp0hK/3c1j2PlzP5azEMOgJ61o2c95p14DGQynqvagDUjN7sSWSIM471ZRJtSmRpSoZTwM81DNrDsuEjIY9fSi0llSVJSM89qAO1t47MWcauGS4T7rCu38N6jJqlg9nfwm4VRhW6la4G0tzNGkkqso+ta9rr6aLMjqrGPplT0+tAHex3DWMJgt7sGIDmOU81h6N4mij1qa33vBOc7fRq5PxhfPqSi9sLkMD12DBFYej6Tf6vfRvHL+9UdTwaAPUfF3iJtR08wSDy5Izy3rUWhyW8mmR3cV4RPHwFlPymsLUrK+0+BTcssg6MStdRon9jnQnV9rb15UDkGgDqvD2vGVBFeRkOejoPlNbWpSyx2wltcsR2HevNvAX2qK8uUt7uMwAkqky5P612EHiSSRpbf7LmeP0IwaAH2c9/f3IaJIoFXiQdzXQxIij5VAPcgVi6DrUV9O8U1uba5X+EjG6t4HnpQAjorptdQy+hrDu/CmhXkjNcadA7nr8tbwOaguIRKjICRnuDQB5F4x+CGl6rdi40wrAc/MhHy1yN78CXDFBFG6+q19Gwx+WiqpJx3NSckUAfL+pfs/3CW+bTDSYz71zX/Cqde0+Yxy2TSDscV9iAepP51VN1vnMSIDt6ljQB8g3Pw81uI7ls5B7Yq7pvhPUAPIuIZA5HQivqnVdVsNMCm+ZURuhIzXF+J/EOlrNDfWhSdIxyEGKAPJtC8BwW1z/AMTnT7gwsc7lXIxXaXXgjwdaWButOLecozt75rH1j4h6hM8jWxjW3IwEYZwK5Oy8SXCXklwQGHXb2NAFyw8RWWhatI32UyN0CsvFJq/iaHXLnZ9nEDHptGKqG1fxTqImDRRAHkDAr0jwr8P0s4TqMyJMsYyAec0AeYTR3Fk++5KyIemTzineH7y2TWVaNWRc8sO1bnjdYL2WWd8QIpwEWuEgu/s2/avy9jQB2viq7/tHUYoba+Jx3c1g+IElsmjlknSR16bT1rl75S0v2h52TuMHFZ91qizReWju8g/iJzQB3cfxA1fSBG1lPgkY25rGn1nWda1NmvLiSFpvvEHrXKw21xclSrZkFdh4duILa8iXUyGde9AFbVNITQoDNjznbneapR63eTW4XeVHYDvW/wCLbttduxa2abLZf4gOtbPhTwjqF7CIrbTjIoH+sZaAMHTY54YvtcqAsemauaXajUL7zbhdpzjArrb/AOGfiE25lZgsScleldJ4C8BfbrDzprpQynBG3pigDkv7CjjlwFjRG5LmvWvBPhLQ30pJHt4rhz1JGapXXw6trqfZd37iNf4VyM10nhnTpdGVrWCVTbD7m7rQBoyQWmk2rLp0EcU2MKqiuPgvbGzuprjV45Li+bouMqtbmtg6bbzX89ypuG4Vc1j6pr2n2HhzzYoo7i/lXpgEg0AHhm4i1W4uGgnW3izyinms7xD9quJWtbS5WCMcM7nBrkrHxFJY6dN9ntPLvpiSWPQVzl9qNxOwS4ndpXP8JoAm8QWNhZysILiW4nHLP1GaxbW4E0oVmZwDyD2q5rVythZhZVCsR6cmsObWIrWzLRRDc460AaWrawQVt7QEHpxWHqUNyFDSTYLchAaj03U4o1eWdcuelZV7fzXVyxBPJ4JPSgCea7gQeWwJYD5qznv5btwkSCOFep9aztbvEgwqnfMeWYVT066e5OWbZGOoHegDXudRMWQm5sVi3mqS26PO6/Qmn6tqkFmRtGewHrWbLFJqoV5TsiHIX1oAqSeIpJmyxxTIbo3U2VYDHc1DqkEMDBIYtxxzWdbRPLIQjbPWgC1qsqtLtU7sdR2rovg2DJ8U/DJA4F6lc5d2IRQyNk9zXSfBxmT4peGUU8fbUoA/R2iiigBk/wDqX/3TX5sePZWi8ba9tX/l8k5/Gv0muOIZD/smvzh8aj7R4v8AEAI+b7bIf1oAoWNw11abWAJHrV+BIhH84w1ZulqsT7CCK3PLDjkZB70APsQrHAYAVbn05Sm8YX3FVobEdY3wauRmZSIz8woAigF3ZnzYW3oOqmpLvUEu4wdmyQdQKlUvFIC6nH6VV1FYWkDQcOetAElv5sW2ZM8da2La5klUSIckdQaq6ReLCgjuody+uKszLCs3nWj4H92gDVtb5JjtkBU4x0q5bzBGKOCV7Gsm0kFxgsg3A9q6+wS1ktvnGHAoA07DxAFtFiddwXt3qeeazuI90UmMjlDXOSTQWshLrn6CoL65iEYltFJ9aAL0upwWV0qR+vKnoa6Rb1pIYbuxgaKZcZCjqK8yuFkuJBIY2Ddq67wpqV1p7K053RHghvSgDv28QQahYmG/LIcYJIrU8EwaSk+0XiujdVJ6Vzd7dabNAJG2FW61v+ELXQmkVoShduMA0AdlD4Yjk1QzWk4+yHrtNVLzwfqVpqDXmj35UjnY3etnThBospNxMY4pOQGPFbP223eIzQTxuo54NAHFWN7rMupL9u09GlQ7RKO9bl7rOp293DGbI7GOCyjNXINS+3yeVaPGkinJJ7itgAhRuOT3oASJi0aMVwWGSKeoOKpX+owWKFpWJ9l5qla+JNPuVJDlMf3qAL2o6jFYKplDEE9hTV1C3eMMWZQfUVRuNa0aVlae4jO3jBqeRLHVrfbbzIfQoaALtuyBcrKrk+9YHjRbdrVT9rNvOPu7O9YWt+DtXaMvp2osrA5Cg9a5PUL3VdPQR6tas2zgyPQA+4uLjUphZ3WoKyDgbjzW/aeA/s9g0lpMJ9652k15mbm1m1qKeKQDBBK17f4c1+yj02NZpURgAOKAPnTxdpLwajNbMpjIOSBXMwQ3YmMNorFemTXrvxPutMj1Ca7t5BJkckmvND4us4YWW2jUSetADLmyudItGuROyueWUGuj8O/ETWpNMNhb3IWLGPmPNecX+qzTyM87swc8LmiF52jHkJtb1AoA7OTVIVumj1N/MLHJOe9YevX9r5oW0+6PSqtvpdxebVlVy5/irb0rwhdpN+9gYhuhYUAcnfW9zeoPs6ts71a07TTHGpkjGe5NdfNouqacTHHbZjPcLWxpvhWS7tEmdZAhPzYHSgDH8M+EjdbnE4UnkCpNZ0OOBjbJG005PBUc16vonhODS760ljm82NgMg812tj4Xii1s30kMTIR8ox0oA8u+GXgm8klja/svLiHO5xXuFtafY7cRWixpgYwAKkvIt8IxL5QU5yDgVz+o+MtMsS0SyLNcLxtXvQBe1mIy2u28uXhDcYQZBqnpjWfhyxkE8gWAncCOpqqPGmly2wN8m0n+Fq43xj4x05oWW2t3uBjoOVFAHodt4r0S7Ust1GB05rD8ReJLeS3kh0qJpJMf6xe1eOWlxb6lN5nlm1iU5PatqbxMkMBstIUMSMNJQBjeK/EF0ZFguZHXB6kms7SfEVulyfNmMmB3ORXK+Kb+YX5WdxIxPOeaS0tYZ4ASyRnr9aAOnmv7q/uZZS6x246fSs6DU44NR8xm81V71m30Nzcxra2Zk2jqwrH1CVdIQQ53u3U0Adfd6kurzZkQCMetYmvNbFBEhHHpWHHfnYC0m0dgKry3tvCxlncsewoAmkuBBHg1mz3Esr4B2r6iqV5qbXkuVXagpI73kAocUAPuFTcFILDuaY6kJm3G0CrE97AqcAVQudTVo9qLge1AGPe+ZLdBEUyNn8q3IJTDbgSkKQOlU1uktVaQJ8xHU1lPeLdO3mMw9getAD9W1FZGKQgZ7mspGdW+Q8mppLYqGkbKr2HeqxY5B9KALU08qxhGOc11Hwax/wALT8MZP/L6lcYWJ6mux+Df/JUvDH/X9H/OgD9IqKKKAI7j/Uyf7pr81vHUjR+O9dKtj/TJOPXmv0puBmCT/dNfmv46Tb481supKfbJAT+NAENtcRFV3sN1advLtI+b5T0rCNnE0qFCQDXQ2doAm1jwRwaALqfMQVPNXgQ0X3sPWYkDwHg5X1pJrhlXAPNAFtrlwSsnI6UJAjjfu+b0rJW4lcnjNNeS7jYNg7aAOmstRjBEM6KMcZp1+FjPmJ930FYtjLDMwM2VatKYhQEVtymgC9pA86YPC+D/AHa6GO7ls5VMsfFcisUtsyywZHfNdDa30k8K+aokI6k0AdG2qabPHtkTDEdxUEfkW4MiAPEapvbWl5Zlt4jkA4rMtrprbMbHeoNAHRxXltdOF2qgHStuO2jNrhdjE9Oa4W8vImQGKMh/aq9pqF7vKRuwx0BoA6i8uJLXMFxGQrdCK1PBSQDV4BJLJGpbg5NYVlcteqI75sbejGrk07RyxpENpB+VhQB9AeLdGurjRkktp/MVFz+FcXZjT5LB0uLuWGdeCAxxmovD/j69tdOayvkWWPbgMfSsDV54bhJJYf3e7nigC5tu9PukutP1JioOdpPWuvHjS4u9PaN7hY5QuM15GbphBsZ2J7HNUZRcRsJEkJX+7nrQB6t4a8YzW9xcLcTLctzgMM1VvvE815dyCeJLdD/drz601S2RCGRo5vUVHc3c86/IGYE9aAOh1LUVEciqSxJ4Oak8Napqtlu2SOVPQZNZa6VOLJJ5WAU9u9dN4f0g3FqZbe8QSD+EmgC7D8Qdat2MTrJweMg1yPjTxpquqloZwUU9eK6O6WS3vEN5PCAPfrXIeOLyOV8QhMjoR3oAzdKjht4xLLIQx55NTz+IniVo4Jz7c1z0PnXOFuDsQVqWmiR38iRWpO8nvQBk315PfylZXaRT1Gao/wDCMm93fZzscdq9x8M/CcSQ5uZVR2HGK03+ElzagG2uQ5znnrQB872fhm/trkefFJIuewJr0nw54UfUgsYheN8cArivfvC/hi1sLFVu7dJJh3YVqNYxQ6lHKluiRqOWAoA8d0Xw5Npdx5dxaNIw6HbXd2OlS6nsjubMQov8QrtwElAZFQ89aS63iByhCkCgDJOlaTZIqzLHuPyjdjJq5a6Xa28LRLGnlP2wK8012aa41YOszO8Z4Uniorj4hS2qmK+QxunAb1oA9CXTrCymMkpGRyqk8VxfjfxbfW8gSxlEQ7Y5rl9f8XjULISwzksOcA1yt1qlxq8RaGP5lHU0AWtV8S+JLqGUPets7gHFUdG1mK3gY8Pd9yxzzXI32p39rK6Tnk8YHpTtMigYNKJGaZudtAHeWUqak0j6hcKnoAapT6iLCR7ZQrwN/F1rzbULq+gvipLRp2qvb6vM97skdmxQB2mqavaWfCsQD1rBOrzyMyWEnlo3eqOuBLlFLHBrLtIjBOgZ8LmgDSMbrOZLrMx9a0tLgjubpWlYxxDnFD3tpFBlMO4FY0+pSbi+dg9BQB3+q+ILOwsvItI134xu715/qMrXxZiBn1rPur/zPm+aqwu5sEhfloAmkgSFSZZckc1nedFeSFGHyr3qb7NLcsWlYhKY8cEJ2xjJFAEU7Q7ljhXp1p14ALbGAoA604yRwgyOuO/FYWsaqt0DHCDgd6ABZ4txHmFm9KlknjgQMy1maWVE4BXJ96074wpHl1BoAzrnUGlYhV+Wq1ujPJleD6+lOjkjW4LFfkParlmqXE52Daq8mgBlzL5ChB8zkfeNZx9TVvUmU3BCHIFFisRJ838qAKldl8HP+SpeGP8Ar9j/AJ1y97saXEK4ArqPg7/yVPwxn/n+j/nQB+kNFFFADJ/9S/8Aumvzu8UpHN4x8RAjcftsnFfohOP3Mn+6a/N/xpLPbeONdaEZ/wBNkyPxoArGyDt8rYYdqvRTSwrtYZA71m/bPN2tgq/cVq2YeRB5oyKAHQXwmfytwU+9F5A4XcrA1m3tli5Dx5Xmta0y8ISXlfUUAZiz3EDjemVro9Mlt5o8S9T61nXUDKBtwR2qGGXyyA4/LtQBoXtjGJswsMVYhXCAPziq9tH5h3bjj0q68exAyUAW7O5tz+6mJHpmpRKLQt5ThkNUVlt5I9siYk9aqOhifBY7T0NAGu0iSHe0hX1ANPhRS4eE5HfNY8EZcnBLCp4JWhkKOxVT0oA3XlVDuAG4dqS0uFeQyFQMVnrHIPmR1fPbNWbV2WTDx4WgDXttQjabZKAB2qnqeoTJcAxsCgP5VbNlazRlw4D4zXNX0TmV49xAzwaAOoi1nzIVyxzj1oTUZ9x/e5T0rmYEmtFU53rWnYGO4l3MNq0AbVrfm4YoAAM4yaWWVo3ILZx6Vk6jCFwbJzx1Fa/heNLmQNOCxHUGgDLaWRLnewyme4rSXU3l2JAMEe1dTf3OiJD5U0GGA5IFYYuNGdhHbfI5PFAG54avbyS5EdzbtJb/AE4rS1WZLWY/ZC0GetVNE8SNo5MciI8Z6GoPEGtLrEqLDEq56mgClqEU9+P+PkEjuTXN6vbyI6ozM7dsVqzaVeQyAhiQ3pXW6LYWtlbiXUYRKSO4oAreBPAp1yJZZ3IX0xXpVl8P7LStvXJ/iFZXhXxJFYNIlkiBW6D0pur+Prm3kaG5YKP4WoA9Os1tdPt4/vsyjqTms7W/FENq8aQSfMTyDXlKfEK+2vsuEYDpk1yd/wCLLqe7ea5YE5+UA0Ae0av45mhZIooevJeuV1j4mzxXAtyMg8EivN7rxbeOoDLkVlXWpx3LqxwGHJoA9Lv/AIjX9tFstgcMc5qtL8QtYvolihmCk/eJry2815kmEMeHXvVXUNR8uMPC+0nrigD0C78SyC7CPIfOHXb3rE1e5vNYuViC4BPU1yVrr6wOJZFDyjualvfFNzMVeBBGw6YoA6O+sb/TLUHyiUHWsQa5dxTBLZSpPUCmHxTqFxCI7pzsqjb3ite56H1oA1bhnuHD3RAHfNTWd1aiXbb43L1NVZtF1LU232hypqrLolzYN+/cI3cZ60AaWrPBfuFbGR3FYF5HBZ5eIbj61pQmFUO0FnrPuUUO3nnAoAwpry4nc4BwPWo4Lku+Jz0q7Pa+a+LbJz6VELH7IC9yMfWgBhn2ygoDt96eSk8y7SWY/wANNtBDdTHc3yDoK1LexjFwrRfKPWgCO50iQQCSdljTGRWbB80u0HcvsK6y9tGuIgszHZiqAFraJ5Vui7/7xoAw5xKAwAIWs+KN0kJOSDWtqswSLBcFz2FUg+YgCQM0AUb0faFKZwKwbyGO3+WIgt3rowEZiqcmsvVNNUbpS2PUUAYaMUbcp5q3JMJoOTyKrl1VSIxn3NNRVPLnA9KACPbkBq0EaNVEcRwW4J9KoKhdj5YyKFZo8j+I0AXpoYETaWy3XNUiVU/IM+9R/Mx7mnqkh+6poAcrH7rcA966/wCDalvip4Z29BepXHvGy/fzXXfBwkfFPwxg/wDL7HQB+kFFFFAEc/8AqXx/dNfnB40ulh8ba+svU3kh/Wv0fnP7mT/dNfm543eN/G+vJOuc3khBx05oAy47qJweOfWtC31FY1AByKwpovJkyqkoams4knDKh+b0oA2ZNSSQEOMA96n0+cgEDlDWWtpKV2SJgDvV21s5cYRyKALF7JIB8jHFU4kd3zvJNWGSZAUlbIPtTLTMU+CAQfegC5aXjWkgVwSO9dJa31tKoJHFY7tDMoRox9akltCtvmFsqKANO6WIrujA21nTNKylduR2qjb3XlsVkcj61dtrlHJZJAcdjQA6zkcZXG00+SCVjnIYUyVpGJZY8j1FWLKNXIZnw3pmgCKMDeMSMknpmtSW5uY4RvjBT+9VS7tEkkBD4YelJJcTqBEclfpQBXvbq5UZh3DNV4ZrzOZwSp7mtpYjLGo2VZls3jiUyREpjnAoAyrMzGQkPuj9KnhkcXfXavpU0SwK2EOwUXGBGcKGPqKAN22nihUOAGPcGkvNQiTD2biN+4FYEENxLHlT8vpmt230WSW3QlSM0Aa+hXsRj36jGJFPerGsW+kHbdWi4Yc4FbvhT4d32pwEJMAmM4NR3ng690iaSK9TMI6E0Ac8zpfoiRqUPTJq3LoN3b2hmjYt3GKk02zlu9REEOxI1OMk13h0C6toVPmpLERyN1AHHeGjPOpM0nK9mrpm06+v7Y/ZSkmOwNcz4sm/s6Mi1h2HuQa4+LxFrVnmW2uGjX0zQB09zb6hpV2xlRomzk0zVtftry0ME8Q3/wB6uWm8fX1xGyXThyO5Fchf6zLd3BZJdgz0oA6C/YhwInKj1BptxcrbwjfKHIGetc950rIdsuT7msy7e5VjuyR65oA6Jtckn/dIcCq13dSwp8r5z1rDtZ1hkzkljWtlriPBAwaAGJeOseUGX9ajNy0uUdiCamgjMQKhQTSzwKYy2FDfWgCS0g89ginc1dBF4S1SaFWiiO09657Q5pbe4GYWHP369Es/HUOnwBJB5hA60AYFz4aubCDddvz6Gsdo5YHLBMqO+K2vEnjUamw+ULGKw5tZjuYti4FAGhY+MriziMEStk8ZFV7ye71Ama4uDk8gZrKgtbiZmaBck+1TRJd26sJ0+btzQBat79rJSGw3uaoahe/aG3SyBENVrmVkfdcjjtWVqd+0nEceUFAHQ2uqpboFjKkf3qS+vftafvefSuIe7mZsQoV+taFhNeEZkGQKAN+zgIbONororWWG2h3MwY4rgrm/uHBHKgelP0/U1mbynkY46g0AdTc61JNIUziMVnXFxEql2lwPrVG5HzAQR9e5NZOtKNgRdxk9ulAGrHcW9xMRG24j+I9qztZuvJOI2zWT9qkSERp8g7471C0hZfmGT65oA0LG9eOT5m61bvruMR/O25z2zWBU0MXmnlqAHRRfaHYghBSzQxxHG4E1HNtVsRk+9RHmgCfzyqbVG33pkSNK4UDOeppI0aRgorYMaW1rhmCsaAESW1tIhGqeZNVO4vJd3Map7Yqv5uxyY/zNMd3lbJOWoAmN07kAqDXcfBjT5G+JvhuaXCAXiED1rhPJkVdzLj612nwfu5X+KHhdN2F+2xjFAH6M0UUUAR3H+pk/3TX5weNbtI/GmvrLFuzeSHOPev0gn/1Mn+6a/OLxlIv/AAmfiAOoP+myfzoAyknt7ldqja3oaqi3e3uQ8TDHcUjxq7+ZbcEdqmim84ESRlXFAGra3SPlXOGqwpYDcrflWTHAqsGLHmraLJF80bh19KALKyfaCemR60/yYz6hhVIsGbdgo1WEkkXBYZFAFnIK4OR71UbUJoGK/wAFTmfK8gCpIkgnUK4GfWgCKBY7tdzfeNVmU2kv+zmtOK1ERIjPFVbtMElwSaANLT7wvHtA4qwVUncOCPSsOKfyl+UVct7mSVSMUAXpMOu9Wwy0+KaaUbht4rPVpS2wg4okSWBwyk7fSgDdhu3CgAYcdqvNrzJbmOROa5RdWQybGGH7VJPdu64IyPWgC7LP5rGQKAPSolMspwm5R71HBMscW6RSas2VxHJKATkUAbGlKSAmSz+1dTZtekJCysmejNVbw+LCB1ll4IrsodWtb9lhiiVk6Fh1FAG94d0HxSkCXNldL5QGflNVvF2qanLEINQPK8E1qWuqto0CpDdExsPu56VzfiieO9QuLhWY8nmgDlf7Rgs5eAQc8mtWLxjFFHsE4H+8a47U72K2ZlKhyK4jVNWWV22xlfpQB3Hi3xA0zDy5VcHtmuXnvpZIyCQFxXMzszIJPOPHOM1AupySkxngL39aAJrq6CTFQC2TUqvEyfMnzVTe/S2ALRhye9K11LIwKxgCgB0m8Hd8wA9Kc+oxww/OGf2pZHldQDgCqlyqLjJDL3xQAJdC4UyRwkEVNDNO43b2U+lM3wiI+Q+R3AFQ6fKkkpV3IPpQBp27XEhBkLADvVlrsRsAUZ6gE6qdoJB96t2qFnBOMfSgDRttUaWHyxFhcelUrpgTt2dfSty21O0tItrQoWx1rHv5RPL5kWFHXFAGTcW7I4LK23PSrbJAkYK8NViGGW74ZxgVMbFI2zKcigCW31eSG3CWoUNjnNOtria5YmZ9zegpkljG8eLdSARyagtrK4t3JiJPqDQBNeWQkJaUjbWXcG3gVhEA59Kt3sVzJku+B6ZrHuPNibaiZ96AMa9M8sjER7FHPFS6bqHkIyzZreg0ya4j3sQB6VTm0iOSby8jNAFaC/W7n8pUAU960Rp1shD71BHJIqCfR4rKPKSfvCO1VIsxRsZSSfegDRe+tz+7iJJHHNZtwbl5cRoFU9Sap/bkEvyxgY70XOqySAqgwKAKdyuyVgTk1GOhq0bX9z5sjHmqhxk4PFADacCR0pMHGaUUAA5NGcGpYYlZSztgVE4AbC9KAJLdykwIGau3EXm/vHbPoKzQSDxTzK543GgBJPv9KVGaM7gKZznJpSxIoAkkleYgu3Fdr8JBEPij4V8vk/bY81wyjJHvXofweSC1+JfhncN0j3iY9utAH6H0UUUAR3H+pk/3TX5t+OJUXxtr2Tgm8kP61+klwP3Mh/2TX5seN4fO8da8v8X2uTH50AZcEsTvlTtIrTi2EBsA1zrxvDJypBFSwXUkUwbdwetAHTJ5T/Kw69qrSWUsEnm20hKf3ag+0xvht2DViO9BUAEH2oAc10hTEq4YVPbOZlJjbNZV5uLGRQNvemWuoxRYwGU9+aANacY+VzimQAqwIbIqMulwA6vuz29KHV0XMZzQBsRXCoo3dafOv2iPKYrCBneI5HPrUllPPE4ViSKANKyt/MkKSjFaI06SPmNuKZaSDbvYc1ZW+V227tpoAVIWx8w+Yd6imlU/IRU0i3DrlRuT1FQGxacZVvm9KAM6W1jMocEbqmEDSowVgCKsjTZI/mkHSiSzl274jigDO3XEYMb8rRb3Bib7mDWtYW4uiUnOG9avS6GY1DR4egCla6hJjDOQT2rrPC87xZZpNinqTVLSNFEzAtEdw9q1dTs57G34h+TvQA/Vr+YfMl1uX0Brlr3VZnYiOVwfrTrm5QBgyMprHuCrKzDIoAdNfyKT5jB2x3rntTut0TBQAT6VNPIjsQSc+1VGkiwQVyKAMWK7ZHxLlhVxrq2lQAq0Z9fWmXxtkGYxlvSond57YAQjA74oA1xDCYFbcrD3qEahEhKEggVhZkHy7mHtmh42Q/vAQKAOnRluIcbgAe9QpapEjjduB9ay7e7woWNCSKkk1DAACEP3zQBNagQu4C8Gk3iWX90AJB3qzp8q3MZ3rtNNlt/KLGHr60AV3u5Y3AuSrAccda2rKcyRAg4WuUuBKZ/3ikn2rbgnWG1HmAgUAbY8qTCg5Y1btfDl/dtmFTsrnbC4Dy7rcnI9a6QeNLvT7fy1XnpkCgDqtF+H17MoPmbT9a6CDwZZ2MyjWLhQPrXnFh4/1RslXdT9akvde1HUubiU4HqaAPRddXw5Y2bJZSqXArg0vYTI4RxyetctdebuZmkLZ9KgtYpwSyhsH1NAHVXa2SxmR58v6ViNPFJLhVGM8VD5G9h5pIqRrDo8YY0AXJGdYwFbCe1Zj3Cq5KKS3rVlrhIoys77frWPPq6qxS2j3se+KAC71ZQdrglhWfNqAmJDrx2qw9oJEM86EOecVmtBIWLKnFADNis5wcUoR4vmZfzpFzC2WXmmPIzHLMTQBLNcySgKTgDsKjUDIB5plKrFWyOtAFoxwxrlmJPYVWdsscDApGYsxJ602gBSaSlFBoASiilFAAvUZ6Zqe4KcBBUP8qQ0AS2+RICMfjXb/CAwt8U/DTM5ZvtqYHbvXH2NvHMSXfaB2rsvhSYk+KvhiOFAQL2PJPXvQB+itFFFADLj/USY/umvzb8aXAh8c68JB1vJPm9Oa/SO4/1MmP7pr80/iAG/4TbXcjI+2SZ/OgCtcXCyQ/Kob3rJdXbnaQPpVjTlkZ/kGQO1aJO0kFRz1BoAxFJBz1FaNjD5v7xXG4ds1BfRxIcxkgnqtQJ5i4K5UeooA07q5RVMbgg1mxblYsgDD0rRgKuAk2GJHHrQIIoZtxOB3oArQ3LmYbFx6it2IFogelUDYIzedbyj1IqG9nkgZfLk57igDVG77obH1q7axqqfvCpNc3BeTzOCE3Ada12mjeIclGHagDRE7BtqjI9qdJGUUykE+1ULR8NkMTWyt5GYgjpmgCXSteMYETIMdKL6/iWcMikA9cVNZ2tlPzjaxrS/se2aHIkXPvQBiDUWc7WY7ferK3+FCgZFOms4WOw43DgYqrLZNbfdfOe1AGlbpDLhw+1u9dPpWnSzxB7eZTjsTXAqJc/cb6irlrqV3anELuPagD0631UafEUvIk3DowrB1LxALuXA5TPSuTl1W6uyVuGZR61DGxt23xuJB3FAGpqs0cilo1wa5PUJbg58v7vetK91XcQvl49aqTzh4/lUDNAGQx2xk9T3qpIi7C6Pg+9LqAnhzIh4qgL9iMSRgj6UAJNFHIhMIy461DHcypGUB4qRFKgtFIF3dqglQocMQxPpQA7yX2h9wPfrUqTLOBHcHH+1VXnOM0q8uOCx9qAOg0qxhjl3+YGFTappkU+HRwpqnptqwcPuZF9DUuqy4iwkgzQBXFvPbALbuD61qwwMYQ75ZqxtPulQ5lYsBWr/AG/bxR/u13e1AFyytraU5uCFYUmqR2EcXEitXP3F3cX0hMEe0GmG0nEf77G09zQBMbz7PzCi7fWnx6lFMcOoDe9ZqIjvsMhAHvUtzb28MYKyb3PYUAXZvOlI+zFQPar58/7P88vI681zUM0qZCNipGupiApfg0AdHaSNgfx1fi+03DBVXYvrWTpEWzaqyjJro4onhXe0gb2FAFy00pI1ElzIPxNSXmrafYwFVCswHasO4mnnfazER+gqSx0q2upVEmcDrmgDntWnl1OQ+VHtjznIqCzMFidzqzSfSvS5bfTLS2EccYZjxXM6npbENJHHgHpkUAc1qV4Z4s4KegrMW4kVCN3Wrl/aXKhnmGAOlZ3UdOaAAkk5JzTadg/Sm0AFFFFABRRRQAo60p5pB1p8kZTBPegBlPijLsB0FIMDmlaQkDtQBdnkt4ofKRdz9zVIISCe1IhAbJ5rQs4Vny0zKsX93vQBRhR2cCPJPtXpnwdtUj+I3htpF/efa0/rXPaXZwsw8lOPeu3+Gts0fxJ8Ok9PtaUAfdtFFFAEdx/qJP8AdNfmx46nMXjfXhtDA3kh/Wv0nuP9RJ/umvzR+IP/ACPGu/8AX3J/OgDPivI4uUUhvSluNRMyY8vDDvVAKx4xzSvG6D5gcUAToftEZDYLjpUUUkkDEAc+hpsasTuTOR6UTSM+N45FAE0twrqMLtk9aDcsRtkG5ar4JGScVZtZIdu2VfxFAFiyeOKQMspC/wB01euvIcCXAzWTcvGzgQoDitC3Zbi22bdrj1oAZbSK8h8obTmpriUwnMq8etQ2dtKkhYpgg8Vbe4hl3RzDBHrQBLaOJAGirTjk+X5gAa5kXJgkIVWEfqK0La9VsANuzQBuQ3+w7Qv4ipprudkzGSPxrCNyYZgWxg1NdXTtF8mR9KAL9tfSROWlOTU7XEksgbqDWTZ4mjyzZIq0s/lLt2k0Adlol5bogE6KfrU2rxWpQyQBVPpXG2yXErlkJ21dlmKx7JHbPvQA6584ITldv0rLVyJM7sH61OdTjj/dypuHqKkaG1mTfHkE0ANaGNl3MRk1i6pLJauGQ5SrF0zwuRk7RVKe4LcShWQ9KAJPtkdxDngtj7tZM85UMNij2q15dtbt5hYg+1ZNzIHnZgcg9KAGMC5yOPbNIVK4yc0K6jqgNAy33V/KgBh61asrg20m4JuA9qqnrzVmG68pcKike9AGld6z5sO1E2n6Vjli7ZkY4rWiEF3GNybfpV63srFEIIJPvQBz8UZfhWAU9zWlHY2nkgtJlh1xTJ9PAmL5Cw+hqCSeOAbbfB9aADAEhFrJtPoamFvPLj7TMFT/AHqLRLe4O+RSD3xVqaGzZeN2R60AUrixVcGE5XuahmigKgQsTJ3Fa1vZkgkygRelRQ2sSXPy9M9TQAlhoqyxb532n0q3JpNpbLuY7vxrSt4IUYM8gx6U68axCEtkigDEiaGOYbSa6axaFoxiTc3oa5aa7tFyYo8Vc0u5ZzvjX5R1NAHYWdkhy8mKr3zrExW3ADVlSatMBsiUn3qq91JI4Dn5j6UAai6pBZtuuTueobzX/wC0F2QkKoqt9ignx5x3d+aJ7eyt48oAMUAVJ41nH76TI9KybmW2tmKxIG9anu9RhB2xIWIrImkMrH5QD6UARudzE469q0bHT1dPMuCVX0p2k6c80oeRcIPWtm7ubS3hKsA2OwoA5m72GU+SpCCq9Wry689zsQIvpVUUAJRS4oNABSsxbqaQU9IZHGVQkUAR05QT2zUptnVdzjb9aaEKpu3de1AFlbQugYEAd6sWdgzMXZvkpbG2muYdqqc+prQFjNEFV3G0dhQBq6TcW9pHk8113w4v47j4leHth63acfnXCNbqsZaV8AdAO9b/AMIriL/hZ/h1FQnN2mD+dAH6DUUUUAR3H+ok/wB01+b3jaOKTxpr4/i+2SYz6Zr9Ibj/AFEn+6a/NH4gkjxxruOP9Lk/nQBhTApIQuRipY7pgm1wGWoC5IxVq1tVnQndgigCASlXLIMe1Mdyxy1LKvluV7imUATwQNM2AaSeCSBvnXimK7IRtbFWEmYDErblb9KAJ7OeMD/VgEd6uCdCMhR+FVrZYV5jYZPUVMNvmABfxoAuQ3CqCcn8ay9SfEyyKuQa37bTzLGCAGqrqenssZVlZc+1AGfBfQtHtkUD2IpqxRGXzIRz6A1QEeyfywc5rZstNMbBwfwoAcqiTBkVsikeTLbeQK6/SNIivo1DMFeman4LvLdzNDGZF9qAOdszDnCttNWElJl2frTJLNoJx56+WfQ1NChS5UoNyHqaAJ4r2W0fCgYPtVySZL1eSAa3I9LsbqzDnAfFZD6OUkbySWHtQBQeOI5Tgn1qi8VxAx2PhDUt/aTwMWAIrPu2u5EAjkwfSgC+ky7cTlT9aiuYbWYAxsM+ma564ivJGxJ/Oq7Ca3OSSD9aALeqQSI2Tyn1rN79KmkmkdcO5I9Khyc0AJTlYgHBxTaKAHZ9atW1sZYWII/GqdKCR0JoAuQ+dC4A5HtWpNdbLfOz5qyrGfy3w3IPrWtEISwfANAGdDcTSMS6F09KbNbtLKDDEUU9q222EfIAv4VEbgW4YuMigChbw+Udm7B75q8lpG65Zs/Ss9rlriU+SOfer1paXjfNuUD60AOMIDAKWx9aszeTHCAFO71qS3jcSAPj61dktrd0/eMBQBiQiJW3PIx9s1PNGJxwQFFNnt4Y3+TkVSvLiJQU3NQArrbuwiRdzD0q2rfZowoAQdxWLb3YgJKLls8E0vnPfS/vnIA9KALV5cTcmFsL35rPS4mV9yuS1WJreGEZLsajjuhFxGg+poAtLfXu3G0nPeoJpbqU7WU0xr+cjBNLbX0kTZIzQAsdlOh8xlwBzStcb3CxRjf61eW4NzGWlOwVRujDEcW/3j1NAFqS+kt4grH5/QU37Qs8X3BvPes5YpZDwCab80bjdkYoAkni2N8pzUIx+NPkkLtk0w0AIODQ3WkooAcpwcmrQvJVA2YAHtVQUUATPLLcMAxyanSJICDKdzdh6VVRivfjvT5JA2AudvrQBtR6qIIgEADdOKgvtQuHjBGRmqUKxwrvk5Y/dpkt278DpQArXk5X5nz9a7L4MCeX4oeG3H3ReIT+tcISe5r0L4Iuy/Ebw6vY3if1oA/RCiiigCO4/wBRJ/umvzQ+IX/I8a7/ANfcn86/S+4/1En+6a/ND4hf8jxrn/X3J/OgDnyalilaI5U1DTuMe9AD5XEnzHrUYpdp9KbQA89O1JxUltGrybXOM1NNaSQnPVPagCsAc/LnNTxTTLgDkCow4jYNGMH3pZJmc56H2oA39M1YRkbWKMOx7108GpxXkey4VDnjNealiSDzmtPTzKVOXIPbmgDfv9EjWQ3Fvz3xVGS5lhxhCSKVNRubUbJCSh71IL3OG2qymgDW0m/cqrLlWHau60jxS8UG2YBh7155EfNi3RYRqd9olhU5OaAOv8QJZaud6hVfrxXITQPazcElBUNrfOZ8LJ1PTNa0yeZFkkZoAYmogQ/KSD6VY0/UpVO4jPtWPPuQfKBS21ySNucGgDZ1LUPtCZZAPauU1Zo3BMEgWQdq0brzR907gaxdUicoSseCepzQBnJLLI3MmGHvTL13ZgJOSO4pIIQc7w34VZlhhWDOGz2JoAzznNWY5YSuJE59areuaTFADpAA3y9KUKu3lsGmHijFABjNGPSjntR6UASRsixnIJb1p9vctC2Rz7Gp4rASID5gGatLFBCVVo/MPrQAyPUl2nehBp0V6k7bHTOe1S3NmtwAU2xiki0yNcGOcFx70AWRZrszGhXvxVe1v0gnKTM+BVkz3MI2BgwqPYrndJFz64oA1X1CyWMNu5xWJd6mm5tmTSzWUU/Knbiolt7W3J8w727CgCvFeSySYUD8a0WTfF+9jBPqKx7hlEu6JWSrtk93dHajDb70AKbSFkPY1VFrIH/dsK0ZrCRASZOapCeSBiNmfegB32J2G6aUYFNmFp5e1SQ470yRmc5ebCnsKhljVCDH86+tAERwe9JuINSyupwFUCoQCTgDJoAe0jPgE8elW4/KgjDMNxNQQROZVGw9fStq4tUNvlyAAKAMtr9uiKAKqM5diWOc1PIqswW3Uk+tTLplwyb2AAFAFCjNOlUo5UjkUygApaSlFAEkURfvgUOVHygfjTFJHQ4oP60AHfAq9aWsbfNI4x6VQpQxHQmgC/PHAzbQ/NA+zQ/Ljcfer2j6csiCWUZNWLvShcsBCmMd6AM6CCOZxsTIr0T4SW0Vv8RvDu/CsbtMD865SOAWUQRRl63vhdbXM3xT8NSyvhReIQCfrQB+g9FFFAEdx/qJP901+aHxC/5HjXP+vuT+dfpfcf6iT/dNfml8QMf8J1rmen2uT+dAHOUtK2M8UY9qAFEhFJ1NLg46UMu089KAHxKrNjJVu1W1eSFCsxyp6GqGeeOKfuZl2sx/GgCcTo0nzJle9SzW0Tx77diB6GqIGTjpVqzlEb7JfumgCWwaJm8uVQGz1rpLOxtLhQm8IT3rPtbWKccgYPQip5rKSH/VvuA6AUAXLjSpIUO5hJH2qhEIYWKvgVBLql/B8gRig9earSags4zJCQe9AGo8sW0iKQA+lMt7sb9jnIrGa2E4Mlsxz/dqaxs7ovk8Y9aANaazVpFljOz6VqWqylME5X1rMzcxoAyZWrVlfxIwSQlSexoAlu7Fx80Tbj1qjLIMbXG1x3rZup4ljysm3iueubhZpSpG76UAOjuQoKNN7802RftKkGcBfXNUr0rCnzxkE9DWYLmQE4PHpQBdntbi1y6OHT1qm9zJINrYoa6nkXYWOPSmt5ipgpx64oAjZCF3EcUynEnHJ/Cm0AFTQSeUSSgb61EODVhJYFUgxkk+9ADJZA7ZUAUogkIzgYqNsFvlGBSq7qeGIoA1LLy2AEgCkcYqe7Z0XEKKB61k7mK7vMGaakkxcYLN7UAb1va/aIP3knPsapS6dJDMDEzEVYtbyGJB5jbX9KtNf4XdFHvzQBYtbdDGAwKtjrWdfWt4k37tyY6u29/5inzVC+1VpdQ2zhB3oAaLWRgBnB71Qu7CS3cSK285rbjkTGWGD9apahKQpMPLUALCDLDmeFQazpIrmOVmgUque1CzXjMFPPtWmsExhLYIPuaACF5Ft8yLlsd6zHaSech8IvtU0st6W8ogbfXFSfYUwHdju7nNAFK4sjjdHk1EIJCNhGCKs3BIJWOcEDsBVJ3cH75zQA54RH95xn2qW3eOFSx5ftVQ5Y+5pTG47GgDUtLrzGO4hajv7gNld26s9sjvSxBWb5jigC9b36wqB5IHvSXOpSzEhPlFVJdu/wCQ5AqPPPFAAxJOScmm04rgc02gApaSpUZAvI+agCMHHanxozn5ATScu3TNWPtWyLy4lC+poArupUkNSIpZwF6k9KerDB3DJ+tW9OWJJhJMeR90UAdVoNmxgV7hgijtWxLJDGu2ICsKGZpEzGSaeS6jP8VAD5yVYttGfWtD4a+bL8V/DDFztF4nH51mRwT3LYc4Wul+GdvFB8TfDYDZb7Wnf60Afe9FFFAEdx/qJP8AdNfmj8Qv+R51z/r7k/nX6XXH+ok/3TX5ofEL/keNc/6+5P50Ac/S55602igCTzCPenQlTJmQ8VDRQBpTRW7KCMj3FQeS8WHA3x0W1z5Y8twGjPWrMZZdzWvzxnqp7UAQMIZz+6/duPWmpaSSPyRj1FPKxTH51MbVGvmxy7FLY7UAaiNLZRfL84x0qo2q3Aclfl9jUrLM6gOCD/OnXEdu0Q8wEOB2oAWLWmCYlRWzUN1dbiGijYL9OKfYWMFzyrdK0WtzGNigMo7YoAyIJXMqvE2G7qa27dnYqxJWp9P0bzmDhMH1rdi0V1A3rke1AGdnIABzmh9AkuAJVYZ7Vp3NjGidCpFY11qlzZZWEFhQA5rWW3+S4Ace9V5LaAcooDVQmv7i/wA72MbCqsN3KsvlS5J/vUAP1hLlouQPLFZcMsCpiSIMfWt6Z3eFlcgriubcYdhjvQBLJsZg1upHtUxu5gm14+PUiqiOydDinvcSMMEg0ARyNu5xg0ylpKACncU2lFAE8SwMh3swao0Kq3zDIpqgk8DNKAS+O9AFgywbcLCN3rU8TTxJuREC1Xjs5pPugVcjsb4rsAyKAM6VzLIS3BqzDPLDHwy4HvUo0q4SQedGdtMv1ijAVQd1AETXTM2XHHqKe7hsSREbhUVvLhgGVce4oeRRKTGBigCaW8nkjwQR71BFNLnbu/OhpZHGOce1S27wxr86FifWgB7LJH+8E659M05Jr2VMrJxVq1W2uOwH1qxNbpCv7s7j7UAZ8N7JC+2YE/hVgyyXDDbGwjPXii0SR5S00YwOlS3V9GmY1bbQAnmWVshCwF5PpWe7pLIWNuR9BUlvALhzicLU8kaW0ZVpw2aAMyVwG+RdtNM8h4JqdTbpuZiZDSxSRyZURgGgCm3JznmpIYXlztwMetWY3toVYOhZ6rPISeOF7YoAWSIR/wAYzUPQ0uCabQA8nIpoooFACqhbpTmUrwRTQxB4pztuXJbn0oAaM5461Zt7Gac/KMD1NNt5SoASMM3rWhFbXM43yzCFewFAEsWkwxIHuJcn0FJHp4uLkFCFjWoXQRyYMpb8a0YJ/Li+RCfegC3c3MNhBiNC7AVkRalc3E2cAJ7028vGU4KZzVWV5WgyV2p6CgDQu9akjQxwt83citv4PS3EvxU8NM7Mf9NTOa5G0jQHfIPlrufhBMJPih4bEUeFF4nJ/GgD9DqKKKAI7j/USf7pr80PiF/yPGuf9fcn86/S+4/1En+6a/ND4hf8jxrn/X3J/OgDnqKKKAFFSLGGXIPNRg47UA4oADkGpIJWifKnFRU5Bk44oA2AUuUByC3pV2yVMhJFFYkMEsZV05HfFaqFHx82HoA34bKORNvFVNQ0wopwAVrJj1aaym2NytaD6rJKodeV7igCrFbNAcxIRVqKcA4mGCKuWV7bzRkNw49ap3wiuDsU4agDpdFnUgBeRWwl+1rMC8ZMfriuP0SY2TBX+7611g1G1nhCMQPrQBemv7C6GJIwCe+KpSaXp0hLI4XPXIrE1AKCTDJiqL3ciRlSxPvmgC1quhWwYtDKCfasOa2ELcpk1ZQXMh3K+R9aS5nMMeZACRQBlT2kk7YDlagk0OVVLLIG9s1PPq6MhKgBhxVS31h0z5i59xQBRnt5IGIkWoKt3V687HPQ+tVDzQAUlFFABS0lFADlYqcqcVahtHuE3huap1NHO8YwjECgDSsI3hk8tup966W2j2qDkD8a5CO8beCV3NW3aeZcKN29B70Aal1cR7cMc1jXdjFcHcmc1f8AsyRjc75HvUTX0CghApIoAw7m0it1O45PpmqBI5wKv388cspJU/hVcXCL92JT9aAGxyTKPl6fSla6lYbcgfhUxul8vaUx9KqsyY+UHdQAvzRMGz+RrWs7xCvTB96xWYsRmgMQep/CgDSu7+dZCFwBWfJI0jZbrTWYsckk0JjcM8UAT20hjPAbJ6VHPvLFpAcn1qwt4yHCohx3qCeZ5Wy5/AUARk8DFKAc8A5qZZY0A2plvekEjSSgLhaAFjtpJBk8U42xVTuzWpHJFHHjO9vaqN287j/VkL2oAoY5oI545owc89akhhaRsdBQBGeOKADV8xWsa4ZiWqmy7m/dBsUANRC7YHWr1vY5IMrDPpVMFkOB96r9pZzviR2IB7GgC7FZRKw2daffKlvBln3P2qMRz9FO33rJvFkEuHfefagC1poR5S8zA+1a7yrtwijaO9cwVZCCODU6SzyLt34FAGlc3ESjnBNZc90zn5eKRreU5OCR61CRigB0chQ5xmu3+EF28nxR8MDgD7bGOK4XNdl8G/8AkqXhj/r9j/nQB+kNFFFAEdx/qJP901+aHxC/5HjXP+vuT+dfpfcf6iT/AHTX5ofEL/keNc/6+5P50Ac9RRRQAUUtTQCMnEpwKAIKUVoHT9y7oXVx6VSljeM4dSKAJbeaYHajce9JM8qyZJwfaohxypOacEZiCVY++KALcFtNdAE8iteCxmSPCqTSaWFhQFX/AANdBaXUbDDEZoAwFTySfMiZT61jXkjRXReJ29a7+QeYhzFvT2FYd9ZwvnEJUfSgDHt9ZkCbHXdU8Ooz+bll+Wqt5YbRmFTuq3pULOuJUyRQBp/bo2j+dsEisq8efkwSAqferl7ZRPGTJlSOlc65MMp8tyVBoAvQXF8h+R/wpLzULt1KzLxS/PPCHhK7vSq88s6riRFoApHrkjrSGgnJzSUAFFFFABRRRQAUUUUAFFFFAE9tMIWDbcmtqDXgABJGB9KwYyAcsMirDSwFcLFzQBrPqUN0SrEqtVXhtUBZXz+NZbcngYptAE8ihpPlbikaNVHD81DSUAOJptFFABRRRQAUUUq9RxmgB8a7jgnAp8yRqMI+404SCP8A5ZDmq7dc4xmgCSMJj56VxFkbc4qGigB+SD8pNPErnhpDioacoyeTigCyrW68nLGpHvvlwkYFVWVQPlbJqOgBzHccnrWpBNAkS8gGskc/WrMVrK+Ds4oAkmhaabdApI9a04Ga3hDXTDA6Cs2S4mth5a4UVVlkkk5di1AGjPfvckxR/KvrUO2GFT5hLSGptNWEpk4LUzUGVT8hAoAoSHLHrTc+hNTCSMDJTLetQucnIGKAJvtEnl7N3y1C1JSUALXY/Bv/AJKl4Y/6/o/51xtdl8G/+SpeGP8Ar+j/AJ0AfpFRRRQBHcf6iT/dNfmh8Qv+R41z/r7k/nX6X3H+ok/3TX5ofEL/AJHjXP8Ar7k/nQBz1FFFABS0lFAD1kZPuMV+hp8k8kigOc471DTgcA0AWLSdYnG9Aw710ljc2bYOFwexrkqUMR0JFAHoBsrOePdCwDHsDVSOBoHIZSQK5K2vbi3cNHIc+ma3LXxL0W6iDD+8KAOhttR8gYH5Uy51GOT7ygH6VhtqlrM+VJX61Y+0LKgCKD6GgDVQRzpgqMHuBQtn5T7ohn2rKTUpLdgGibb9K0bXV4pCNwxQBJMkUqlZE5rFu9LjViyDg9RXQyKko3R4z1rKu5JhuXbkUAc9PZiIkrIyewrOmLbsFy341r3cF1L91RjvzUP9jyFc7sfWgDKoxUtxC8D7XqI9KAEooooAKKKKACiiigAooooAWgHHSkooAXNWEdFh+7lqrUtAAaSlpKACiiigAooooAKUHBzSUUAOLkjB5oA3dOtNpR7UABGOtJSn3pKAClBpKKAFFJRT1AxzQAsLKsgLDIrRfUY1QCNTn61mfypPxoAkmlMrZNM3U2igBVYqeDilLEnJOabRQApOaCeKSigAooooAK7L4N/8lS8Mf9f0f8642uy+Df8AyVLwx/1/R/zoA/SKiiigCO4/1En+6a/ND4hf8jxrn/X3J/Ov0vuP9RJ/umvzQ+IX/I8a5/19yfzoA56iiigAooooAKKKKACiiigAooooAKmjmkTb5bsCKhpaANJNUuBjftcehqSDVFV8yRflWTk0ZoA6JNeROFDD605tVEw4cD61zZOaKANq4lkKFo5VqmmpXCjBO6qW44xk4ptAFm5uTOPmHNV+cUZpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArsvg3/yVLwx/1/R/zrja7L4N/wDJUvDH/X9H/OgD9IqKKKAI7j/USf7pr80PiF/yPGuf9fcn86/S+4/1En+6a/ND4hf8jxrn/X3J/OgDnqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArsvg3/yVLwx/1/R/zrja7L4N/wDJUvDH/X9H/OgD9IqKKKAIrk4gk/3TX5o/EDnxtrhP/P3J/Ov0xkXepU9CMV5ff/AvwVf31xeXFjK087mRz5nUmgD8/uKOK++/+FA+Bf8Anwl/7+Uf8KB8C/8APhL/AN/KAPgTijivvv8A4UD4F/58Jf8Av5R/woHwL/z4S/8AfygD4E4o4r77/wCFA+Bf+fCX/v5R/wAKB8C/8+Ev/fygD4E4o4r77/4UD4F/58Jf+/lH/CgfAv8Az4S/9/KAPgTijivvv/hQPgX/AJ8Jf+/lH/CgfAv/AD4S/wDfygD4E4o4r77/AOFA+Bf+fCX/AL+Uf8KB8C/8+Ev/AH8oA+BOKOK++/8AhQPgX/nwl/7+Uf8ACgfAv/PhL/38oA+BOKOK++/+FA+Bf+fCX/v5R/woHwL/AM+Ev/fygD4E4o4r77/4UD4F/wCfCX/v5R/woHwL/wA+Ev8A38oA+BOKOK++/wDhQPgX/nwl/wC/lH/CgfAv/PhL/wB/KAPgTijivvv/AIUD4F/58Jf+/lH/AAoHwL/z4S/9/KAPgTijivvv/hQPgX/nwl/7+Uf8KB8C/wDPhL/38oA+BOKOK++/+FA+Bf8Anwl/7+Uf8KB8C/8APhL/AN/KAPgTijivvv8A4UD4F/58Jf8Av5R/woHwL/z4S/8AfygD4E4o4r77/wCFA+Bf+fCX/v5R/wAKB8C/8+Ev/fygD4E4o4r77/4UD4F/58Jf+/lH/CgfAv8Az4S/9/KAPgTijivvv/hQPgX/AJ8Jf+/lH/CgfAv/AD4S/wDfygD4E4o4r77/AOFA+Bf+fCX/AL+Uf8KB8C/8+Ev/AH8oA+BOKOK++/8AhQPgX/nwl/7+Uf8ACgfAv/PhL/38oA+BOKOK++/+FA+Bf+fCX/v5R/woHwL/AM+Ev/fygD4E4o4r77/4UD4F/wCfCX/v5R/woHwL/wA+Ev8A38oA+BOKOK++/wDhQPgX/nwl/wC/lH/CgfAv/PhL/wB/KAPgTijivvv/AIUD4F/58Jf+/lH/AAoHwL/z4S/9/KAPgTijivvv/hQPgX/nwl/7+Uf8KB8C/wDPhL/38oA+BOKOK++/+FA+Bf8Anwl/7+Uf8KB8C/8APhL/AN/KAPgTijivvv8A4UD4F/58Jf8Av5R/woHwL/z4S/8AfygD4E4o4r77/wCFA+Bf+fCX/v5R/wAKB8C/8+Ev/fygD4E4o4r77/4UD4F/58Jf+/lH/CgfAv8Az4S/9/KAPgTijivvv/hQPgX/AJ8Jf+/lH/CgfAv/AD4S/wDfygD4E4rsfg4QPil4YycD7dH/ADr7K/4UD4F/58Jf+/lXNG+CXg3SNWtNRs7KRbm1kEsbF84YUAemUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Theca lutein cysts associated with a complete hydatidiform mole: Ultrasound shows bilateral theca lutein cysts associated with complete molar pregnancy. Image showing 6.5 x 3.8 x 3.7 cm left ovarian cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39540=[""].join("\n");
var outline_f38_39_39540=null;
var title_f38_39_39541="Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information";
var content_f38_39_39541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/38/18021?source=see_link\">",
"    see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/10/25765?source=see_link\">",
"    see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Donnatal Extentabs&reg;;",
"     </li>",
"     <li>",
"      Donnatal&reg;;",
"     </li>",
"     <li>",
"      Hyonatol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F181293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent;",
"     </li>",
"     <li>",
"      Antispasmodic Agent, Gastrointestinal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F181280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Spasmolytic: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release: 1-2 tablets or 5-10 mL of elixir 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release: One tablet every 12 hours; may increase to 1 tablet every 8 hours if needed",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F181288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/10/25765?source=see_link\">",
"      see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Spasmolytic:",
"     </b>",
"     Children &ge;2 years: Oral: Elixir: To be given every 4-6 hours; initial dose based on weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     9.1 kg: 1 mL every 4 hours",
"     <b>",
"      or",
"     </b>",
"     1.5 mL every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     13.6 kg: 1.5 mL every 4 hours",
"     <b>",
"      or",
"     </b>",
"     2 mL every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     22.7 kg: 2.5 mL every 4 hours",
"     <b>",
"      or",
"     </b>",
"     3.75 mL every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     34 kg: 3.75 mL every 4 hours",
"     <b>",
"      or",
"     </b>",
"     5 mL every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     45.4 kg: 5 mL every 4 hours",
"     <b>",
"      or",
"     </b>",
"     7.5 mL every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F181281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal&reg;: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL) [contains ethanol &lt;23.8%; citrus flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal&reg;: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL) [contains ethanol &lt;23.8%; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal&reg;: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyonatol: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal Extentabs&reg;: Hyoscyamine sulfate 0.3111 mg, atropine sulfate 0.0582 mg, scopolamine hydrobromide 0.0195 mg, and phenobarbital 48.6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Elixir, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F181267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush extended release tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F181266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in treatment of irritable bowel syndrome, acute enterocolitis, duodenal ulcer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Donnatal&reg; may be confused with Donnagel, Donnatal Extentabs&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F181291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, excitement, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lactation suppressed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloating, constipation, nausea, taste loss, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cycloplegia, mydriasis, ocular tension increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (may be severe), anaphylaxis, sweating decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F181269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hyoscyamine, atropine, scopolamine, phenobarbital, or any component of the formulation; narrow-angle glaucoma; GI and GU obstruction; myasthenia gravis; paralytic ileus; intestinal atony; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis (especially complicated by toxic megacolon); hiatal hernia associated with reflux esophagitis; acute intermittent porphyria; restlessness and/or excitement caused by phenobarbital",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F181255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: May be a sign of incomplete intestinal obstruction; use caution in patients with ileostomy or colostomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heat prostration: May occur in the presence of increased environmental temperature; use caution in hot weather and/or exercise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with coronary artery disease, arrhythmias, tachycardia, heart failure, or hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric ulcer treatment: Use of anticholinergics in gastric ulcer treatment may cause a delay in gastric emptying due to antral statis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: Use with caution in patients with autonomic neuropathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patients on anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to potent anticholinergic effects and uncertain effectiveness (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use has not been shown to prevent or treat duodenal ulcers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Should not be discontinued abruptly because of the possibility of increased seizure frequency (due to phenobarbital component); therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F14326878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with this combination have not been done; refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F181284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14326102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F181270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Donnatal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.2 mg/5 mL (120 mL): $111.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Donnatal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.2 mg (100): $445.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Donnatal (ZA);",
"     </li>",
"     <li>",
"      Donnatal Ekixir (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F181254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic agents (hyoscyamine, atropine, and scopolamine) inhibit the muscarinic actions of acetylcholine at the postganglionic parasympathetic neuroeffector sites including smooth muscle, secretory glands, and CNS sites; specific anticholinergic responses are dose-related.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39541/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8546 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C2D6B77659-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39541=[""].join("\n");
var outline_f38_39_39541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181293\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181280\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181288\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181281\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181264\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181251\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181267\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181266\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181300\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181291\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181269\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181255\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181289\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181260\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14326878\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181261\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181284\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14326102\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181270\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961919\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181254\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/38/18021?source=related_link\">",
"      Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/10/25765?source=related_link\">",
"      Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_39_39542="Daptomycin: Pediatric drug information";
var content_f38_39_39542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Daptomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"    see \"Daptomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/60/11204?source=see_link\">",
"    see \"Daptomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cubicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6127324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cubicin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1007590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cyclic Lipopeptide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F14783735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gram-positive infection, severe:",
"     </b>",
"     Very limited data available: PMA &ge;32 weeks: I.V.: 6 mg/kg/dose every 12 hours for 10-14 days was used in two neonates [patient age: PMA 32 weeks (PNA: 8 weeks) and PMA: 35 weeks (PNA: 3 weeks)] with normal renal function (Cohen-Wolkowiez, 2008). A pharmacokinetic study of 20 neonates and infants [GA: Median: 32 weeks (range: 23-40 weeks); PNA: Median: 3 days (range: 1-85 days)] evaluated a single 6 mg/kg dose and reported median AUC exposure ~60% of that achieved in adults with standard adult dosing and a faster clearance than adults and adolescents (Cohen-Wolkowiez, 2012). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Data limited to a single case report: A full-term neonate (PNA: 41 days) with decreased renal function (S",
"     <sub>",
"      cr",
"     </sub>",
"     : 0.9 mg/dL), an initial dose of 4 mg/kg/dose every 48 hours was used and increased to 6 mg/kg/dose every 36 hours upon a decrease in serum creatinine (S",
"     <sub>",
"      cr",
"     </sub>",
"     : 0.6 mg/dL) and daptomycin serum concentration evaluation which showed a subtherapeutic peak value (Beneri, 2008).  Further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1007622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"      see \"Daptomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      General dosing, susceptible organisms (severe infection):",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 2-6 years: I.V.: 8-10 mg/kg/dose once daily (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012); in a pharmacokinetic study of 12 children (age: 2-6 years) dosages presented showed similar serum concentrations to standard adult doses (4-6 mg/kg) (Abdel-Rahman, 2011;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;6 years to &lt;12 years: I.V.: 7 mg/kg/dose once daily (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents: I.V.: 4-6 mg/kg/dose once daily  (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      MRSA Infection:",
"     </b>",
"     Limited data available (Lui, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Bacteremia:",
"     </b>",
"     Children and Adolescents: I.V.: 6-10 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Endocarditis, infective (prosthetic valve):",
"     </b>",
"     Children and Adolescents: I.V.: 6-10 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Osteomyeolitis, or septic arthritis:",
"     </b>",
"     Children and Adolescents: I.V.: 6-10 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     IDSA guidelines state  ongoing pediatric daptomycin clinical trials focus on an inverse relationship between age and required per kg dose; the following daily doses are under investigation in children and adolescents (Clinicaltrials.gov NCT 00711802)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 2-6 years: I.V.: 9 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children: 7-11 years: I.V.: 7 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children and Adolescents 12-17 years: I.V.: 5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Skin and/or skin structure infections (complicated):",
"     </b>",
"     I.V.: 4 mg/kg/dose once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bacteremia, right-sided native valve endocarditis caused by MSSA or MRSA:",
"     </b>",
"     I.V.: 6 mg/kg/dose once daily for 2-6 weeks [some experts recommend 8-10 mg/kg once daily for complicated bacteremia or infective endocarditis (Liu, 2011)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;2 years and Adolescents: The following dosage adjustments have been recommended (Aronoff, 2007): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &gt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 67% of a full dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 67% of a full dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis: Administer 67% of a full dose every 48 hours after dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis: Administer 67% of a full dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Skin and soft tissue infections: 4 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Staphylococcal bacteremia: 6 mg/kg/dose every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Intermittent hemodialysis or peritoneal dialysis (PD): Dose as in Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute (administer after hemodialysis on dialysis days)",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) may administer 6 mg/kg/dose after hemodialysis 3 times weekly (Salama, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     High permeability intermittent hemodialysis removes ~50% during a 4-hour session (Salama, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Continuous veno-venous hemodialysis (CVVHD): 8 mg/kg/dose every 48 hours (Vilay, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     For other forms of CRRT (eg, CVVH or CVVHDF), dosing as with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute may result in low C",
"     <sub>",
"      max",
"     </sub>",
"     . May consider 4-6 mg/kg/dose every 24 hours (or 8 mg/kg every 48 hours) depending on site or severity of infection or if not responding to standard dosing; therapeutic drug monitoring and/or more frequent serum CPK levels may be necessary (Heintz, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Slow extended daily dialysis (or extended dialysis): 6 mg/kg/dose every 24 hours (Kielstein, 2010).",
"     <b>",
"      Note:",
"     </b>",
"     Dialysis should be initiated within 8 hours of administering daptomycin dose to avoid dose accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No adjustment required for mild-to-moderate impairment (Child-Pugh Class A or B); not evaluated in severe hepatic impairment (Child-Pugh Class C)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cubicin&reg;: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1007626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Reconstitute vial with 10 mL NS by gently rotating vial to wet powder; allow vial to stand for 10 minutes, then gently swirl to obtain completely reconstituted solution. Do not shake or agitate vial vigorously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neonates: Dilution information has not been reported; infuse over 60 minutes (Cohen-Wolkowiez, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2-6 years: Further dilute in 25 mL of NS and infuse over 60 minutes (Abdel-Rahman, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents 7-17 years: Further dilute in 50 mL of NS and infuse over 30 minutes (Abdel-Rahman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: May administer I.V. push over 2 minutes at a final concentration of 50 mg/mL or infuse IVPB over 30 minutes at a final concentration not to exceed 20 mg/mL",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not use in conjunction with ReadyMED&reg; elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) which leaches from the pump system into the daptomycin solution.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F1007613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible in NS or LR;",
"     <b>",
"      incompatible",
"     </b>",
"     in dextrose-containing solutions",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1007609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); may also be stored at room temperature for up to 12 months [data on file (Cubist Pharmaceuticals, 2011)]. However, the manufacturer recommends storage under refrigeration. Room temperature stability information should only be utilized in situations where the drug has been inadvertently exposed to prolonged room temperature. Reconstituted solution (either in vial or in infusion bag) is stable for a cumulative time of 12 hours at room temperature and 48 hours if refrigerated [2&deg;C to 8&deg;C (36&deg;F to 46&deg;F)]. Daptomycin is incompatible with dextrose-containing solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1007591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of complicated skin and skin structure infections caused by susceptible aerobic gram-positive organisms including",
"     <i>",
"      S. aureus",
"     </i>",
"     [methicillin-susceptible",
"     <i>",
"      Staph. aureus",
"     </i>",
"     (MSSA) and methicillin-resistant",
"     <i>",
"      Staph. aureus",
"     </i>",
"     (MRSA)],",
"     <i>",
"      S. pyogenes",
"     </i>",
"     ,",
"     <i>",
"      S. agalactiae",
"     </i>",
"     ,",
"     <i>",
"      S. dysgalactiae",
"     </i>",
"     , and",
"     <i>",
"      E. faecalis",
"     </i>",
"     (FDA approved in ages &ge;18 years). Treatment of",
"     <i>",
"      S. aureus",
"     </i>",
"     bacteremia, including right-sided infective endocarditis caused by MSSA or MRSA (FDA approved in ages &ge;18 years). Daptomycin is active against bacteria resistant to methicillin, vancomycin, and linezolid.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3265806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cubicin&reg; may be confused with Cleocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DAPTOmycin may be confused with DACTINomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F156940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hypertension, hypotension, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia, hyperphosphatemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, GI hemorrhage, loose stool, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, eosinophilia, INR increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, CPK increased, limb pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonia, pharyngolaryngeal pain, pleural effusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacteremia, diaphoresis, infection (fungal), osteomyelitis, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, atrial fibrillation, atrial flutter, candidal infection, cardiac arrest,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD), coma (post anaesthesia/surgery), eczema, eosinophilic pneumonia, hallucination, hypomagnesemia, hypersensitivity, hypoesthesia, jaundice, LDH increased, lymphadenopathy, mental status change, oral candidiasis, oral hypoesthesia, osteomyelitis, peripheral neuropathy, proteinuria, prothrombin time prolonged, renal impairment, rhabdomyolysis, serum bicarbonate increased, Stevens-Johnson syndrome, stomatitis, supraventricular arrhythmia, thrombocytopenia, thrombocythemia, vaginal candidiasis, vertigo, vesiculobullous rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1007596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to daptomycin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6092225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment required in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Limited data (eg, subgroup analysis) from complicated skin and soft tissue infections and endocarditis trials suggest possibly reduced clinical efficacy (relative to comparators) in patients with baseline moderate renal impairment (&lt;50 mL/minute).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1007597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity reactions and anaphylaxis have been reported with use; discontinue use immediately with signs/symptoms of hypersensitivity and initiate appropriate treatment. May be associated with an increased incidence of myopathy; discontinue daptomycin in patients with unexplained signs and symptoms of myopathy in conjunction with CPK elevation &gt;5 times ULN or &gt;1000 units/L or in asymptomatic patients who have CPK elevations &ge;10 x ULN. Myopathy may occur more frequently when daptomycin dose and/or frequency exceeds the recommended dose. Symptoms suggestive of peripheral neuropathy have been observed with treatment; monitor for new-onset or worsening neuropathy. Use with caution in patients receiving other drugs associated with myopathy and rhabdomyolysis (eg, HMG-CoA reductase inhibitors); monitor CPK levels; consider temporarily suspending the use of HMG-CoA reductase inhibitors in patients receiving daptomycin. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea and pseudomembranous colitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Eosinophilic pneumonia, a rare condition of eosinophil accumulation in the lungs with typical pneumonia presentation that if left unrecognized or treated may lead to respiratory failure, has been reported with use; generally develops 2-4 weeks after therapy initiation. Monitor for signs and symptoms of eosinophilic pneumonia, including new onset or worsening fever, dyspnea, difficulty breathing, new infiltrates on chest imaging studies, and/or &gt;25% eosinophils present in bronchoalveolar lavage; discontinue use immediately with signs/symptoms of eosinophilic pneumonia and initiate appropriate treatment (ie, corticosteroids); may reoccur with re-exposure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Daptomycin is not indicated for treatment of pneumonia due to its inactivation by pulmonary surfactant and its poor lung penetration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Successful use of daptomycin during the second and third trimesters of pregnancy has been described; however, only limited information is available from case reports.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1007628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of myopathy (muscle pain or weakness, particularly of the distal extremities), weekly CPK levels during therapy (more frequent monitoring if history of current or prior statin therapy and/or renal impairment), signs of peripheral neuropathy; observe for changes in bowel frequency; monitor renal function periodically",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1007616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough concentrations at steady-state:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/kg once daily: 5.9 &plusmn; 1.6 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/kg once daily: 6.7 &plusmn; 1.6 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Trough concentrations are not predictive of efficacy/toxicity. Daptomycin exhibits concentration-dependent bactericidal activity, so C",
"     <sub>",
"      max",
"     </sub>",
"     :MIC ratios may be a more useful parameter.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1007614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daptomycin binds to cell membrane components of susceptible organisms causing rapid depolarization by calcium-dependent insertion, inhibiting intracellular synthesis of DNA, RNA, and protein resulting in bacterial cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1007617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates and Infants &lt;3 months: Median: 0.21 L/kg (range: 0.11-0.34 L/kg) (Cohen-Wolkowiez, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years: 0.14 L/kg (Abdel-Rahman, 2008; Abdel-Rahman, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 7-17 years: 0.11 &plusmn; 0.02 L/kg (Abdel-Rahman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.1 L/kg; Critically ill: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 0.23 &plusmn; 0.14 L/kg (Vilay, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90% to 93%;  patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): 84% to 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minor amounts of oxidative metabolites have been detected; does not induce or inhibit cytochrome P450 enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates and Infants &lt;3 months: Median: 6.2 hours (range: 3.7-9 hours) (Cohen-Wolkowiez, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-6 years:  Mean range: 5.3-5.7 hours (Abdel-Rahman, 2008; Abdel-Rahman, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 7-11 years: 5.6 &plusmn; 2.2 hours (Abdel-Rahman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 12-17 years: 6.7 &plusmn; 2.2 hours (Abdel-Rahman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 8-9 hours; prolonged with renal impairment up to 28 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 78% of the dose excreted in urine primarily as unchanged drug; feces (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates and Infants &lt;3 months: Median: 21 mL/hour/kg (range: 16-34 mL/hour/kg) (Cohen-Wolkowiez, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-6 years: 19-20 mL/hour/kg (Abdel-Rahman, 2008; Abdel-Rahman, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 7-11 years: 17 mL/hour/kg (Abdel-Rahman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 12-17 years: 11 mL/hour/kg (Abdel-Rahman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 8.3-9 mL/hour/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 15% removed by 4-hour hemodialysis session;  high permeability intermittent hemodialysis removes ~50% during a 4-hour session (Salama, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1007631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/60/11204?source=see_link\">",
"      see \"Daptomycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report immediately any burning, pain, or redness at infusion site; any throat tightness, respiratory difficulty, or chest tightness. Inform physician if muscle pain, weakness, peripheral neuropathy, persistent diarrhea,  or if new or worsening fever, cough, shortness of breath, or difficulty breathing occurs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdel-Rahman SM, Benziger DP, Jacobs RF, et al, \"Single-Dose Pharmacokinetics of Daptomycin in Children With Suspected or Proved Gram-Positive Infections,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2008, 27(4):330-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/18316988/pubmed\" id=\"18316988\" target=\"_blank\">",
"        18316988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abdel-Rahman SM, Chandorkar G, Akins RL, et al, \"Single-Dose Pharmacokinetics and Tolerability of Daptomycin 8 to 10 mg/kg in Children Aged 2 to 6 Years With Suspected or Proved Gram-Positive Infections,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2011, 30(8):712-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/21317681/pubmed\" id=\"21317681\" target=\"_blank\">",
"        21317681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ardura MI, Mej&iacute;as A, Katz KS, et al, \"Daptomycin Therapy for Invasive Gram-Positive Bacterial Infections in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2007, 26(12):1128-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/18043450/pubmed\" id=\"18043450\" target=\"_blank\">",
"        18043450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beneri CA, Nicolau DP, Seiden HS, et al, \"Successful Treatment of a Neonate With Persistent Vancomycin-Resistant Enterococcal Bacteremia With a Daptomycin-Containing Regimen,\"",
"      <i>",
"       Infect Drug Resist",
"      </i>",
"      , 2008, 1:9-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/21694874/pubmed\" id=\"21694874\" target=\"_blank\">",
"        21694874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al, \"Daptomycin Use in Infants: Report of Two Cases With Peak and Trough Drug Concentrations,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 2008, 28(3):233-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/18309318/pubmed\" id=\"18309318\" target=\"_blank\">",
"        18309318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen-Wolkowiez M, Watt KM, Hornik CP, et al, \"Pharmacokinetics and Tolerability of Single-Dose Daptomycin in Young Infants,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kielstein JT, Eugbers C, Bode-Boeger SM, et al, &ldquo;Dosing of Daptomycin in Intensive Care Unit Patients With Acute Kidney Injury Undergoing Extended Dialysis &ndash; A Pharmacokinetic Study,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2010, 25(5):1537-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/20031929/pubmed\" id=\"20031929\" target=\"_blank\">",
"        20031929",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NCT00711802, &ldquo;Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years) With Skin and Skin Structure Infections,&rdquo; Unpublished data. Available at",
"      <a href=\"file://clinicaltrials.gov/ct2/show/NCT00711802?term=NCT+00711802&amp;amp;rank=1%20\" target=\"_blank\">",
"       file://clinicaltrials.gov/ct2/show/NCT00711802?term=NCT+00711802&amp;rank=1",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salama NN, Segal JH, Churchwell MD, et al, &ldquo;Single-Dose Daptomycin Pharmacokinetics in Chronic Haemodialysis Patients,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2010, 25(4):1279-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/20007981/pubmed\" id=\"20007981\" target=\"_blank\">",
"        20007981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vilay MA, Grio M, DePestel DD, et al, &ldquo;Daptomycin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(1):19-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/39/39542/abstract-text/20890189/pubmed\" id=\"20890189\" target=\"_blank\">",
"        20890189",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13009 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39542=[""].join("\n");
var outline_f38_39_39542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156919\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6127324\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007590\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14783735\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007622\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156900\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156888\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007626\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007613\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007609\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007591\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3265806\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156940\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007596\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6092225\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007597\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299126\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156894\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156896\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156909\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007628\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007616\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007614\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007617\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1007631\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13009|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=related_link\">",
"      Daptomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?10/60/11204?source=related_link\">",
"      Daptomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_39_39543="SLE Membranous EM";
var content_f38_39_39543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph showing membranous lupus nephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 234px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADqAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBPCfwH8IanZxPc3F+ZpFBCiUAg98jFaI/Z68KJeNCGvZmGCR54GB+VaniWW98DIbgSyO8LBAAP9YPWuh8F+IotfurJtQzFJcxbyqnHAPFAHnGv/BDwdYNbBRqKGZsYMucfpUvh34AeHbm/xefavsqjDMZdvPbFfQGqafZaxDb+Ww3RPxx+GKrapfWkMUdvLGdwO0kccDNAHl+p/Af4f2SCVLO6kiUqH/0kk81i+Nvgb4SsdLhudLsbjefmdTOxOMZr2rTJhqcV5AI9luAoSTGO3H5VieM9Nli0gCadkiQZEq5JLHj+tAHjui/CLwlcm3laxaRREGkh89g2Sf8APFdBo/wL8GXWruZbYG1wCIlmbOemOuaoaTofiAamxSS4Rs7Vk7S/X2rq4fDXipYorvTJY4biIlGUnIf3oAyvE3wf+Huhgu+mABlKhWmYn2YDNYNj8MfA+ouxi0sAMCECSNx+vWuss/B99feIY7vxjq5nlRuEQ4RT1ANehRS+H9JKRyy20TyHA+YCgD5Q1f4c6dFeRIloIU3NuUEkhQe9bmg/D/wyupi3utO81GYKHLFh0ya7jxBeJ4p8az6donyQwpi5lI4cZ6Ct670SDSLCe9sikcyKEzI2c4GMgUAcDfeD/C25bHRvDUN4wl5nIPC9xnP1rkfEfhTQtH1HyfsEBSUExqVJYexr3H4aTRtoM8rQ7rneynPv3FeX/Etpn1yWREEbNtEjEfxY7fWgC/4csvBH9hXM13oNjs8sxI5jyxcDkitv4ceEND1OxW5ufD+ly2xDeU/kDc6juRXlmkaiReRadqkZWyncEZGCM46ele9eErO00fw83kzuGiB8hSckDHWgDpbT4ceD5GUjw3p2SASfs4Gfw7VQvvAWg/2m1wnhvSlsIzgAW65OOtT6f4qnkmt0LRgOMtg42DoSa7e0ul8jyyoMJG1XzncTQBwF54H8P3jpbW+haXC2PMcC3QNjsOBwKvapoXhnTEigTw5pHmKuTI1ugA/TmsLxr41fwxrK3MsCtIR5JGcZTrn61Ti8X32vSR3Wm6dHLOBtMTNlcf48UAbv/COaFexQTT6LpFuJSURVtlw3oTxWF4w8JeGL24jt7qxsLW8tk8zZFEo3KPXj2qt4e8fDUvEQtNZs/skls2RAy85ANegxxaVq1/clxFJcPEdxA5A9KAItC8O+H7HQUR9NsHyhZ3MS7vUdq8j1DTru58SR22m2FoEnJXzFjGMDt0xmu+dXuZpdOspilpEOHdj19PpVjwlpsUVwZhONkeSxHILHjNAGt4Z8IaPo0bXRsLd7l1AKyIvynHPas7x69stjLJBa2CwRQmQhYxlj6cCotc8XwaPK32i5jMcpKFCOpGcYrzPw7qOq+IL+8dWEVgkmItx+93x9KALHhDxFLDptxcSQ2shlIPzRDK84+UY9KzvHHiPWbGW1XRLQRC5+c5QFW7CrdraXEE8rwJmKOR1mXA2qOeRS2OkXPiKB78zSoR8sUYPAUdxQBPbaj4ju7Y6drF9DAWVjMIIxuAI7Vn6BpOi6Gt2lzA09y3MVxMwZgT2z2rQtvCPiLUbyOG1DqUzvucY4PQGuutPg5LJ5T6hqMjy4ySOimgDzXSYfsz3X2oxhWjbqBwf4QDW1At3runW+iaFcXBgmP79TwAc84Ppiu2f4Ts9ytvI0bwN8xuCTuHPpXoPhfwnp/h63VLVd0g6uwGaAMu28BaevhA6S1tB5jx7S7rnB7n61Y8LeC9C8OTSJaxo15KnzNJyxUcce1b+r6raaTbefeSBVPCjqWPtUPh/VYdaszewx7U3si7h82BQByrfC7SG1Z7sSzJCz7zbpwueuPpmu8iRIY0jjUIigKoHYelP715L8V/E2u+HtWs2svLS0clQ7glVPqaAPV24cHbnrz6CsXxpoS+ItAurBiFdhuib0YdK5L4V+M9R8QXV1Z6kkcnlKGSeEfKRzwfyr0S4uILcB55Y4xnGWIFAHkmifDfU9SuN3iK7ZLaL5VijPLfj6VuzfCjRnCeVcXcYA+YB8hq7V9Z01G2tf2wbGceYKhi8RaPNdtbRajatcDrGJBmgDmovhppEaOryzyBhtO/B49K4fxR8L77Trn7RoQFzaxjPllsSAf1r2m2vrW6dltp45Sv3tjA4qwR196APm5NL8RG2FnFpV6yBtxZl7+59q7XwN8Orn7ZFqfiHZlWDrb9cn1b/CvXcYpHZUUs5CqOST2oAEUIu1QAPaorq5hs4HnuZUiiUZZnOAK818cfFO001jZ6GUuLsnDTN/q4/x7mvJdd8VarrUoOoX7zxbsCJBhM/QdaAPX/FHxV0+zkEGh7L6Yg5fJCJ9T3rlG+JHiYsSDbjnoI+K5Pw9psM8yyzOpijPzKvUH3FakqWSyuvoxHegDsPDviaz8V6DJa+IrJINUWLeYnGc47ivNJreISrNbz3ljdXEhSNFU7IweODVO3tNe0DxS0zI88wTYSfmBTPX6c16dcTweIPB0+nqEg1KDLp8vOevFAFvQLi48OQLb3F690qfvHnxwvsf8a2bi9huBPdQxfbWdAFVSDkn3/GvH9I1u/s9GuLHViZfMYwvEv3+nBJr1r4c6XBJ4c2Ws7ZY52sMMlAD9IgubXSmFxG8UqEsctu46/j6Vj6d4tl1+G7ttTtWtbaKbyw7/wARFdw0QspUWVg6qrFz1/D864DUrmLTWnjFuGiupO/8PvigCbX/ABSmjZ222+OJMwOOcnv+lczpXxaurOOcvai6gDlw0TZx3xj1qLU7WTX7lIZwIrRFwFzz7EY6VsxeEvCOiaQ6Qxo9xnzMSMdxNAHD6gviz4l37Xs802m6YrKI448gt7mtO28Gw2F9HZX9zLdyOd+ZWy+FI5Ge1N0bxolpr9ykJdLCBfMESjqRxVPxJ8ULnUL6C3h06MPcOEWT7p8s8YB9aAPQrTTtD0Brqa2hLAqFdie5Hf8AOt600HTdYsIpridZUXrzxjHSvN9Nt9TWzvftf7+Ety7MSy+gHrirym8Phu/jtmmRGBZJmbaC3ZaAL/jvSbDwxoN1rOj30kMkXzRojfKxPQY714dqOvS3zSXmpOGknOW3jkehFbfjK51aG0tNL1q73jy9w2njPv71w+oRbJ18wNJHuwF7sMUAWdOlW+8R6ebqVjGJFZi38KgivRPFPi9odUFrpbGTzECocdMjHGOtcDp3h3VtRt5WsbOQJkF5SOAvp9a9Y8M+BrWPTdJnuSzXULh2nH8A64oA7DwlY2MttbCeMSTuBFPjOFbFbfiU32kmJ7KJmgQjEA4yvc5qxDN9nt5Ps1rnbyGxj/gR9ay/F/ja00rwq819G80jqYxhed2KAOQ8VRRahrrTNAJYJBuHmHIQd65+01r+xbuafTAsa5+RRk59x7Vk6z4rudQ8OvLotvJnzNuMZIXHcVf8JxW+teH830CpcQofmwRs96ANG28Sad4q1OBTDFZ67DJ8rEbRcL0K5rpdClvbDVp7Z7Q288j7o2JyCcjqfSvJtV0K7PiTRG0GORm80ShiOVGe59K9t8W37w6X9ocq12pVRtOCrY/kKAI/EMlxpN2q28qzyEbxAoAGMckn0zS+H5podN1K4vXR1mbzUROM8fd/DFZNjcvcPDFzctICZpV6qOuKy9d1efUriPTdGZyzt5QVR0B7/hQBia3qVhrNyw1C3LT4OyKPJIH4dOlWdB0DxJ4heKPTbVrO1QHEh+UD/E1634G+HVjo0CyXsaTTuOSV74r0G3iigTZDGqIOyjAoA8atPhctpYy3XiLVpydpLRROVB4/Wu78AaXaDQbSaOx8hCmER+Tt5rpLywivPlnyVBzirUaqiKijCqMAUAIkaRgiNVUewxTzUFxcQQxsZnULjkGvJfHnxI+xvLBZyAIoxx1JoA9Xury0gTfcTRqqnqWrn7/xjpEMjQvcmPjKuMc47CvmfVfH+pXpMUCM5LfKc5ANZGoHULyULqKuoxvBjzmgD0v4u/EiFtTtW0xlliSNk+8OHJHP5Vynhv4q6/YWYW3mhSJSSUlGd5J68Vx9lp8M9y6yJ51tHh/Mzz7gn14NbsWk2d1FmJGUBsnnOFoA9l8C/FtbyUR67NDE7df4cH8a7y+1nwvqkYF3e2EoKkASOpGK+T7rT7WyaRCxMnUZGcjNR6hGsZjMMYCyZ6jqPWgD6L13x54a8I2L2/h1Le4un4SG2xjPqSK8S8Ua9rGsSvNfXUsmWyY1chF9AB7VlaHYC1ka5hkUPx5Y65NX9ZFwqSl2QyYDb+59aAMhLcumFnCzDvuOfXGa1bKH7RboEJDqeSh5/P1rlpHlMbSuOrYwDyTV20u2ijPlMOSCRnqaAO9068utCuFn0m8aG6U5wPuvjsR3r2LwT8S7TV0jttSCw3o+Viv3Sa+b0uWljcKQZyMYB6Gn2UeqWs6vasQzDIbGcUAfV/iHxroegP5eoXYEuN2xBuP6V5j8Rfira32ky2OjrMBKQGkIxuHoK8hmGpTrdy30krTbss8nLEfWst47oshVJCcjaSOKALU7zSgAqRk5YCrWnzGzicOu1vvIaZDsCNG8hEjDqBUN/CtsiAzee4GODwBjpQBbttVfT72SRHYlidyBsgg/1rRHiwkfxf8AfArnLV3IO+Pcu7BJGdvFXlkwoAgXGPWgD1rQtQgmmuJNRuYiJDswyYLLn1rP8QarZ6P4gsbzQGWS2hcRXRPOFbofesnx54Z1LwzfW7Xt0slu2dsqp39D9a4jUdXmmv7Wys4HT7TKkTeYuA3PagDv/E+s+HdO8X3xuUJkKxNwOCeua6yPx9bwaUZrWNrWNlwWYYLDOAR715Tqksll8RtRgu4Iy0sCKocbsDHWu01vwneXvgo2sTQyMwMiSKcFccgfjQB3Xw28TW2q/bBJNLPJCw3PKMcEVf8AFz6ffvbIzxKu/AcEEnivnvw/4k1LT9GMWlRiPUxmGR3GVYZ70kfiXxTEzPJYiU5EaMEyEOOoFAHp/iSBvD8T3UMgZSpZn4wR6g1wmpWmp+KZorqG4eIr8u1GwD3Ga9B8N+DtW8RaYs+u3TRQuCVgRccY75rh4DLoHjLUNHgcbYdoZm6kZ4x60AZfiHw3cDShqFoJBcEhGt4yc5HB/WtL4diK3RZvE6x+bAGaGFl+ZRXdzQO5urnAijKjCjGc964XX9Sgv45rOBo4LwH5g/BcZxgH3oA3tX8SwpEdNjuUAuU+UhgME1naDqf2GG40i91OG6ifEqRls4Yfw/n/ACrktP8AB9zqunXTiA/aWkzD82dqmsp/C2tW+M2z+bA+0sTtIHrmgDp/Gt1aSBriQG4LHbGB/C9QeA7LT7nUoP7Rt5LhpW27mICL9KzbDwyPOkl1a+EUSsCqh9zbsVpXevw6GtummWBmaJflO3IAzncfegD1H4t6hb+DvAAg0dBFcTMI4hjpn1q98KdUiHhmGy1BlE8aEySNyOozzXm9z4nj8c6S1vqMDNeW4EiqB2Her1r4pXR9B2xWsT78B1yc9MZxQB6J4n1u0itYwLvhn2y+SOSorzP4ieNoLqxj0o2uTt3AqAWQdifrVSDUDezXEswWJNnmowbhQeMGvO9WSaHU7lpZA5lJCuD1FAHT+AZtR0+G+8lIJIZQCd3JwP5V28fiuzsrdLiOzjjMpWOe3ZOTz1ry3w1qcum6hbtCpaRm2uueCp4IIr203el3bw3t/p0MUsEQiLvj73bAoA0tD1bS4NMnuPIM2pM37mEL8yg8Ae1TtoO5bi/1Iu77dxXHyrx0ArF/t7ydFdppbdLuTI3xrkgDpmlvvGPleH7COSbzLpT5ku3jK570APn1i10PSbi1062dZ5F+855JPFdB8KfDyPJJq02DJnanHQ964/RbKTxn4nL20bxWEWHZyPfkV7fNcWGgacqZWOKJeUXlj+FAF3Ub2CwtzNcPtUdPeuR1Px/pen+Y295MjJ9Pwq/4ntJNc0dDCjqSMqp4NeBeNdMurFngmBQnpnpigDvr/wCNduImFtZt5w4Uuwx9a5q5+N2oFWYJEAwONoPHpXjUuZJSiNk5oFlMzOFbOBk7u3NAHZav8QdZ1Z2WGdxkZwOoHeufmuLq+nLzMOOuR+P+Nc7qWoT6QLV7ONRPNcLFlozIdpz0UdTwOO9Xb7VJltIIms5J7uSGS4chPIyqtjlWyQcEUAbFrc26TFLVjvb7xOBn/Cn3Os3TXJiXDW4PTqRXPyPDLaWt1bFyJ41bDDlciprNjFKfMfBUAkAdB60AdNap5Vq+IGWJ8ZGMAtir+nT24Uq0RClcFQe/Y1gTasZLZoIg0hPKqgOR68VQka/KI0MJjXOBk/N+IoAfqKzi4e5f5ljPrxmpLNprq6WbBYk8p2GaqSw3zFvtDAYYblJ6mtPR/toYW9uEJHzncOD7UAXr9JLSwhkQ7FZygXP3T/nFWZZnuLNHcqvyj5D3AqlrUzC3iGoxSpMoJUjlWyetQ2+pRzr5TK0ojG4lQc0AUNViYrBHGCjHL4PTFQ21qRCrg4cZGB0NO1G4muLiNQjAKT8pAG0VPa3ElqT5kIZz0xyAKALulWdwPLneEBM8t68dK6O3mjj2yKWESja5LcE+1c7/AGhqNpbgSQNJCxyo/un1xU+m6lFcxtulAbIOwjqcUAdNfTG4ulRlRYREMgnIdh159s037ZbRusEq5hYg5XqX7/hXPW32m9kdnzJFkkgdz6Cql5Dcp5bKpjjB4+b+dAGxqMMT3cv2cbUJ+UAfMR71ky6c2x5GYohcL16n3rU0dJT/AKZcupUfIoJ6gVZ82TVLlrK1QNLkliBwvNAETW0zWvlbfL2KGK+tZJ0y6Jz8wzXVtpGspp0xjnguc/MVBw4I54qkus3qKFkt13qMNlT1oA9R8ceIbLxDpssLqoJXjP0rx8yXMN3bTXFvG1pbzKyySHleQOK0NT0K/s72W3YzqeRg5Oe3FA0l3to4r1JZIMAsFzk+ooA1fjA9na+KPD2oWA3T3MXlsFPDj0/WsdfFPiOxgcbFSxc7F3nAQg9BVu90rRL++0+Rrm4LxBkEMr/6sY4rG1Tz5ZbWxm/49csC3JJx0+mKANTw+lvdaH5UjRPd3U7FEHUEHk/SvRrCF/Clih1ZPOtUbfG+zOBjua4jwn4esdI1yPVL1ZY7crmJyThCRzxXey6rbXIvY7vN5p0ybImTJxnqMdqAH6F8UNJvNQlt/MEUbcxH19q4nx7ozN4y/wCEi0sLcWqKPNBPIb1rj4vBonc3Vi80RMpCI3B/OvQfhJc+TfXuia2PnYgp5vO72oAYviWObQ0iEO28di7hzx715JDbXOoeKpjcxhUuGJDSHp6c13HjPV7Kx8X31nCqeUx2M6cj6Y9a6qPw3H4m0PbZStYyBQ0LbMk49TQBRm8Q2/hqzi0+ILvBALqeR+NcF4g1TUvFd7cyaXcS+RGMSIOCPeprvwpqElxLYz3iSzRuS2Dy6/U11/hLw7BpGlTz3UUY84YOX6H0oA8wtdB1NreSG3FzOj/fZQQVOOoru/Dup2mlfZtO1S1SS3KCLzV5IJ7tUusLqWm6ROtrNK8rN+7YHgIey/mK17fwwur+EbaaWF4byOEszA7S7DpmgCl4mu7S2iZtHsgtxawnJQhd319RWvF4u8M+I9EhW5hSzuEQbty4IwOQDXFeH/D0+m315caxcqfNVkK7i/BPeo9fv9Pht7e00+1BlG4B2XIOTQARaX52j303noA03mQIzYJTPANUbiHTpNNNvOhe6yMGLnmu6+Hvw2vfErrd60ZI7PACqeMj2r3DRPAnh3Rgn2LTIFkAwXK5J9+aAPlrw94f8vUIm0zT7q5u1+YlwduPyrv7TwJ4j1EJG0AhWUksZSTtNfQ8drBEcxwxqemVUCpSQKAPGD8EoRbRs2qXJuQQZCD8pHcAdq3tK+EegQKrXPn3bj/nu5I+mK9GaWMDlhis2LXdPELNJdRDYxRssOooAWHT7HRrVvscMdugHO0YzXC6vZXGsa/FcmYCJCNu0EjHof0q14q+IPhsF9Plvg+75WaE52+uSOlW/Duv6JJYO1hdwyhVLA7snAFAB428Zaf4W05UuJQ1yE+SMdTXzxr+uXvie9muNQd4rbd+7RP4R71h/EbxPNfeJ7+SRvNzKVjwf4ewFTaRbarcWqNtgiTYOJXwSPpQAkFjFNIY4CVc4xk81HqVq1qF3kMBxgf1/Gm3FpqNrc4ViXCbtw7Cst1upncB5Sep5zk0AWZtN0+5sjHq7rKyOHjCFkKtggYII6ZqveaVo8stsfNkFrBC8PkmR8nc24kvuyR1496wrg3pdlCs5BOSTjFamhWpty094FlY/wAJ5xQBa1K/s44Fjto1jVThdo+UY6AVUsop9QnMVu2IcZdwPur6VsanqEF5LAfsscTghAoQYHvXXWdvBBtS3jiCODuIXAY96AOasI2trXZajy2DABh95sj1p0mHXcQTKACAeg96t3zRLOVRWMa8jHf0FOUMsW7CqpG7B64FAFKKIeeGd9+4c/7Jz6VbP3l/fggEqFHVT/nNUgSXkZR5YbnLeme1WQVG4iIcf8tVHJoAku5p5QElxIqqAHPUCoGd0jICbJSPvDjdTkSRJQw/1TBu3fsK5DUtX1CPUNX8s2/laasbeW6Hc4Zct8wPBBBxxQB0jRGNFl2pvY8nHersSRAjGOgLEg/lWdps32yGNwGKuN4DdRnnmtETtDHvMQDlejUASzx+cgDTbCOdwP3eO1Zd3bQyI2/DShQVkUYya14lj+z7miOT2Hr9KqSRNw4UABep7e1AFFZdS06ISQsZYIxlmUcpmrZu1u4Y3CeYx4wM+lXYInMEkSqpRlyzeo4qhHpaeYZYp3RfXuOelAEKCa8dbW1lO1TyT0Qe9dDpUqWdu0drmNtuJJV+8aLCKGBY47famRls85+tX44wgbAHmjK7F5BoAmtbqfaT5wRlGMg0okkwN0qE9yetZ8qySKIkTauN3HByOuasKZCoJYZ+lAH1Dd6ZZXfM9vG7epXmuf8AHi2eleF7u7FtETDESqbcAn0rItviZpofZMwVQPvZ4qj4z8UWXiDQzbaa2+4ZldY+PnAOcCgD501afVtTvI7w2qW0TnAkjboM9x612t5ouveHorO6byLmF8eVMOM8ZwRWtq2j6lrt/bWNjpckCTSIZpSm1Vx1aup+M+oW+g+ELDTovmnG3yx3AUcmgDzzU7+6e3hJzJOH3uo6DvUuneMY57drWNBbyIc4b+9Wr8Epodf1O8gv4gzRR5UHvzWx8Uvh1p1nYnVNKTybiNt5VTw1AHO6VC95Y2VnNIsTu5m3HgjB6GtazsdJ/tRY7pJlYYH2qJjw3bJrnLXV7WO3he6uI0YLkHvn0rUsdagtdLS6RlUNJ5kp+9voA6HTvhnoh1pr9rrz5d5kfc2Sw7VcGuW+kzPbRqGjGUCjGAPeuDstX1i+FydGtruZH+5IE4HqM1v6P8M9f10SXWrXZs1l5EUf3mHv6UAauqvpyTm+gjjAaMqHQ9HPrXKXmqWOoaHKMvA1pKMKx4fIro9W+FGo2Nm8ularLKUy3ky8q1eca9b38kaRXtp5BjO0bTxn1xQBrWOuwPd2/wBth/0CBSZSw/iHIrV8S+KltdPli0xS6+WFO7j7w4H1pkGnaNd+FkYXkbXWA0sp4xtPIxV/QtFi8b+JrNbaLGmWiK0zBcKXB4AoATR/hNqmo6Xa3kutSx3EqZKYyoB6Cu58H/Cax0yX7Tq8gvrgHjK4UfhXpltAkEMcaKAEAAx7VISB1OKAGQRxwRrFEqoijAUDAFZfiDxJpmg2bXGpXUUKAdGbk/SuX+IPxJ0vwvDJAkgn1Aj5IUOeff0r5w1fUNR8Q6l9s1mVpHlyVTsg9FFAHrHin45BWMXh6z8zj/WT/KG+grir74seK7wvGZo7Y7cqqpyfxrkraW2jfZNH5giJLM2Bjjp+VVLy/t2ud0ahogTkqOenFAG0/i3xHMV8zVZQu3aMyEdazJ/MmSSN7hnkYF2kEhOW96z21E3X7tLEtInU9BxUSasEDrNGq7uzDvQBrQRpDYERAk9Scdu9UFtrv7tjePE7Lu2BsEjv+FSWOpRNDtkBA6MR6Va+227ZcorlVKo2MNzQBg2miumr77uQSSdR3Fd7JFt0+Ly0VnK8yFu3pXLSzBpi7bj8ny7RzXUC9gi0RN8uXKhlXHagDMk3yO5keXzGHJA4GK1INMEVv9oY7vkyvb8KXTJobvSpWQNLK/RsY2gHmoDFdMzKJJBGoJbPRRQBzOuyJHLH+7CrIOw681L9ptjG8cEajaoO719vrWtc2K38C206los/LIo5B7YNVo/Bl5FaPjUINoGSGU59qAMbSnjuNXjQIZBHG7MvvjA/nXXx6obe0iSRPuDKjHAqvoXhxNPCln827kyZD0wOwFa8emrLKBIQoHygEccUAZGpyxu6TWkboCvIYZy3tVSaWeR1UPkEcnGMe2K39etpI0gkt4x5ec7h0z71z5WVrjjO3cxUjnB6GgBkCy3XmRIpdUT5V7571fngKabA0i4ZiyqM46dT/KtLR9PaIxsCUlZTwRjOev6VYvIUawSOJGZ0fq38x60Acyssm0NuLgZK1lXeh2FzdyXcluWklZBIC7YfA4yucHGPStmO3mhkZZcg4P3ucfhUbltiSRqdm4AsF5J5oArzxyKoIBjViBx7nvSq293hJYsDnk5q/FIZ3ZXUsh4HHU1INGuBN0O3OQyjr6UAV90wRGWQgjkevFW5I2aL5mJLY3KepGetXEtpFUxyREsp2kkd6nsUaZmjfapU7WGOABQBlXEbwQAwzNk4ATHbNMjKSAo3D5ClUPGfU1antC+oPGxbcW4PYVdk09zBuEbKQ2cjgYx1oArbI0skaL5yrEMBweatWcyCJJAnz8nI5+bPWqTShgqoi4B29MEmpQkkUX38HldqnJoA0kkCXhMzADopxVZlZmJEp5OetNgsZpVUkttB9eg706R5UkZDFypI6UAY1r4a1yZWeNHcBsHAqSxjvtIu4obwMkqt8meBX0bp3iDR57jyrExKvLMCuF4rE+Jfhiy1nw/cXtqoS4RS8ZHc+lAFz4XeMYdctGtJvlu4AAQR1FcD8eLeWfxFZeTEXPklTzx97OP0rL+GFzdXHiyxFuhQom2ZQOSehJr2vxH4Ug1ua2luCyshPQdRQB5h8BvD9xDf3erSxmNG3IB71sfHnXPselRadbkh5TliPSvTrKxh020jt7ZNsSALgd6+cfjFfzX/AIySDI2RkKR6c0AdF8Lvh3Yarpp1bW4/NZl2pC/IHvXGeLrOz0XXr+xsPl0+PkoTkjPUD8a94iuotC8ERTttjWK3Bx74r5yQz6xqdxczAOLhjxnBHPWgD6F+Ed5ps/gyw+ybVVI/LcDqDnk13IkQMuyTABxj1r5Mv7e70G6ij8P6tcQRSxec4jJKj8KbaeJvEljMDHrdyxOWxJyGPbFAH1m0gaQpkYA55rM1Tw9p2oyo01uh55OMHBr5w034leKrSUSMwuY2wWLLgDnrXdeDvivf6nqK297aIit1lQ8D8KAOvj+E+gNqYukWUQM29oN3yNz6V3un2FjpFuIrOCK3i6BUAFRQXi/Z/OZwF25GRxjrXh3xP+Ikl7qLafo128cFuP3k0Z6v6CgD0zxt8RtI8Lq8cj/abzGVgiOW/H0FeQeIfjBrGt24j022WyReHJO5jntXlhE0928lzPLNcMfmbP3s+9TadeCJXJyHRirDPX0oAbqbXVxO91cSGWeRtxZj15qa1uvMkkmlDs4wDtbgY44qhcXm0hoxu4Ib0B9KjiluFt5FiV9jckkc/SgC5cWzao8jwEJFnBbPJPSrU9hb6ZB9lRldiAWcVk3V2bbRdSC74ybWTbt6htp5zWPoUolu9OFlPPcQvaA3u92dY5cDuehJ7CgDqZZMSsYlGSgIYcdKx9RtBcZLMwm7elbiwNO8SRZBX5RnmnXml3JVyigMpzkigDjklls5GSYcAdx+XNX7G9gfaXZix6gDNa0do00hj2KWbHvmussLKGCxKfY7cS52h0UZNAHIT6hbCQNArgj5QSv8OO9Y8t3Lcy/Z90jsflQDqT2r1WxVI0ZJ4IWQKeWXmmrbWkdss1rbRfaQckgcg+lAEGgWLaNodpC+8zudzjH3T1NaF5c+bZndGCc7Tt67T3ptrJI8pklPB4JP16VW1yV7e0neHjsp9f8AOaAJIRGJIlUjZgEGrmo3axQlmjVmZQef73aub8O3kxkInOQD2FdTewRz6ewUYkkBJz2PtQBnWkhl3PEpMudpDnn/ADii6LELtR1feSAT0pbW0mhmAX7oxgjvirq2zuqP1c85PTNAGfd74rV1Mckq56Zxg1lW0sizIfKAYcFf8a6C7O8IBuwrZJrLjiU3jSjJO45J9KAHyvdNdLKwPAA49Ksl2gkjOzIAydx4p9wC4UBgpQDNTh1mg8uVlIPG48ZoAznuUmnZdqhlUYyeAKhdYlhKxxgZ4bn+X61UvEa3uJY2iDO5G05xjHuK04ImMcay8IOcdxjvQBTtHW3WQxodyMQufT/GnW9zKTIFl3BiDkdvanT5khMUY+ZTlcjBOetJbRItrJFGP3mOSRxzQBai1OQzOxYMgHJPJNV47mWTUZvKCr3I/vVl2SN9qe3OQCCCSfbrWnp1o/2l/L3LuwA3X8qANNJFMySCLEijJVz156Vs6hcbdL2+WocMX3DG3HpWJOrFPnwGBxuP88VcfZd23kSq2WABxxQBi3kke4rIRh8Y2gDnOf6VHppY3UckiFonzkE9B9agvrV/tB2phAxBLDritqxgKwAjDH7oxxgY7igDTmItiyxIDC6Fix61kGw1BiWwozz2qzaNIAwwPm4O6pxChGdp/CgCx8MLWXVddjQEvBj95u6DFfQX9nwzQLC65QcbewrlPh14Yg0DS+EAllPmOfriuo1XUodNspbiRsKoJwDzjFAEGneHtN0uWWfT7SGKaU5d1UDJq9cTrEu6V1UDqOgrxXUPizq1/fPBodnCY1yC8jcA+teS+PfFOut4r0qfWdaeKz2TI/ksViBxwrAcEn3oA+kfF3jnTNJik/fpJIuSAp714LZSy+KvHNtKF3GabOPRPU1wHhS08Qa42gaZZNILnUjdFZblC+VTDAjJHY/yr0L4a2Wp6dqGhWWk3VpY6hq2rapZTXb2on8sW8e4FVLDnIPfv36UAdv8dNQeK00zSLdj+9ILhT0UV5qt4ttK0COiBBjOOSe3PpWH478U67qemaJq97cpHf3FlcnzBEqRS+TM8Z2k/wAR2ZKr69hWt4H8A694wu9cK3sMEun21vKkHlbvNae282PLZGACVzwePSgBLrU0jiEbsXlKFNy9Me1UdO1JobiJ/JJkC7dzc8ev1r074BeG7TxfBf61qNh5dhb+VaQxTLhjOsam4J/2Q7bR9D34Hs6+CtBRVB022G0/3eOtAHzBo2n6nrV3LbaZp8jGVeWI2op7HNev/Dz4VLosb3mtzefdtyVH3U+leq2+nWtmdltDHGMD7igdK5rx/wCL7Twvocl1OQZD8kcYPLN0xQBw/wAWfGT6FYjQdNkUXU6HLA8op4/OvEpElWXKkk9wRnPvVe/1O51fU5r+7bdPPISQT27AewpLi4eGWPeXO89EGWPHQfpQBNNGfKZ2l2bMsUB+bin6Bo8mpRyXN2/lWSHoeDIaSx0K51GdLjU2+ywr8xRj8zj0xWlqdwYLOO1tGCwIDjHfNAGTe2CQToLZgYc7imMkVHq945hiFqjeUud4A56YqVWdLZ3ABHAzV/SI452L7Ssec7D196AKvhzSLi6jEwRnUZPXFOuRcRNJayqwjT7q7ec12NlIk0UUWPLiXIG3jHsarXxjknLyR7gxxx/D70AZujQC3iE8y7mOAM9jWo84kT+LJGMAd6ZeJC1urAMrU2xuPMKxSgAkHGOpoAzpIPLUsicnuDVu0hbykkZyGjbgZqd7dl3KVOAPyqeBCHRY4wWUd/60APkj8+OSJ96MOd/Y1V0h2jVMklyWUjGcituFVWR2lU7HHQjqafYwxswZUAZV3egoAitJIjbyxkquc8kdOKTULcyaaLd1BYjgrzn3rTgtEYbJANvXcMcnr1p0EJikk3tgIO/vQBzej6YkbAyMwkIzjGMGtiKKaSR41AMfXnn8KmZFJEkOAynd9fWmiRgXaJ9pH3gD/nFAFj7H5gWOCQCQckKOM+tVIRJHM8DyBk3EbuhxWlFA6RiVPl2qDkHHWsLWr9Fu7ck/609R0BoA0L0QQWxKKDIvOSeme2ax0gdZn8qLzU2kllHANPutQs2EcDzAFuuT37V1ujX+lnQVtp7uKGYqeJPlyc+9AHIALNDGgOGXO7jpU5geXYgj/dgZIH0rEudbs4/Ot2nRJ5H2hgwwOa3rAxC2bZJ8ybQ2eetAGZPZsXe4JxGQAqkd/ariFjIphZdpwSccj1rQvYIPJzE+6MKCR3BPtVFVeOUFQNrLxjvxigBv2MBnkmj7k7s5zVX7O2ScDngVpEmRwquWQD5kbuasTQhbceWynA3YxgDmgDn0g8jUgSjMWUkv2HtSm6jtzLNcyxxRL85cttVB6knpWyAPKVdi46lxkn2rlvGujXGo6BPbWoj813SULIcLIUYHYT7/AOFAFlfEej30ct2mo2wggA3sXwFDHAJB6AnjNW9N13RjavqL6na/ZInAaQSjapJ4GfXkVxes6N4n1jQtfgns5FSdYTY28rwb1xIGcblx8oHTcc8etRjwtq13pOtwSWUrLeX0EscdxLG07AEeaXZTtxgcDNAHbXepWt3eS2f2uJLw/vfJBy2096uaIkhj8t5B5ikgH1Hoa43w74QvtE8ZQ3UzPdQfYnja5cgEkEKi7c54VV59a7y1tmgTAUFs9hzQAELEzl+XHB4yKtg3WBtX5e3Hakm4kCjhc5IPPPpVkYwMbcduaAPVNX8Z6JpEbNcX0GTwFDAn06V5t448eWWr6fLFbSHYw2xhOcmvJY7bTraOSW7LSHGApJJ57mur8FeCdZ8UCKaKP7Bpv3fMZeT3+UUAY/hSPV3vn0/R7VXu58ZY9E9SfSvbPBHwvtrANe6+Uvb+QZYsuVU9cAV1nhDwnp/hnT1jtIlMjDEkp5Zz3JNdIZFQ4cgDpQBxVj458FWq3UNrq9okdkrySyIjCMKhCsQ+NrAEgHaTirUPxA8Ky2N/eW+rxSRWLJFcFEdijP8Ac+UDcd3YgEHtXj/ir4ZyaVpHidbHXI57zULOWCHTbeMWcMru4be6tKY8jBwVCDmrupeGLeWy1a41XxtFFrN99kMjw24jhENuOIWjWTLq25tx3jPGMAYIB6a/j7wmmlQ6u2s272k8xt4mCsXaRfvIIwN+4dxjIqYfEPwg91Z2A1y1M16kXlKCRnzR+7DMBhGYdASCe1eIaRY6JoZsrjSvFlvHq1hqF5f29wNPBgAuUVXiMXmdMKMEMMVyXiXV9Oh1661OO/S/ubloJLxbmyBDzxKo8yMBwEztBwQ2D0oA+rtE0zRvCGgQaZpMSWdhb52R72blmLElmJJJJJ5J61V1PxlolkXE99DvyPlDZr5U1nxzrnii4828nYW/OIUOBWJHJI7zsWdCDxySKAPpfxB8UNPtoZWtG3Njgnpnivnvxj4kvvFupzXN1MTBH/qkX7qjPWsINLLtid3aItu56fjVzesVtiMxnJ2njAIoAqRuonj3vyQBjHIGa6Pwv5Ta5d3sxAjgwkWW/i7/AI4rmLgEKhA3hWySev0rW8ONN9nu3hReXBA/ukUAdBd3st1qLLHu2dkfv2pL7TTtWIAA5rIjku9QnBxko3Q8cetdFbwot4JZ5XkTAIGcE9qAKSaY6xsIwpYAHrxkd6t2zxqrMpUsvUAYp8vdYCRGTgYp9lbRwARS7XOc4XrQBIVjiRJI2wG7nnBp1xKslvkbhIM5bGB/+qhbRJoyOVj3cKT3rRe2QWqJGQ6AYI9qAKVsJpbVlZV+Xo2O1Z9tbLDflcEnnBz0rprKLMTqsZ5GcMarf2eQzlSuCwJ46n0oAarQRsDNvDScKFGcnFatlbIYyrAb2G4bjz9KgkUJC6Pt81RnniqUmpqsDXFxLEAvGc457UAbjQhvkKkZ9qivgtii7RycB1B6DFc0dRvdeuYrHS1ZZj1lbICirmmeHda1LV7uwF2piUIrv1J9cfSgC62o+UzKRGIUXLfNjFclqXjGP7ULezWecMcsUXjPtXWar4P0/Treb7Q5mulO3YSeWx696o6ZZWdreRXmyEGNcGGM5DZGM/WgDPttbvpYXS1sJneZSd8w2henT1703yfElvGY7SOLFyvLFN3GfWultpPs2mf6Vb/aoWYhmjPzLk8CrmptNA1rDbzZVlwoUc9P5dBQBzkU+tWFp5mrxK0C5iaSEYYDtkdxVGTw3qGvbLiI7bcsdiHICj14rozLJrVkXMhijtwY3iK4JOOpqLQ/HkHhfRpLDULR5tSDYAH3WU9DmgDm5fCUEDWkX28teux8yNeSD2A71S8XwHTdRNvOjHbbjCt2565qtPPPqesXOq20yxTJLvxk/KeuBWnIW1e1mjnaNrt4nYSsc9qAMM6LazxRHTJhcXLpmUSDhW9BUlrFrmkwjyg+0EbkA3q1LpcTW0CokiRuRtIIz+JrrdO8SWdgz295GLhM43LjOfagDOk1fUMo0cR/ergh4iob8al1TUbmHTLaOO03u+SzRnAHtSapqtxrLEW7lLKMhvKA5JqjptmovSjzTNGQzLtJyjf4UAW11yGGcb3eM7ckyLjBx0qxJ4ns2UFpYGDcfuz2+lcbrVzBLclonuHxwygA9PQ1HBHF9g3G0nVS37t1Ybh+FAHb23iC1Jkdiyw4Ch15Xr3px12xa0LPcQsyHozfeOetcnBZxXVolnbtKsrTAhW65PUkd8Vfk0a4VpE22+FBU7vly3sMdaAOmi1axmuI0+1xgTfKhLg+lbVt9mFxG0NwxdiSc8jHI4rgrPRXvYZFAgjSAA7NvzP75onju7S+jMdxJBar8rMrcJnufagD0i4t18t8IwfjH070jWp3o0xZGPDH+96fpXDzX15BOsi6qs4KbgAueQOFP1rUvPFEE3hvzj5v23ciug6Kc880Ab91BJ5BCkMc7gSMEVbgsIGhjZpFyVBPB9KwLPWmm0uO5lm8vzOMlc7e2Kzf+EvA4UOVHQ7ByPzoA7L4c/CyaS9h1TxH/vJbYyB/vV7haRQ2tuscSKkajjii4uILO3Msjqqrn7xx3rxv4n/Fm0tLeTTtAkE9y2VaRD8sY+vrQB2HjT4jaH4dgmSS6SS5jT/UxnLEntivBPEfxK8SazcfaILp7KEf6uKLggf7Vcd57TXDS3aklyWLuMljnqTUt7dRWsAKspkA+YdOtAGfquv6rcTSTXV3NcSkY3FqwfL1bUbjZAk0v4kiuo0W3t7yWWe9JRB7Yya2v7Sigj+zWKKiAZyBjNAHCQpe2ziK5JiVuoz3q2YEluI03DsS3dq6e+0r7ZZG7ZgGxujA649DVfTlsrbTZPPTNyWzuPOB6CgCM26xWqlZSX2dMY4qvbSF5JNql1Ubm+uKfe6j59r+5XnGFHpVewAWJkkJLy9MUAW7PbHbymRNrlSuD39DUXyOjDAJ9+3FZk1xKWCDIB4Y5pEllU+TCjPKx2gDn60ALcXyx3IyA68ZVe9b/hFGktrl5I3VWk+Xt2qbQ/D8cFwXJDOfvM3pXS25Y3KKcFUTGMcZoArafZoIyxUAkd+xpt6jRzEoHGOmRxWstusmVLjdn8KbHEroyzylwOn+FADLRd6CSRRyM4Wg2zM7S42BerMf0rQt4FhwkSsUYAgj+tWGSNAq3TYycgZ6+1AEGl7ZY1B/du3AHb86dCY0n2yHc/RcHgY7029uoIoZXEaoitnJ4/KuMk1S+Ny32YBomH3wpIAoA76XVolO2JFUgYZieDWBceJY/NimSKaVfMwQq4UkY71QbSnngNxfNJIcgDIwpHXArTaNxaqZLfbDEmDhPun1FAFS8u77VJZLhZPs9qSF2RjcSPr2602XQxbxrKiCV1f5i53nHBzitXwEizXlxHMUdEXzVUnBIPUYqDSfFFk2u3QntzFbliIww6kcY9qAKdtqzvrVrE9rP5srKGeNtuF5212fhC3ns9cv5iJ2SNR0OSW7j+VZGu6hY2sUV5Y2iSJI/wC8fB3A+gNem+Boo/7Eh1ExlQ/O3rkHvQBwfi+eGZJdSadtqvtby85RunIqjpV7FaRQXBmhKH5TkZzkfzrtfHMtnDpV1JaWiq0zjduAAJ9a8b1HXl0iSVLtUVGfckaDqO+fegDt73WdOuFe0s5Eikd/9VtwFz0ye/Sreg6nthkkuFRntYyWDrnj/ZP9K8qtfE1jKd72JjlVvll3816L4ZkhutP3NcxYuQxEn90g8A0AXb7UYbya2ufJZLVkLOyDG/04rCOlaVf+Kmh1OBzHcRqYZOflYY4NbmroqafHLNcKVtlG6IcBjg9PasWC8aSW0lfy8KCN3t1AzQBT1Ow06G4mtbRDGVYrgdSRWnpWiWqMLuIhhGmZVY98c4rP8SWjvq0VxGshR8Tbl6E45xWXLrl3OssNi6xpkq8nTj/69AGZ9nNzeTi0f5zluegFY16ZoLz5vnMZGHXkVtWtndCab7A6mWVQnzdNvciooUXT7lluCrggiULzkeooApRXktvOJ02xiQZUN0bnoPT61qTzXdnGskjHM0ZUn1B9KzNVgAkEUEhMB+dD2Iq7q1wbyzhiRgyRRhAT1XHGaAHaZFHAY13RN83z7x2q+LY2phJxJCxJ246NzgfyrDsTIYntppCY/ZcsX9PWtuWG71eQwxIWt1l3nc3TaABj6UAQwT/bplWJGS6tyWSUDBzwTn9a0rjXRJAokspDcpklo+QxBzk1rWHhv7LptzcX9zAXKl4234DDH3eO9crK92bqGOIowG5YwjYaUNjg+woA07nX1vmg/dNAzMA3bitqyt4riCe1Y7weWzhh9BXLXUcggUXkcSPJGGBVv84+ldt4OuLbULELbERTwYQqRkyEjk0ASw2FrbwJFJGoWJMgqOvvWdNpFu0cFvbcW875lfb941s6tMY7f7PLGnnKh5XgjvXLtq81nMrHzHjBzgHIOeOlAG5Bb28hGn2iq6jHJ7Vdex8Pq7K8EZYHBwo61h2x84q1t+7kcZXB5JrGntZhPIGuXzuOfzoAl+JPxF1HxLqNxb2U7wacjFEROrgHqa4C2gMTh3clXYAADkH1o02U+e8cCl5Og9M1bSK4wSzIBu2L/vUAT3F3E++2hga6kXglBk8VXFokwF1c8SZ2pFjhfrW/osbaaJ4soxIDl8csfrVOURPOgyc7sqRwM+9AEI0xg/zM2WBYEDjNQm1MRUrg+pxW6LxoF2qodyCGDHPHqKypTJcyxKMqpPJ+lAF+zJkjjjBOUfd7HjvWZ4it/N8yeIhSASVA6mtez2JbzssxOMA4HBPesydpd+FK8/dzxjmgDjbW5XzGZmx1BGavw6hEWX5yWHBqa50eGW4wchiTuA6Vq6P4ctt5LrjYMnJ60AZkmn3c0STJGY1kf5WI610+laDFDbwpuLzvlpJAP0FbK2iPaJGjDbk7VPapLK2nPEJDAjn/AGaAIfKEIjQfdC44+lWreJjHzyyLk+vWp/s4KxlDyDjH860LKxWFmeRg3fGexoAz4d8jRkHkDBGOK0LPT2MJbI3E4birllYK0LkxqCVJU+n1q+j2tlbq8zq/y7uDnmgDHvrsafabgTyOdwwAK4nVdautX1CGDR4WlkRhl+gJrW1p7vxDfSadEoS2Q4LL/Gc5xmtDTtMj0eSGOEK3mRZJI5TB7mgDnv7Jna6tn1W5ad5pOI1OFFaXiA2lpaxTWGUJPl7A3APp+lX7u2RbgW1rKpu9vmRs7blA749OtcV4yV4MQr8qliSx7+4oAj1vxVO+lrDHIwhZ8oxblWHtUeneLb3+z7mFZ3mLDueme9YSadc31gu4rHBFukLdyDxUVrZKVuBLIocJldhzxwMfWgDV0DxNNp9yZMqWyNwbhiDnIB9K9B0LSrG9uXkv3MEM+GiZR0fr1ryeeOC3kEa/vVbDK8nGBntXXWXjFWsvsroIYY3DooX73GPyoA7jX449I8P3MUUyTBJh5KORvbOMkVoXXi690Twfpawyh1u32F2HEa14nq2ufbtUUyq5TzPM2Ken0FXvEviC71C2gs5CRaRpuAQDgnpmgD026vLzV7UXEN3HLawkkRg8kjqRXknjWdtR1KadVMaE5UGuk+GQuZnnTCpb5+eVm+5mum1rwfHqehBkuFa7bf5R4G/aeg/CgDxaGNsxsWOxztOema9Z+D15BFHfQ3sRuGA/cqpzmvNbjSdTijeE2z7A5HAzg16v4B09dAt7GSS3V7ggGUnllDccfnQB1Mll/b8CNFKF2HfLGWCnAz8p/Kqn9jjULUwW0Aii3bg44AGPWuj0zS98WoF5VacyZWELgOMZAzUMN9eWnhy8RrFUe2lBBI+Rl9Ae9AGZYadPqWh6pZGUvc6fEwjKn5SCuQK4JNj20UEcBEciESYHO4HNen/C7U0uvEurwScCZRPg9h0xXneqXSQazqRshm3a7fZjtg8n+dAFaC2k0y3dpMFsBVZTztNQTW0HmRqztiRm246gZqxqt9bNcCaVZXlfAZc5XHTNRJBLd/JblVKhm5OSPpQAlloy3Md5FC2/ySGh/wBk9TzVNIY4/M3K4YceX6t6ZrufA+n+dpN6Y1HmqCWweTXD6jO9tqF3HOjeWDwc8Z9TQA+a0QRh0kQSQqWY5+63b8avaaZ4kkVnSUbTIwRduPlzj8Ca5eB5FLTzFZGmynl7u+eD/KrH9oyWZWV0E7TRtGWx0wcHIoA2tZukOnWpu5JZYId21MbWJI65HvWp4a0xtVtHu4Su4IXYAbTEcfKAT271i6PDNfwyGQxJYRYYxnORjqf5/nW9Pd5tZLO0LjTbjG+OIHeQvQZ9OKAKOl28kctrBfEeUqku/wBD29eCK0tDVLSW4khfBabbHIfTrmql1NazlLWzC20ZOXZ8nyx6D1zVrRCsqvYWNtPeOHIMkcZI+poAvasGuHlWaVxI653A9/T8q59hLu8gBYpGYAAnIC+td8fBPiq4tEuja2ybxxG8mHP/ANes+x8I6vq2pxWd7HHp8yLlWc7iwHagDMgg/s3TULymSfJAKjO33+lWlFsFAkUM4HzH1NdzZ/Ca8uEX7XqBAUcFV5//AFVWf4XQq7KdUvQQcEbP/rUAfPvh1TbQz3G7kDLd8CpobkPcI0ozuBOB6nvQbK7g0kT74/s8zbWAOGB96ZZwxb13uEwvGaAN9w+0ecfLRlCgnoRVeSIQybY3DKpKk4yPwqxLdCW1BZFyPlX24pLdODGXVg2CWzwB70ANa+83TWTCKFbGT1PrVNZguGVvnDAH/dq/PbwbCgkVixGMLj8qiW1jRkYAnJwRjkUAanhu2iyAybkc4OakvvDym88svlCAN9Txwf2XYPNK4WVl4Q9RWfb6nJI43vkHuaAKMumNC7tu3IBgVZsZD53yqApwDjirTxbixB+U9Pbii2iAQNKxRBxnFAGqsTuy8KFXuOtXIZmBI27EbgnGDVWEFAEjB7EOD7GtS0BlGxk3HsSOMUAJZ2u9WPACcgdTz3q+liTAccPjgY6jrUqeXFa+ZGwEhO0gDpioLjW7OHfE9wgm4+Zux5oAtm7t9LsS5bDleENYF9cWl9ptyYnSK6kPlpF0x74qPWlmt7aC/u3SeOXd5bA8d6z7aM+ampw2rLLG4kMjcjPoB7UAbem2MekRfZ57fazMHdEbLE7cZz2qvqOuG1tZbWO3UwsN0YlHzgAcjPfNZmoeI7mO+lcyBWnYZJXJArvvCnhC316H+0tUZpIVCiOM/LkjuaAOJ8M+FtR1XWJtTeKa0hibckeDh129Kk8W6rDrK+TZaQTDbYSaRlwyDODj3rt/iP48tdCH9l6KUa9aMgbQSEIHTjvXlx18jS54rzzIGnAdygwxJ/pmgDO1jTLkWzx6dahIJnVS/oMd6wrrQpdN05JJY08zzWAYN1xyAf1rutP1ZrmC1tY1DWqSmUs+PmP+Arm9Rmmkv7mWSVJbTcd2B0PTj8aAMmbRr7Vx9p8gQsy5Q9goHTFYbaVe+YbYQnzXIA3nkY5yPavZftkMWlWb3pM0SxsAqryvHX9BXA69frc36y2jMFQbRxgg4oAp6J4VnnkWaZRBArAPMx4XHWtm88Ho2pRR2sm9J08wNj5Sfc1Daa7cpZpaSY+wZzJgAmujj1iFfD6Lp8myRGyAxwSuDwBQBX8OXdhYyi31BoLeJXFvI8x2oWPTJ6AcYyeM4rvoLS0+yukjo4Q/6O4/5ZkjHNeWpaXfia0n06DSWuGmbEkiDBH49K4qw1fxX4K8Qnwzcq8xSVYVtJnwPmI27GP3Qcj256UAe32FnbCzSGOJJblCWcFs+Y3Xilt9W05G8wKwucAshJ+UjnH6VPZeBvFGqXFrKEisU2ndIJdxTPXGOprRvfhC1pEZrvWyse3G9kwc0AFx4lsb7SLaO2eS3uPN2zTd84zkeo7VS8Oyvd6q1vfXhl03CgI7Dcz85OPSuevtAfTtwtLozqDuCkdR7VoarY6QdKSfT7i8k1RlA4+XHqDQBPNe22heN7A6fNF5J3QzBWB2qeefyrlNb02a2vbp4p91uxJ8vqDk9aWDQryCKO5l025khZwxdVySP5mtGA28ru8J3HzAPIc7WQ+mDzQBy7xEXYkKsbdgBsxls+hPpXSaVZNchyf3excjbx70PouqWLXOoXNnO1oVGVdQoUZzxS2OpQXUBjtRIisdrjJAUY9aAOg8ESCy0LUrkuENxOsaAjB29z+tYHimwtodfv4XePyLpVkid+VIx2/Gt/w7dWIEmlNG08Dp95D0b61p6l4dsNT0q2t7uR41Unypc/PEOg//AFUAeHzQm1uY43ePew4C8hQenHrV+0W4t/NlgJmiYMUkZc7T3/Gug1/w3Lo9yRfKs1s6kR3cHIPHGfQ1Rt7i20+1ljRgzORgJ06dz60AUrCW9t4rtTcwws2Q6uMl8jJxV2Ozvrmxju4h5MKEQxvjBkJ7KPz5rS0zwvqOt3qf2bEt1Jw8zYxEnt/tGvTtG8Ni0uof+EimEhgz5USRkLHxy1AHN/D/AEWx0S1ur7xOHUHHlPKvy8/5FevfDyDTm0+SbT2jfc5JZBx1rW1Tw1p2u+HDYuimGSL5CR+tSeDfDVt4Z0uKzgUEqvzMO5oAuam6BLQ7FaRHGM/w8VYks7a4ZJniQyKNocDoOvFV9Q0s3sw3SOkYGPl71btIYlhiWJjsTOMNw3bn1oAsRcLgDgHApTEhOSooXAVelPoA+GoLW4v0+z7CsUIJYg/ebtWXqn+iXKQS5BxksfStewvZLMJIj7FmzkEZrnNYcebNLKWecthR6CgDbglCWgYfMDgcjp71qabJYm8ia43bAfnPb2rAsHm8tVODwFwa0IDtm37Nyp82AOD7GgDp7i7tL2Ro7aECCNwTJ0NRXFqtvbmSGTdluPYVBbF7ppJJRGiOo+ReKsIighCWMeRyfSgCrLIbtStyzO+cLk9QKrzWQWRWi3bQvY9TVieykjnWWP54933AcED1q4scmwbDjpyffigBLJBJbMhYhs5wat29krkhlJ9sflRZ2TecyygbecHPBqy9ylkHWWVUKnlB8xY+3egC7aWgjl5x5nUg+lPutag06ItlVjHUHnrXMXOq6lfXgj0+0uHmUgAbcDBrX/4RuZdJl1LWl8swAN5IOefpQA+fV5tQkMem2U0kpX733EX8+tA0a00vT5bzxErNcytgNt4yewFdn4D1DSfFVqUjh8i9jIXDDaGx6VqfFLSFTw5I8joYoyGCkZPSgDxxtUl1HSxotvGY44L3zEb7xCHsPbJrq9Q0rUbTRVlhh81fLZpEC7dpAxn69K5HwKPPvJLl3kXyyRtU/eU8c+1eifappbH7K96EJckfNglRjA5/KgDk4tEhutZ0k7P3Fw3mOxJIJA+ZfavU/GfiK28M+GsWhTMwCQ46bjxXF+NQyaZYTafdAXMTiTYBkR5GM8dqwNUhuZ7iHUb+7E1uyCJYx91SwweO3PegDmNDhnGpFtSZpELtI0gbGX7YPpXS6n4bt7/T1lgmaO4CiSRsZDKSePrSzBRJBauYmW1G/fwAc+9ZcviGX7JNYQIW3yHa4PUf3QOpoA5m5lhS1l0qxk/eAfvJnOO/O2ks5GmkhtwpdB8ojQZaQ+4q0PCs15OGa1u5LhgTsRNo/Emuv8M+BNf0SQXCCK2uGwUDKGOT6k0AWLXwr4h1Gxb7YY9LsEUHLcybfSuc1Hw2Z7wRWUl3fyD7x2rGuP8AJr0vS/Dur3ty1tr+tH7QxBWJev0x6V1Wp+FrfTNFZbZn84tuV0Ubyff8aAPMNP8AAWqtLDFDp1jarGMs7gyFvrXTWGiTeHLtGvLKykbcSXEIXH416Pa6deSPayzzGNQBu56+uaPHGp22mWcbvGk8rkKiNzvoA4i78WNIk1h4X0ktetnMgTCJx1Jrm9O+G8XiC8kutauGuNSnjKS7+oTP3cemT0r2y0igTTEuI7aKKSRQSEXpkUDQILfUxqyHy5vK2SEdCO1AHi5Piv4Z3MFl9qF/oE0gitbi4YnymPSGRuxPRWPB6HnGdt9X8S+KL77NNpjW0I+XaWBGR3Nde7y6rd6hpWrWkVzpl5EdocbldTwVIrF8JxXfgnWbfRNa82XSLuQR6ff8u0Tt923mPqeArnr0POCQDS0/wJHGd17IWYKDkdM5rp7fwppflKklujshzkrz+dUPGsWoWt1aalYtJIsJKvbJ0cHHJ+ldPpkzTWccpP8ArBnkg49qAKV5pxjKfZ7eIwgjKnjHvXEa74T0vVjJPHboZJCR5yAAoR/Fn2xXcHWYLm9lsEOWC9vTvWVq0sOlG3sXVxa3DeUGQcoWzyaAMbTfhxaXoE+qajdajHwEWR/kH4Dg1BqfwxsEmSPSYGtxIf3zRkAbfp613Ph/Tbbw5o8dnFLLJGGLL5jbmOTmrsF4swlUAqVG4Y5OKAPPdJ+F0FiXKy4YH5W9fenS+FI72O4aW4HlwAoWQZO76V6Fp12l/ZCWInByvPBBBxVLSdKFok4l+ZnYtxQB55pfw/g1fT2dNRuQN2wMDgHHWr9p8HdAhuEln8y428lZTkFs9a7iLfYzQWttb7oirO7L2rRRt65HAzxjvQBnadodjpy7bKBIR6KMU+XR7aW8a5kDNIybME8Y+laOaDQAxI1jjVEAAUYAxSkY574pSTnpTJj+7YZwSMcUACkOF+YHIzSqBtGOwxUUKeXGij5to2g+tKwbcOCBn/JoAkUcgA9P1oMak9D+dMiLAlTzipqAPhy4ezU3X2LDW8OPLbP3vauYUC6uy8qtknIxWqkiW9hLHsXzHOxVB5B9afHpv2SKJhIJGZck9wfpQAQKCUAyUUc9jn0rX0mOJ7s5+6einsKrW9i0yLIGIKnDgjpWxbWmGxEqkjkDFADhAIb5hBIGUDoO3tWpEUeEggjJ+971RFtLFOw8sbXI6/yra06zcQgbFZRgYPTNAFYx77kwyH5sZAP8v1q/LbJFbRs3l5Y4HrijUPLUAuq+apHzjrz/AErIu72S7a1t7fDjzfnkP86AJXluNS1JNN0lMSjJkYjgACu10LwRc28f23UNs16hxn/Zx2q/4Ns9L05po0dG1A/vJHj5yO34Vrat4z0rTtQt9OuBLmVNzP2UUAZWm6SbC4vr4sJCEBCBepq14l0G31rSYLiAyRsVy/zYyO4IrY1iKGxkhe1ZgtyuPZR1zViyuFlQCQBTCpDB+jD6/hQBiaR4PTT9YstTtnPkJkNCnTpwa4v43a5JHdGBJHaKRSEUnGD616pa6vEtiy7POijbCY46/wCFfNXx+nmj8WRiKTKSIMDOcZoA0tBh+y6VC1uZJd48zIxn5SOntXUI0b2s96VjaVsAk4+RfYVleFjp9n4cgnnWaQJFgY6888Vy+q6jLqd+q6PAywICq5JJl/DvQB3dxq6WcaXQMex48MxHUYrltQ1z7XFPbrbYicEfPwMetRJoUvySardyMwGVsw2ACOcN6D2rtvA3gqLVEGr3TrMVbdDEOi49fegDkPCngjUdbVIpN8EAAIaUknGOw7V6p8OfBek291cw3cJe8B+UynLFR3X0Fdhp7QWIiaZQDMoQYGfm59Kfp2i3i+MDqJnQWiw7Y0C4O49QaANmDSLaN12xoxTkHbyBS6jp9vdFZXTLIeB060Wmr20uoSxhl3INrc9xWmhinJH8LKACOmKAOXstIik8RC+WMnEYDFunHTFaHiEx20DX+4BIFLFs8Y78VubYbaNYxtAY7RzVO/toru3mglT9y6kMp6H1oA5ZNdS68Oi4nmUCRQ5K8cZrh9cCeJmkXS2mL2+AgxkEev511CaNFa2t9G7I0DERRRnHCg//AF6teCtBt9EedQG+0TNv5bOR6flQAvgLU76Ypa3duxWJAu8jGCOMV2+oXdvFD5czKocbcHufQUxbeJQwiwhZT8wHeqdppEUMSm5la4kRmdWfnb9KAKejpbzW8Xkl8CU4DcHg9PpVq6vorG+B8t3DHDFeQo96t2v2P7ZLJAyB2+8Pf1rMNqkuvyRk7Udd7/7WO1AG3crDc2km7/VuoGfrWNas2kWkyTqPs8WCpzyF9TXRIVVVRQMEdPamXsMFxbyRThSjrhge4oA57wzpdu13Lq8JJNzjg87fXFX9d0qO8mt5d+woeQRkPjoDV63a3tIViiKqiDAGeMVW1O7D2sqxMrHae/H40AUpb6N9VeDGTDGvIOQCasabKH1FgRtJiJIPXrxWD8Pt8lvqlxeN5lwZ8MzLgYA4x7Uf2mbnxDbeTwWcqvoy9/w6UAaet6tBoECRbvmcM5xgEVq6NqEerabFdQMGVwefQ14x8ZGluNe+zSTmAFEYBT1FekfDKEW3hSARjCsSyj2zQB1oVQw9QKWNFjQKgwKq2EvmvMQrBN3Bbv8A/Wq2BgetACnpzRSZPfFJyM7sc0ADEBSe1Ywvd2tbOyrtwM81svjBz0qhY2oRpJjIZCzEjIHyj0oAs7grAZJPvTzznP40j43cjgcn2pj7/MQgjZnLZ6+2KABWBkBBypqfAPNQhf3u7LfL2zxU+Pc0AfB9lZPeatFaRMvyNukfH3a35NORgwVhuQ4yO+O1XNCtLfT7L7M6jz5BmaQnnd9auWdsZAYzwxJwfegCpA37p47YELj5iRjJqWxgaWZWkdugztOKuR2E0cyu5Oxh34watJHjcBHncc0ARRyKsv7xuO7VpC6C2U06KVgjXG7HU1zst4JpRb2Ba4uem0LnHPNbFp4avL2B/wC17ue0QqWiiQ4B45oAw9buJNQn22WWRUUyuTjGegrq7KTSNG02wsXkD3rkTyNGMkD0Hr1rsfC3h7R9MsDbNEHW5GWMvJOR6155430dJvGcNpp8yJHbRAxogwwJ9/SgDt9K0K1hBnhkMM9xvOc87c9D7Vq2Vtp6zxrewRyTRAsCw3cdsmvK9D1y/wBFv/L15WeCJWJDffOT2r1Hw1fJ4pto723jMFvym1uGYdv1oAhuLy61DUoJZowlkD5YVuAAOCRiupn0+KO1MQDCCUhdxOcCvPtdllt/FECQwSXNsqAqigghgeT7+tdnBqFxqk4DKTFbhSVQ8OT2/CgChq27R71IowJ9OtyDJgZYZ/yK8x8eaPY+KfHsIZxFD9lfnH3SBkH869B8e3Nr4a0O8d5ZJpbiTcVZshSeg+leRw22p6lm4eTyYmH+sA5we2aAMq6sL8XFrpkN8sg25IiU/KPQ10Om+G9Xs4ll02BZJSCsTYO5B612nw/8MW80uYYHYRkLJI4zuz7163c2drpOnqY4lGCAAq8k5oA+YtP0yWy8QLaXt2WaZPNlZj1JPPWu6+GEUj65rOlWszCzKhlZT91j6V6F4p8HaFroN3csLeSFS3mR4BUd8mpvAfh7S9Bsp5NOYuWG9pGHLcZFAF3wX4eOlxTwzM02HOx5G3E10b2hjimMH+sfkZ6ZrN07UxJZvcMVP8Qx6fSsvWPFbWZTbEXDnAHp05oAuQ6fbL+81BE+1ZYfKeoPp+FWdDwCoil/0dMrsPb05rjL/wAY2HmLK8sf2hEwsYbLA/Sud1nxHeQ2ckWiyNLeSMCY05yh6/jQB6JeWl7deII7qe48qxhc5iz144Oa3YJ4bmJZbeQSRc8jvXjGveLbmfS4ob6SW0ChXRlODMAMEH8a6nwl4w01FXThKpdV3AqOPfmgCXxnoDXd2rpdtb27jfIq9cjkMD2p9+Ro1lZXrO002FiLE9VJ61ka94+0mHWXsPNV5vl+902964678f3l1qiWyWAe0hJG98hWHY80Aeya/e3caWj2U0UKu3z7+SeOmK1YruNsRNKnmbQWweBxXzjq3ji3ublYLq/81FJdWjJUxk9veuW8QfFCVIZbGxmkkBH+uDkMDjpmgD27xTM2leKorqxa8ndRuMUJ3KBnkkV0Gka1Nqt+zQfu51GzYy4Kj39K+S9P+KOvacJTaygO/WRvmbj3NOg+K3ii1lnnivisszZcgDmgD7QWLUwpYX8K46jbnAq1CJJNOeW4mEjkdVOBXxX/AMLY8UkMH1Jzu5ZRxV2z+Mviq0jEZvA8ZJ+UrnAoA+qb64iCt++BAHduQe1U9Avn810lceQcqGPrmvnPw98Urd74Sa7BM7MQC8LlePcd69O0vX7LXSZ9B1RQsGHS0kOGZj/OgD1ie7QwjT7MDzJGPmbeCF47+p6Vr2ui26zW90Y9k0SbVUHgV5N4Y1q8s9XeXxEJbfM2V3IdmMddwr0rVvGGm2OkS3sc3nlULBIxuYn6UAUPF/g628RatbzTELJHjBz1X0P41tyQSwaS9rYRiOZI9sZHTNcH8LPiPD4j1S5sbu2ngu8b18xTwO4P416fDcJMGEbDev3l7igBunJMlnClztMqqAxAwCe9WTzUdxvMf7ttpyOfbNPB+bBoApapfrYWrTyAbFxkZpdL1O21S3M1pIHQNtPsfSodXijv7Se3dPMUL8y1zPw/lvYNKKXkRUM7SAHqoJOAfyoA3dVvpYr21tYkJ87cWcH7ij/IrRtN0UMcb4LEZLDjNZCs91PM8kOQoPluP5fpWbaeI0XWPIuQ7SA4VUGQPr6UAdjIoIyT3yKGwOCRz1rHbxBZf2pHpzuFnmTdGrfxe1a3JQEjrQASY3AnoD0xUw6VCUJYbegzUozgZH60AfItnB5iRuQI1fJBxkmr0NrI+0cgHIH1qvMSLSHBI5PT61owM2Op6DvQBPGjDYJFZ0AOT7jNY97JcXl4sGnuiSPkM45CL3JrrMD7LGcclTn3+Ws/wEitqOv7lBxFxkdKAK3g62s9AvWYMjXUx2JKx4bPcZrotSmm1qYBWRJ4QySxRnIX3rjvHIC6Np7KAGBGCOor1nwRBF/ZlzJ5Ue9kBZtoyeB1NAHKf29FppS1uJ4RLgcv0z2ryzU9UvNP8e2+oXcylHYIxTgsmeDirficBvGV0GAIKA4P+9Wh4jt4W1W0ZoYywSPBKjNAHoHirw7D4i0uO4sY1MvDEH7zCuW8JahrFtdXkNtG3m2kvlR22eSDyf5V0/gGWRreANI5ARuCfetLwdFH/wAJt4jbYu4XC845+6KANiwH9nacdR1uWAXgBLZIAQHsa55/iNpOl2dyNM/eyux2hVyQTz+PNR/En55kR/mRnTKnkGtbxJY2kXhVTFawIQowVjAxQB5NqWqah4r15oL+I+Q3L/NgqOxIrs9I0ea62WtkvmoFAJZeCB3Hqa5fweAdafIB3TAH3Fe82saJPp7IiqcYyBigDY06yg0XQx5UIUJHuIxgnis/RPE9rrNi0rwvG6HBiccip/F7sPDt1hj931965TRgES62Db+5Xpx2NAE3iSWyulaLzCsLMVlQd1rC0bxBJb6KxidmsrcFQ5HVRxzTcltRXcScxnrXK+J3aKyu0iZkQk5VTgGgCG8+ITfY7qK3CRqEwCc7jk9q838UfFbU51MNuwjCDy/fFct4llkF9PiR+BgcmuVk5IzzmgDek8YalIpIkw2clh94/jUcHirV4GYw3cqMxzuVjmsMcDj1FPkAUx4GPpQBuP4t1SaMfarl5gnAVzkVo6b48vbR4XVVCRDhVOCa5W4AFuCByc1GqjevA6CgD0WX4iAXkVzNpttLMh3+a4y2PSofFPxJ1HV0ZUihjQjYpRQDiuAuPuv7EY/OnW3IOaAJJ7meV9ztjnn61UVsMW5LGppSfPlGTjP9abaf8fI/3qAJnQvteOIgH0B61YeydAQynd/dAzmu/wBfiji8JacYo0QmMZKqBn563ktoG1Tw8WgiJa1csSg5+tAHliaDqKwRXLWkqwtj5mQ8/wCNRT2BcK8PmFT6rgV9AaZ81xbxtyi28hCnoPwpmh2lvNYWwlgicec/DID6UAeAXVjPanM0LBSAcninWOpT20bJGoD/AHg4OGX6GvTPjGiRyyCNVUAR4CjHY15ivNvMT1BTn86APQvCPxX17Q7dBeTLfW6sD5dwNxx9a9h8JfF7wfqdygvIPsdxK2WLjKH1Ga+UGJ+y9T9/+lPtv9cv0/pQB9oeN73T1it9Z0C6tRBuH2gwY3MpGMgj61L4P+I0Fzeql9CtqjAKsztgvivl7wDcz/ami86XyjjKbztP4V7rrkEJsIyYoycDqo9KAPfra9guUQwyK4b0NSSTKi5PfOK8G8E3Vx/wk1vH58vl4k+XecflXssbMbNyWJIB70AacLBos7QpPUVk6w8sSqIFHzja5AzirGnElLXJJypz79KuSgb0GBg5oAqWqNDYBTyx68dTXn66/ZeGNTuZNVt3hiuCGDsuSWJ6cV6igGBx2rhPihBC+jXbPFGzCFiCVBI6UAVYNEGpeOrbXohmzigAjZXyGznHH5138Z+T7rYHNcv8LefBVjnsG/nXXDvQA0vhemMilDnA+U0N3+lPHQUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of membranous lupus nephritis. The subepithelial immune deposits (D) are characteristic of any form of membranous nephropathy, but the intraendothelial tubuloreticular inclusions (arrow) strongly suggest underlying lupus.",
"    <div class=\"footnotes\">",
"     GBM: glomerular basement membrane; Ep: epithelial cell.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39543=[""].join("\n");
var outline_f38_39_39543=null;
var title_f38_39_39544="Management of mucous membrane pemphigoid";
var content_f38_39_39544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of mucous membrane pemphigoid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/39/39544/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39544/contributors\">",
"     Kim B Yancey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/39/39544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39544/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/39/39544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39544/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/39/39544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10872275\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membrane pemphigoid (MMP) is a rare, chronic, autoimmune, subepithelial blistering and erosive disease that affects the mucosal surfaces of the mouth (gingiva, movable mucosa, tongue, and palate), eyes, nose, nasopharynx, hypopharynx, larynx, esophagus, genitals,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anus (",
"    <a class=\"graphic graphic_picture graphicRef52208 graphicRef63997 graphicRef73874 \" href=\"mobipreview.htm?38/4/38985\">",
"     picture 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Limited cutaneous involvement (typically localized to the head, neck, or upper trunk) also may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMP may cause significant morbidity due to the tissue destruction and functional limitations that result from chronic mucosal inflammation, pain, and scarring. As examples, gingival inflammation and scarring may lead to gingival recession and loss of teeth, conjunctival scarring may contribute to blindness, and laryngeal scarring may result in airway loss.",
"   </p>",
"   <p>",
"    The treatment of MMP, particularly MMP involving the oral cavity, will be reviewed here. The management of ocular MMP (ocular cicatricial pemphigoid) and the clinical manifestations and diagnosis of MMP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link\">",
"     \"Ocular cicatricial pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15273?source=see_link\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3770?source=see_link\">",
"     \"Management and prognosis of bullous pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10872348\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of the treatment of MMP are to halt the progression of the disease, improve symptoms, and prevent adverse sequelae of chronic tissue inflammation and scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Few high quality trials have evaluated interventions for MMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, treatment is largely guided by clinical experience and small uncontrolled studies.",
"   </p>",
"   <p>",
"    The approach to therapy is influenced by the following clinical factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Site(s) of involvement",
"     </li>",
"     <li>",
"      Severity of disease",
"     </li>",
"     <li>",
"      Rate of disease progression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While patients with limited disease of the oral mucosa may be successfully managed with local therapies, patients with even mild involvement of sites associated with a higher risk of serious morbidity (ocular, genital, nasopharyngeal, laryngeal, or esophageal MMP) require systemic agents as initial therapy. Patients with severe or rapidly progressive disease also may benefit from early treatment with systemic agents. (See",
"    <a class=\"local\" href=\"#H86588898\">",
"     'Extraoral disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link\">",
"     \"Ocular cicatricial pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After clinical remission is attained, treatment is slowly tapered. The pace of tapering should be slow (eg, over several months) to minimize the risk for disease flares. If discontinuation of all therapy is not possible due to relapses, patients are maintained on the lowest effective topical or systemic maintenance regimen.",
"   </p>",
"   <p>",
"    In addition to pharmacological interventions, proper management of MMP includes consideration of the need for multidisciplinary care. Based upon the sites of known or suspected involvement, co-management between dermatologists, dentists, ophthalmologists, otolaryngologists, urologists, internists, gastroenterologists, or colorectal surgeons is often needed. Whenever feasible, patients should be managed by clinicians experienced in the treatment of MMP. (See",
"    <a class=\"local\" href=\"#H86588898\">",
"     'Extraoral disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86588195\">",
"    <span class=\"h1\">",
"     ORAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity is the most common site of MMP (",
"    <a class=\"graphic graphic_picture graphicRef52208 graphicRef63997 graphicRef73874 \" href=\"mobipreview.htm?38/4/38985\">",
"     picture 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/6\">",
"     6",
"    </a>",
"    ]. Our approach to the treatment of oral MMP varies based upon the severity of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10872355\">",
"    <span class=\"h2\">",
"     Mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patchy, localized involvement of the oral mucosa and skin can often be treated effectively with local therapy. Topical corticosteroids are the first-line local treatment due to extensive clinical experience with the use of these agents for MMP. Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and intralesional corticosteroid injections are additional therapeutic options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289514\">",
"    <span class=\"h3\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids, which may be used as monotherapy for patients with mild oral disease or as an adjunct to systemic treatment in patients with more extensive disease, are important components of the therapeutic arsenal. Randomized trials to evaluate the efficacy of topical corticosteroids have not been performed. As noted above, clinical experience supports the use of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174265188\">",
"    <span class=\"h4\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class I, super high potency topical corticosteroids (eg, 0.05%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate) in an ointment or gel base are recommended by most experts for treatment of oral MMP (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). Gels and ointments can be easily applied to mucosal surfaces and lack the gritty texture of topical corticosteroids formulated in dental pastes that some patients find unpleasant.",
"   </p>",
"   <p>",
"    Treatment is applied two to four times per day immediately after the affected areas are dried with soft disposable tissue paper. Drying the mucosa prior to application may enhance the adherence of the medication to the treatment area. Patients should avoid eating or drinking for at least 30 minutes after application.",
"   </p>",
"   <p>",
"    We encourage patients to do one of their daily applications immediately before bed since oral secretions are lessened during sleep. This may allow the medication to stay in place for a longer period.",
"   </p>",
"   <p>",
"    An alternative mode of topical corticosteroid administration for patients who find the direct application of topical corticosteroids difficult is the use of 5 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    as a swish and spit mouth rinse two to three times per day. Patients treated in this manner should be instructed to avoid swallowing the medication.",
"   </p>",
"   <p>",
"    Drug delivery via gingival trays is an additional method of drug administration that can be useful for patients with gingival involvement. The trays aid in the application of topical corticosteroids to lesional sites under occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The gingival tray should be fashioned in soft vinyl and fitted to cover the patient&rsquo;s gingiva (ie, not the patient&rsquo;s teeth). Trays containing topical corticosteroids are left in place for 10 to 20 minutes per treatment.",
"   </p>",
"   <p>",
"    Beneficial effects of topical corticosteroid therapy are usually evident within several weeks. If topical corticosteroid therapy is successful, treatment can be tapered slowly (over several months) by reducing the frequency of application and using lower potency agents. In our experience, patients who experience disease flares during topical corticosteroid tapering may benefit from a maintenance regimen in which treatment with a topical corticosteroid is alternated with topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (eg, topical tacrolimus applied Monday to Friday and a topical corticosteroid applied on weekends). Intermittent use of topical corticosteroids may help to reduce the risk for corticosteroid side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1770885\">",
"    <span class=\"h4\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of potential adverse effects of topical corticosteroid therapy include mucosal atrophy, oropharyngeal candidiasis, and dyspepsia. Topical or systemic antifungal therapy is effective for secondary candidiasis. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289616\">",
"    <span class=\"h3\">",
"     Topical tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , a calcineurin inhibitor, appears to be effective for some patients. Case reports document marked improvement in oral MMP with topical tacrolimus, including some patients who failed to respond well to topical corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1% ointment initially is applied two to three times per day and is tapered as tolerated. The method of administration mirrors that for topical corticosteroid treatment (see",
"    <a class=\"local\" href=\"#H174265188\">",
"     'Administration'",
"    </a>",
"    above). The higher cost of tacrolimus relative to many topical corticosteroids prohibits use of this therapy for some patients.",
"   </p>",
"   <p>",
"    A transient burning sensation may occur following the application of topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . In addition, concern has been raised regarding a relationship between the use of topical calcineurin inhibitors and cancer, resulting in the issuing of a public health advisory by the US Food and Drug Administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/12\">",
"     12",
"    </a>",
"    ]. However, a causative relationship has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289522\">",
"    <span class=\"h3\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional corticosteroid therapy is an option for disease in the anterior aspects of the mouth that do not respond sufficiently to other local measures. Support for the efficacy of this treatment is limited to clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injections should be placed into the superficial submucosa beneath erosions; deeper injections may increase the risk for mucosal atrophy. We inject 0.1 to 0.5 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (10",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    per injection site. We limit the total dose of triamcinolone acetonide administered during a single treatment session to 20 mg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289668\">",
"    <span class=\"h2\">",
"     Moderate to severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with oral MMP that fails to respond adequately to local therapy or who present with widespread oral disease may benefit from systemic agents. Systemic glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    are frequently used to manage these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1\">",
"     1",
"    </a>",
"    ]. The local therapies used for mild oral MMP are often prescribed as adjunctive agents. (See",
"    <a class=\"local\" href=\"#H10872355\">",
"     'Mild disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6525575\">",
"    <span class=\"h3\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids are frequently used for oral MMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1\">",
"     1",
"    </a>",
"    ]. However, data to support the efficacy of systemic glucocorticoids are limited. Our treatment regimen for systemic glucocorticoids is based upon clinical experience.",
"   </p>",
"   <p>",
"    We typically treat patients with 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day given as a single morning dose. Since long-term treatment with systemic glucocorticoids is unfavorable due to drug-related side effects, we taper and discontinue prednisone within six months, if possible. Topical therapy or a systemic drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) is used as a glucocorticoid-sparing agent to maintain clinical improvement during and after prednisone tapering. Patients who respond insufficiently to 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of prednisone may require higher doses of prednisone or alternative therapies. (See",
"    <a class=\"local\" href=\"#H10872369\">",
"     'Severe and refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Systemic glucocorticoid therapy may lead to endocrinological, musculoskeletal, cardiovascular, and other system abnormalities. The adverse effects of systemic glucocorticoids are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289599\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    in doses of 50 to 200 mg per day may be used for oral MMP that cannot be adequately managed with local therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/14\">",
"     14",
"    </a>",
"    ]. Data on the efficacy of dapsone for oral manifestations of MMP is limited to a few uncontrolled studies and case series in which some patients improved after the initiation of dapsone therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. As an example, dapsone appeared to be effective in a retrospective study that included 11 patients with MMP localized to the gingiva. Treatment with dapsone (up to 150 mg per day) for at least 12 weeks was associated with major or complete improvement in 10 patients (91 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/19\">",
"     19",
"    </a>",
"    ]. Additional support for the use of dapsone comes from studies performed in patients with ocular MMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link&amp;anchor=H192070#H192070\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Mild to moderate disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    is initiated at a low dose (eg, 25 to 50 mg per day) and is titrated upward as tolerated (eg, 25 mg to 50 mg per week depending on patient age and tolerance). The slow dose escalation is accompanied by close laboratory monitoring for adverse effects.",
"   </p>",
"   <p>",
"    Hemolysis and methemoglobinemia are pharmacological side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    that occur in virtually all treated patients. Patients with glucose-6-phosphate (G6PD) deficiency have an increased risk for this side effect. We assess for G6PD deficiency prior to initiating treatment. Other potentially severe (and usually rare) adverse effects of dapsone include leukopenia, agranulocytosis, aplastic anemia, hypersensitivity reactions, and neuropathy (usually motor, though a sensory component may coexist). More common adverse effects include headache, nausea, weakness, dizziness, and fatigue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the potential for serious hematological side effects, laboratory monitoring is necessary for patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    therapy. We typically obtain a complete blood count (CBC) with differential, liver function tests, and renal function tests prior to the start of therapy and repeat the CBC with differential every week during the first month of therapy and twice monthly for the subsequent two months. Thereafter, monitoring of the CBC, liver function tests, and renal function tests can be performed every three to four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10872369\">",
"    <span class=\"h2\">",
"     Severe and refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive immunosuppressive regimens and biologic therapies may lead to improvement in patients with severe MMP that cannot be managed with the interventions described above. The potential for serious adverse effects",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high cost of these agents limit their use as first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289572\">",
"    <span class=\"h3\">",
"     Immunosuppressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressants, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are used in combination with systemic glucocorticoids for patients with severe, refractory oral MMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/24\">",
"     24",
"    </a>",
"    ]. Support for the use of these agents primarily stems from uncontrolled studies of patients with ocular involvement and clinical experience with patients with oral disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1,21,25-30\">",
"     1,21,25-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link&amp;anchor=H2913554#H2913554\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When treating patients with severe, refractory oral MMP, we typically utilize a higher dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    than the dose we use as initial therapy for patients with moderate to severe oral MMP. We prescribe",
"    <strong>",
"     1",
"     <span class=\"nowrap\">",
"      mg/kg",
"     </span>",
"     per day of prednisone",
"    </strong>",
"    in addition to one of the following immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      (2 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day; dose adjustments may be indicated based upon thiopurine methyltransferase [TPMT] activity)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      <strong>",
"       mofetil",
"      </strong>",
"      (1 to 2.5 g per day)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We continue treatment with both drugs until disease control is achieved and has remained stable for at least four to six months. We then attempt to taper",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    gradually (eg, over another four to six months), while maintaining the dose of the nonsteroidal immunosuppressant. Once disease control is maintained without prednisone for four to six months, we attempt a slow taper to treatment discontinuation. However, because MMP is a chronic disease, most patients require continuation of some level of therapy. Whenever feasible, we attempt to maintain improvement with local rather than systemic therapy. (See",
"    <a class=\"local\" href=\"#H10872355\">",
"     'Mild disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon the findings of a retrospective study of six patients with MMP, combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil may be another useful treatment regimen for oral MMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential adverse effects of immunosuppressive therapies include bone marrow suppression and increased risk for infection or malignancy. The adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link&amp;anchor=H4#H4\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289544\">",
"    <span class=\"h3\">",
"     Biologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may be effective for oral MMP. The high cost of these agents is a limiting factor for therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289551\">",
"    <span class=\"h4\">",
"     Intravenous immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immunoglobulin (IVIG, 1 to 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    body weight administered over two to three days every two to six weeks for four to six months) is an often well-tolerated therapy that may be beneficial for patients with severe, refractory MMP, although the response to treatment is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/32-39\">",
"     32-39",
"    </a>",
"    ]. The use of IVIG for oral MMP is supported by a retrospective study of 20 patients with severe oral MMP in which 12 patients were treated with conventional immunosuppressive therapy and eight patients in whom conventional therapy was contraindicated were treated with IVIG (1 to 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per three-day cycle, initially repeated every four weeks). The mean follow-up period was four years. Patients treated with IVIG had better outcomes than those treated with conventional therapy; IVIG-treated patients had significantly shorter durations of treatment, fewer relapses, higher remission rates, fewer adverse effects, and better quality of life assessments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/37\">",
"     37",
"    </a>",
"    ]. The mean time to disease control was six months for patients who received IVIG compared with approximately nine months for patients who received conventional therapy.",
"   </p>",
"   <p>",
"    IVIG (1 to 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per three-day cycle, initially repeated every four weeks) also appeared to be effective in an uncontrolled study of 15 patients with severe MMP involving multiple mucosal surfaces that was poorly responsive to conventional immunosuppressive therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/38\">",
"     38",
"    </a>",
"    ]. All patients responded to therapy and were eventually able to discontinue concurrent systemic treatments. Treatment efficacy was evident within a mean of five months.",
"   </p>",
"   <p>",
"    The frequency of IVIG infusions is slowly tapered once disease control is attained, often by progressively increasing the period between treatments by two weeks and discontinuing treatment after a 16-week disease-free interval occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Potentially severe adverse effects of IVIG include anaphylaxis (especially in patients with IgA deficiency), aseptic meningitis, acute renal failure, hypertension, thrombotic events, and fluid overload. Other adverse effects of IVIG include headache, back pain, chills, fever, flushing, myalgias, hypertension, nausea, vomiting, and phlebitis at the site of infusion. The adverse effects of IVIG are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=see_link\">",
"     \"Intravenous immune globulin: Adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15289565\">",
"    <span class=\"h4\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , a chimeric,",
"    <span class=\"nowrap\">",
"     murine/human",
"    </span>",
"    IgG",
"    <sub>",
"     1",
"    </sub>",
"    kappa monoclonal antibody directed against CD20 on pre-B and B lymphocytes, has been used successfully for the treatment of severe MMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. The drug usually is given in combination with a systemic glucocorticoid, with or without other immunosuppressive agents.",
"   </p>",
"   <p>",
"    In a series of 25 patients with severe, refractory MMP involving the eyes, pharynx, larynx, or esophagus (including five patients classified as having mucous membrane predominant epidermolysis bullosa acquisita), one cycle of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given weekly for four weeks) was associated with complete responses in 17 patients (68 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/41\">",
"     41",
"    </a>",
"    ]. All patients were simultaneously treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunosuppressants.",
"   </p>",
"   <p>",
"    The median time to remission after one cycle of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    was 12 weeks, and five additional patients responded completely after a second cycle. Relapses were common after treatment; 10 patients who achieved complete responses after one cycle of rituximab relapsed (mean time to relapse = four months after a complete response). However, seven of eight of the relapsed patients regained complete responses after a second cycle of rituximab. Two patients who were simultaneously treated with conventional immunosuppressants and high-dose systemic glucocorticoids died due to serious infections.",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    as two 1000 mg doses separated by two weeks is an alternative approach to therapy that has been effective for some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/42\">",
"     42",
"    </a>",
"    ]. Additional data on rituximab in patients with ocular MMP is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link&amp;anchor=H192225#H192225\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include dizziness, nausea, itching, fever, chills, sneezing, myalgias, weakness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dyspnea. Severe adverse effects of rituximab include severe infusion reactions, tumor lysis syndrome, acute renal failure, severe mucocutaneous reactions, cardiac arrhythmias, angina, and progressive multifocal leukoencephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864849644\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of additional agents that have been reported to be effective in small numbers of patients include tetracyclines with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/44\">",
"     44",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/45,46\">",
"     45,46",
"    </a>",
"    ], sulfapyridine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/19\">",
"     19",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86588944\">",
"    <span class=\"h2\">",
"     Adjunctive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with oral involvement should follow a strict regimen of oral hygiene to avert the accumulation of plaque, the loss of gingiva, and acceleration of tooth decay. This includes brushing of the teeth two to three times each day along with daily flossing and obtaining regular dental cleanings every three to four months. Use of a pediatric toothbrush with soft bristles, toothpaste that lacks sodium lauryl sulfate, and mouthwashes free of alcohol facilitate patient compliance with oral hygiene measures by minimizing pain.",
"   </p>",
"   <p>",
"    Topical anesthetics (eg, viscous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/46/26338?source=see_link\">",
"     dyclonine",
"    </a>",
"    ) may be used to reduce pain. Patients may apply topical anesthetics before meals, toothbrushing, dental procedures, or other occasions in which pain control is required. The anesthetic should be manually applied directly to painful erosions, rather than used as a mouth rinse. Care should be taken to avoid spread of the anesthetic to pharyngeal, hypopharyngeal, or laryngeal areas to diminish the likelihood of aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86588898\">",
"    <span class=\"h1\">",
"     EXTRAORAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extraoral MMP (ocular, nasal, laryngeal, esophageal, or anogenital MMP) are considered to be at high risk for developing serious functional limitations as a consequence of mucosal inflammation and scarring. Thus, the approach to the treatment of patients with these manifestations of MMP differs from the approach to patients with only oral disease. Overall, pharmacological therapy is more aggressive; systemic agents are utilized initially regardless of the severity of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, early involvement of ophthalmologists, otolaryngologists, and gastroenterologists are indicated for patients with ocular, laryngeal, or esophageal symptoms, respectively. Consultation with an urologist or colorectal surgeon may be useful for patients with anogenital disease.",
"   </p>",
"   <p>",
"    Data are limited on the management of patients with nonocular extraoral MMP. In general, the approach to drug therapy of nasal, laryngeal, esophageal, and anogenital MMP mirrors the approach to ocular involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. The treatment of ocular MMP (ocular cicatricial pemphigoid) is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link&amp;anchor=H2913554#H2913554\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to systemic pharmacological therapy, other interventions may be useful for managing the extraoral manifestations of MMP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nasal involvement",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Twice daily irrigation of nasal passages with saline or tap water via a bulb syringe, a piston syringe, a neti pot, or a nasal irrigation device helps to gently remove crusts",
"     </li>",
"     <li>",
"      Humidified environment",
"     </li>",
"     <li>",
"      Nasal emollients",
"     </li>",
"     <li>",
"      Topical corticosteroid nasal sprays or drops",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Esophageal involvement",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Soft diet",
"     </li>",
"     <li>",
"      Interventions to diminish gastroesophageal reflex",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastric acidity",
"     </li>",
"     <li>",
"      Esophageal dilation of strictures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anogenital involvement",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Topical corticosteroids or topical calcineurin inhibitors",
"     </li>",
"     <li>",
"      Stool softeners",
"     </li>",
"     <li>",
"      Dilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adjunctive measures for ocular MMP (eg, lubrication, lid hygiene, and management of trichiasis) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link&amp;anchor=H192358#H192358\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Ocular care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864849990\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mucous membrane pemphigoid (MMP) is a rare, autoimmune blistering and erosive disorder that may affect multiple mucous membranes. The oral cavity is the most common site of involvement. (See",
"      <a class=\"local\" href=\"#H10872275\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The approach to the treatment of MMP is influenced by the site(s) of mucosal involvement and the severity of disease. Multidisciplinary management is often needed to minimize risk for adverse sequelae of this disease. (See",
"      <a class=\"local\" href=\"#H10872348\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mild oral MMP (patchy, localized involvement of the oral mucosa) may respond well to local therapy. For patients with mild oral MMP, we suggest a high potency topical corticosteroid as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and intralesional corticosteroid injections are additional options for local therapy. (See",
"      <a class=\"local\" href=\"#H10872355\">",
"       'Mild disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gingival trays may facilitate treatment of patients with significant gingival involvement by allowing application of topical corticosteroids to lesional sites under occlusion. Patients who have difficulty applying topical corticosteroids directly to affected sites may benefit from treatment with a corticosteroid mouth rinse. (See",
"      <a class=\"local\" href=\"#H174265188\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with extensive oral involvement or who fail to improve adequately with local therapy are candidates for systemic treatment. We suggest treating these patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use prednisone more frequently based upon personal experience of better results with this drug. However, the side effect profile of prednisone is a limiting factor for therapy. (See",
"      <a class=\"local\" href=\"#H15289668\">",
"       'Moderate to severe disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since long-term treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy is not desired, topical or systemic glucocorticoid-sparing agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil) are used to maintain improvement during and after prednisone tapering. (See",
"      <a class=\"local\" href=\"#H6525575\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe, refractory MMP may benefit from more aggressive therapy. High-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      given in combination with immunosuppressants, intravenous immunoglobulin (IVIG), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      are options for therapy. (See",
"      <a class=\"local\" href=\"#H10872369\">",
"       'Severe and refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacological therapy for the nonoral forms of MMP is similar to the approach used for ocular MMP (ocular cicatricial pemphigoid). Nonpharmacological interventions are also useful for the management of these patients. (See",
"      <a class=\"local\" href=\"#H86588898\">",
"       'Extraoral disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=see_link&amp;anchor=H2913554#H2913554\">",
"       \"Ocular cicatricial pemphigoid\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/1\">",
"      Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/2\">",
"      Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/3\">",
"      Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/4\">",
"      Lazarova Z, Yancey KB. Cicatricial pemphigoid: immunopathogenesis and treatment. Dermatologic Therapy 2002; 15:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/5\">",
"      Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003; :CD004056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/6\">",
"      Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/7\">",
"      Lee MS, Wakefield PE, Konzelman JL Jr, James WD. Oral insertable prosthetic device as an aid in treating oral ulcers. Arch Dermatol 1991; 127:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/8\">",
"      Gonzalez-Moles MA, Ruiz-Avila I, Rodriguez-Archilla A, et al. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/9\">",
"      Assmann T, Becker J, Ruzicka T, Megahed M. Topical tacrolimus for oral cicatricial pemphigoid. Clin Exp Dermatol 2004; 29:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/10\">",
"      Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol 2011; 91:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/11\">",
"      Suresh L, Martinez Calixto LE, Radfar L. Successful treatment of mucous membrane pemphigoid with tacrolimus. Spec Care Dentist 2006; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051760.htm (Accessed on November 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/13\">",
"      Ahmed AR, Kurgis BS, Rogers RS 3rd. Cicatricial pemphigoid. J Am Acad Dermatol 1991; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/14\">",
"      G&uuml;rcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009; 10:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/15\">",
"      Rogers RS 3rd, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/16\">",
"      Ciarrocca KN, Greenberg MS. A retrospective study of the management of oral mucous membrane pemphigoid with dapsone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/17\">",
"      Arash A, Shirin L. The management of oral mucous membrane pemphigoid with dapsone and topical corticosteroid. J Oral Pathol Med 2008; 37:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/18\">",
"      Matthews RW, Pinkney RC, Scully C. The management of intransigent desquamative gingivitis with Dapsone. Ann Dent 1989; 48:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/19\">",
"      Rogers RS 3rd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol 1988; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/20\">",
"      Hegarty AM, Ormond M, Sweeney M, Hodgson T. Dapsone efficacy and adverse events in the management of mucous membrane pemphigoid. Eur J Dermatol 2010; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/21\">",
"      Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/22\">",
"      Tauber J, Sainz de la Maza M, Foster CS. Systemic chemotherapy for ocular cicatricial pemphigoid. Cornea 1991; 10:185.",
"     </a>",
"    </li>",
"    <li>",
"     Hall RP, Mickle CP. Dapsone. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE.  (Ed), Elsevier Inc., Philadelphia 2007. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/24\">",
"      Kourosh AS, Yancey KB. Therapeutic approaches to patients with mucous membrane pemphigoid. Dermatol Clin 2011; 29:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/25\">",
"      Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/26\">",
"      Megahed M, Schmiedeberg S, Becker J, Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001; 45:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/27\">",
"      Lugovi L, Buljan M, Situm M, et al. Unrecognized cicatricial pemphigoid with oral manifestations and ocular complications. A case report. Acta Dermatovenerol Croat 2007; 15:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/28\">",
"      Korman NJ. Update on the use of azathioprine in the management of pemphigus and bullous pemphigoid. Med Surg Dermatol 1996; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/29\">",
"      Korman NJ. Update on the use of cyclophosphamide in the management of pemphigus, bullous pemphigoid, and cicatricial pemphigoid. Med Surg Dermatol 1998; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/30\">",
"      Doycheva D, Deuter C, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm 2011; 19:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/31\">",
"      Staines K, Hampton PJ. Treatment of mucous membrane pemphigoid with the combination of mycophenolate mofetil, dapsone, and prednisolone: a case series. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114:e49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/32\">",
"      Segura S, Iranzo P, Mart&iacute;nez-de Pablo I, et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007; 56:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/33\">",
"      Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study. Ophthalmology 1999; 106:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/34\">",
"      Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/35\">",
"      Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up. Ophthalmology 2004; 111:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/36\">",
"      Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol 2004; 111:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/37\">",
"      Ahmed AR, Col&oacute;n JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001; 137:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/38\">",
"      Sami N, Bhol KC, Razzaque Ahmed A. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid. Clin Immunol 2002; 102:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/39\">",
"      Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/40\">",
"      Ross AH, Jaycock P, Cook SD, et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/41\">",
"      Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/42\">",
"      Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/43\">",
"      Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 2013; 68:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/44\">",
"      Reiche L, Wojnarowska F, Mallon E. Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin Exp Dermatol 1998; 23:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/45\">",
"      Carrozzo M, Arduino P, Bertolusso G, et al. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg 2009; 38:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/46\">",
"      Carrozzo M, Arduino PG, Baldovino S, et al. Minocycline in combination with mycophenolate mofetil in oral mucous membrane pemphigoid. Eur J Dermatol 2008; 18:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39544/abstract/47\">",
"      Duong DJ, Moxley RT 3rd, Kellman RM, et al. Thalidomide therapy for cicatricial pemphigoid. J Am Acad Dermatol 2002; 47:S193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83575 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-002C802214-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39544=[""].join("\n");
var outline_f38_39_39544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H864849990\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10872275\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10872348\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86588195\">",
"      ORAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10872355\">",
"      Mild disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15289514\">",
"      - Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H174265188\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1770885\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15289616\">",
"      - Topical tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15289522\">",
"      - Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15289668\">",
"      Moderate to severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6525575\">",
"      - Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15289599\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10872369\">",
"      Severe and refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15289572\">",
"      - Immunosuppressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15289544\">",
"      - Biologic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15289551\">",
"      Intravenous immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15289565\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H864849644\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86588944\">",
"      Adjunctive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86588898\">",
"      EXTRAORAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H864849990\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/83575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/83575|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/48/20226\" title=\"picture 1A\">",
"      Mucous membrane pemphigoid lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/49/38674\" title=\"picture 1B\">",
"      Mucous membrane pemphigoid palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/7/33905\" title=\"picture 1C\">",
"      Mucous membrane pemphigoid gingivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/83575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15273?source=related_link\">",
"      Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3770?source=related_link\">",
"      Management and prognosis of bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4138?source=related_link\">",
"      Ocular cicatricial pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_39_39545="Evaluation and management of the cardiovascular complications of cocaine abuse";
var content_f38_39_39545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and management of the cardiovascular complications of cocaine abuse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     James P Morgan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/39/39545/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/39/39545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is among the most commonly used illicit recreational drugs worldwide. Because even casual use of cocaine may be associated with acute or chronic cardiovascular toxicity, the large numbers of exposed individuals represent a reservoir of patients who may present with sequelae related to the cardiovascular system. Thus, the cardiovascular history should include questions about cocaine use, specifically focusing on the occurrence of symptoms associated with ischemic heart disease.",
"   </p>",
"   <p>",
"    Cocaine use is more frequently associated with acute rather than chronic cardiovascular illness. Among cocaine users who present to emergency departments, cardiovascular complaints, particularly chest pain, are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In such patients, acute coronary syndromes (including myocardial ischemia and infarction), aortic dissection and rupture, arrhythmias, myocarditis, and vasculitis need to be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardiovascular effects and complications of cocaine use, as well as the management of cocaine-associated ischemia, will be reviewed here. Other issues relating to cocaine use, including the general approach to patients with chest pain and a history of cocaine use, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major cardiovascular effects of cocaine appear to be caused by the inhibition of norepinephrine reuptake into the synaptic cleft by sympathetic neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/2\">",
"     2",
"    </a>",
"    ]. Since reuptake is the major mechanism by which neurotransmitters are removed from active receptor sites, this inhibition results in potentiation of the response to sympathetic stimulation of innervated organs and to infused catecholamine. Cocaine may also enhance the release of catecholamines from central and peripheral stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/4\">",
"     4",
"    </a>",
"    ]. The ensuing sympathomimetic actions (increased myocardial inotropy, heart rate, systemic blood pressure, and coronary artery constriction) are mediated by stimulation of the alpha- and beta adrenergic receptors and result in increased myocardial oxygen demand. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H3#H3\">",
"     \"Cocaine: Acute intoxication\", section on 'Pharmacology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other cardiovascular effects of cocaine include promotion of thrombus formation (via activation of platelets, stimulation of platelet aggregability, and potentiation of thromboxane production) and proarrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The cardiovascular effects produced by intravenous, intranasal, and inhaled cocaine are thought to be similar regardless of the route of ingestion. The clinical consequences of these effects are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR CONDITIONS ASSOCIATED WITH COCAINE USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine use is associated with a number of cardiovascular conditions, including myocardial ischemia or infarction, myocarditis and the development of a cardiomyopathy, arrhythmias, coronary artery aneurysm formation, stroke, and aortic dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Most cocaine-associated myocardial infarctions occur in the absence of high grade atherosclerotic epicardial coronary artery stenoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;From a practical point of view, all patients with a history of chest pain and recent cocaine use should be evaluated for myocardial",
"    <span class=\"nowrap\">",
"     ischemia/infarction",
"    </span>",
"    and aortic dissection. However, many will ultimately be diagnosed as having either noncardiac or undifferentiated chest pain. The approach to these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H6#H6\">",
"     \"Cocaine: Acute intoxication\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute coronary syndrome is the most common cardiac condition associated with cocaine use and can occur with all routes of cocaine ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The precise incidence of myocardial ischemia, with or without infarction, is difficult to quantitate. However, it is likely that the number of patients in whom cocaine use is identified as a potential causative factor and who come to medical attention is small relative to the total population of abusers. In some cases, the relationship of the ischemic event to cocaine use is unclear based upon the time of onset of symptoms and the known pharmacokinetics of cocaine and its metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that preexistent cardiovascular disease or other abnormalities are prerequisites for the development of cocaine-related myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/11\">",
"     11",
"    </a>",
"    ]. Many patients who abuse cocaine also smoke cigarettes, but many have no other cardiac risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. However, certain subgroups of patients may be at increased risk of manifesting cardiovascular toxicity if exposed to cocaine, including those who consume alcohol, are pregnant, or are infected with HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based principally on the ability of cocaine to inhibit norepinephrine uptake and promote thrombus formation, three mechanisms have been proposed for cocaine-induced ischemia. It is likely that more than one of these may contribute to the clinical syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased myocardial oxygen demand &mdash; Increased myocardial oxygen demand results from the sympathomimetic actions of cocaine that increase myocardial inotropy, heart rate, and systemic blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/16\">",
"       16",
"      </a>",
"      ]. This may pose a significant problem to patients in whom coronary blood flow is compromised by the presence of fixed stenoses. However, most patients with cocaine-induced myocardial ischemia do not have significant underlying coronary disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/8,12\">",
"       8,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coronary artery vasoconstriction and spasm &mdash; Cocaine can constrict the large and small coronary vessels under some circumstances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/16-19\">",
"       16-19",
"      </a>",
"      ]. The vasoconstrictor effects of cocaine on the large coronary arteries are mediated primarily through stimulation of the alpha-adrenergic receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coronary artery thrombosis &mdash; Pathologic and angiographic studies have demonstrated coronary thrombi in some patients with cocaine-related myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction (MI) is a well-described complication among patients presenting with cocaine-induced ischemic symptoms and is unrelated to the dose or frequency of use. While the most common acute condition is myocardial ischemia, only about six percent of patients with chest pain and recent cocaine use sustain an MI. Approximately one-half of patients who present with cocaine-related MI have had previous episodes of chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported incidence of MI in patients with cocaine-associated chest pain ranges between 0.7 and 5.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Cocaine-associated MI is particularly prevalent in younger patients as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Third National Health and Nutrition Examination Survey (NHANES) of 10,085 adults between the age of 18 and 45, approximately 25 percent of nonfatal MIs were attributable to frequent cocaine use (frequent defined as 10 or more uses in a lifetime) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of almost 4000 patients with acute MI, 38 (1 percent) had used cocaine within the past year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/13\">",
"       13",
"      </a>",
"      ]. The mean age of cocaine users was significantly lower than that of nonusers (44 versus 61 years). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=see_link\">",
"       \"Coronary heart disease and myocardial infarction in young men and women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MI is usually temporally related to cocaine use. In different series, approximately two-thirds of infarctions occurred within three hours of cocaine use (range one minute to four days) and approximately 25 percent occurred within 60 minutes after cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. The risk of a MI was 24 times greater than the baseline risk during the initial 60 minutes after cocaine ingestion and decreased progressively thereafter (",
"    <a class=\"graphic graphic_figure graphicRef64056 \" href=\"mobipreview.htm?35/41/36509\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cocaine-associated MIs occur in the absence of high grade atherosclerotic epicardial coronary artery stenoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. In a report of 92 patients with cocaine-associated MI who underwent coronary angiography, 35 (38 percent) were considered to have normal coronary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/12\">",
"     12",
"    </a>",
"    ]. Among these patients, the anterior wall was the site of infarction in 27 (77 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of cocaine-associated MI may be more frequent than MI in the absence of cocaine use. As an example, one prospective study of 479 patients age 50 or younger with acute coronary syndrome identified 24 patients who tested positive for cocaine on admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/22\">",
"     22",
"    </a>",
"    ]. Cocaine users had significantly higher troponin levels (53 versus 23",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    lower ejection fractions post-MI (45 versus 52 percent), and higher in-hospital mortality (8.3 versus 0.8 percent) than non users.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004073\">",
"    <span class=\"h2\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute aortic dissection can result from the use of cocaine and commonly presents with chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/24\">",
"     24",
"    </a>",
"    ]. It is a frequent cause of dissection in a young, inner-city population (37 percent in one report) and occurs more often in those with untreated or poorly controlled hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. In the International Registry of Aortic Dissection, an association was made with cocaine use in 0.5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coronary artery aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery aneurysms are relatively common in cocaine users who undergo angiography. This was illustrated in a review of 112 consecutive patients with a history of cocaine use who underwent coronary angiography, in which 30 percent of cocaine users were noted to have coronary artery aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast, only approximately 1.5 percent of unselected patients are noted to have coronary artery aneurysms at the time of coronary angiography or autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Coronary artery aneurysms can be a potential cause of myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=see_link&amp;anchor=H25#H25\">",
"     \"Congenital and pediatric coronary artery abnormalities\", section on 'Coronary artery aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Myocarditis and cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis is a common autopsy finding among subjects dying from cocaine abuse, affecting as many as 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/1,29-32\">",
"     1,29-32",
"    </a>",
"    ]. Myocarditis has also been reported on myocardial biopsies of active users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/30\">",
"     30",
"    </a>",
"    ]. The precise mechanism of the myocarditis is not clear, and hypotheses range from hypersensitivity reactions leading to vasculitis and myocarditis to catecholamine-induced toxicity. Though potentially life-threatening, cocaine-induced myocarditis may be fully reversible if identified early in the disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with an acute episode of myocarditis should be managed in a similar fashion to patients with non-cocaine-associated myocarditis. One notable exception is that drugs with beta receptor blocking properties should be avoided in cocaine users. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=see_link\">",
"     \"Natural history and therapy of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dilated cardiomyopathy has been documented among cocaine users, although a cause and effect relationship has not been definitively established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/34\">",
"     34",
"    </a>",
"    ]. In a study of 84 asymptomatic and apparently healthy cocaine users, left ventricular systolic dysfunction was found in six (7 percent) on testing performed after two weeks of abstinence from cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/15\">",
"     15",
"    </a>",
"    ]. As such, otherwise unexplained cardiac enlargement in a younger person without a family history of dilated cardiomyopathy should raise the possibility of cocaine abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of cocaine-associated cardiomyopathy is not well defined but the following may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine exerts direct toxic effects on the heart, which lead to the destruction of myofibrils, interstitial fibrosis, myocardial dilation, and heart failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cocaine-induced hyperadrenergic state may produce contraction band necrosis in the heart and other structural changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/36-38\">",
"       36-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both myocarditis and cardiomyopathy may be caused by infectious agents in patients who abuse cocaine parenterally, either through direct invasion of the myocardium or stimulation of an autoimmune reaction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=see_link\">",
"       \"Etiology and pathogenesis of myocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic ischemia or prior myocardial infarction can result in a cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"       \"Diagnosis and management of ischemic cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abstaining from additional cocaine ingestion can lead to complete reversal of the myocardial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, patients with permanent myocardial injury from a prior infarction may not recover normal left ventricular function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arrhythmias and conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias and conduction abnormalities are uncommonly seen in patients abusing cocaine. The arrhythmogenic potential of cocaine is poorly understood, but because of its pharmacological profile and ability to induce a hyperadrenergic state, it is likely that the drug can produce or exacerbate arrhythmias and conduction abnormalities under some circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H5#H5\">",
"     \"Cocaine: Acute intoxication\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the abnormalities that have been associated with cocaine use are sinus tachycardia and bradycardia, bundle-branch block, sudden death (ventricular fibrillation or asystole), ventricular tachycardia and accelerated idioventricular rhythm, heart block, torsades de pointes, a variety of supraventricular arrhythmias, an ECG pattern typical of Brugada syndrome (a pseudo-right bundle branch block and persistent ST segment elevation in V1 to V3), and QT prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/1,9,42-50\">",
"     1,9,42-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine acts like a class I antiarrhythmic agent, producing local anesthetic effects via sodium channel blockade in the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/51\">",
"     51",
"    </a>",
"    ]. Thus, other factors have to contribute to the development of arrhythmia. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Altering automaticity by a direct effect on myocardium",
"     </li>",
"     <li>",
"      Altering autonomic balance by increasing circulating catecholamine levels",
"     </li>",
"     <li>",
"      Inducing ischemia with resultant electrical inhomogeneity",
"     </li>",
"     <li>",
"      Creating an anatomic substrate for reentrant arrhythmia",
"     </li>",
"     <li>",
"      Altering repolarization with QT prolongation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rhythm disturbances associated with cocaine abuse are typically transient and disappear when the drug is metabolized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of ischemic stroke may be up to seven-fold higher in cocaine users versus non-users [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The acute management of cocaine-induced stroke is similar to that of stroke occurring in non-cocaine-users. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of cocaine-induced brain ischemia is multifactorial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine stimulates vasospasm, presumably by increasing levels of extracellular monoamines, particularly dopamine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cocaine may cause thrombus formation in the cerebral vasculature, in the same way that it causes coronary artery thrombosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cardiovascular effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term cocaine use may cause pathologic changes in the cerebral vasculature (vasculitis) that impair cellular oxygenation by exacerbating nonlaminar blood flow and sludging in the vessels, with consequent increase in platelet aggregation and thrombus formation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/3,57\">",
"       3,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the precise mechanism, cocaine-induced cerebral ischemia can cause marked hypoperfusion abnormalities associated with severe neurologic deficits. More subtle cognitive deficits also can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/58\">",
"     58",
"    </a>",
"    ]. Over time, repeated ischemic episodes and subsequent reperfusion can weaken vessel walls, thereby increasing the likelihood of cerebral hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine abuse is also associated with intracerebral and subarachnoid hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Miscellaneous cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine abuse can produce a variety of other cardiac complications, including left ventricular hypertrophy, infectious endocarditis among intravenous users, and mesenteric ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/11,60\">",
"     11,60",
"    </a>",
"    ]. Accelerated atherosclerosis has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVALUATION OF COCAINE-INDUCED CHEST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a patient with chest pain following cocaine ingestion is similar to that of non-users with chest pain and includes a complete history and physical examination, electrocardiography (ECG), radiologic studies, and serial serum markers searching for evidence of myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, the typical patient with a cocaine-related MI is a young man with chest pain and a history of repetitive cocaine use but without cardiac risk factors other than tobacco smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. The chest pain is often accompanied by anxiety, dyspnea, palpitations, and nausea. As a result, all young patients with an acute coronary syndrome, particularly those with the above characteristics, should be carefully questioned about cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Toxicology assays for the drug or its metabolites may be useful if exposure to cocaine is suspected or requires confirmation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"     \"Diagnostic approach to chest pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) is often difficult to interpret in young patients, given the relatively high incidence of early repolarization changes and left ventricular hypertrophy in this population. As an example, up to 84 percent of patients with cocaine-associated chest pain may have abnormal ECGs; up to 43 percent of cocaine abusers without an MI may have ST segment elevation &ge;0.1 mV in two or more contiguous ECG leads [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. On the other hand, MIs occur in some patients with an ECG that is normal or has only nonspecific findings. Because of the difficulty in identifying cocaine users with chest pain who are at low risk of infarction, most are admitted to the hospital for further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=see_link&amp;anchor=H2#H2\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Early repolarization'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3285?source=see_link\">",
"     \"Electrocardiographic diagnosis of left ventricular hypertrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Serum markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of circulating troponin in serum is specific for damage to the myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In contrast, chemical markers such as myoglobin, CK, and CK-MB may be elevated in the absence of infarction if skeletal muscle injury, rhabdomyolysis, or increased motor activity has occurred. This was illustrated in a study of 97 patients presenting with chest pain, 20 percent of whom had recent cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/67\">",
"     67",
"    </a>",
"    ]. The specificity of myoglobin for myocardial infarction was significantly reduced in the setting of recent cocaine use. There was also a nonsignificant trend toward reduced specificity of CK-MB. However, the specificity of cardiac troponin I remained high and was unaffected by recent cocaine ingestion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=see_link\">",
"     \"Biomarkers of cardiac injury other than troponins and creatine kinase\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF COCAINE-RELATED MYOCARDIAL ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cocaine-related unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction are, for the most part, managed in a manner similar to other patients with these diagnoses. One notable exception is the use of drugs with beta receptor blocking properties, which are generally",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended in the early phases of acute coronary syndromes in patients with recent cocaine use. This section will highlight the ways in which treatment differs for patients with myocardial ischemia or infarction in the setting of acute cocaine intoxication. The treatment of acute coronary syndromes and the management of cocaine-associated chest pain, including the use of beta blockers, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been no well-designed, randomized, prospective clinical trials to compare treatment strategies for cocaine-associated myocardial ischemia, and thus evidence comes from observations in animals, experimental trials in the catheterization laboratory, observational studies, case series, and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21\">",
"     21",
"    </a>",
"    ]. Our approach and recommendations are generally similar to those made in the 2008 AHA scientific statement on the management of cocaine-associated chest pain and myocardial infarction and the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    Task Force guidelines for the management of patients with unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21,65\">",
"     21,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004210\">",
"    <span class=\"h2\">",
"     Medical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with revascularization, the medical management of patients with an acute coronary syndrome and recent cocaine use is similar to that in the broad population of patients with an acute coronary syndrome. One notable exception is the use of drugs with beta receptor blocking properties, which are generally",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended in the early phases of acute coronary syndromes in patients with recent cocaine use. An expanded discussion of the early treatment of cocaine-associated chest pain is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H16#H16\">",
"     \"Cocaine: Acute intoxication\", section on 'Chest pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004402\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is an important part of the early treatment of chest pain associated with cocaine use, particularly given the propensity of cocaine to induce thrombus formation via the activation of platelets, stimulation of platelet aggregability, and potentiation of thromboxane production. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Cardiovascular effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004409\">",
"    <span class=\"h3\">",
"     Nitroglycerin and calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual or intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oral calcium channel blockers are safe and effective medications for patients with ischemic chest discomfort and ST-segment elevation or depression. These can also be used for patients with normal ECGs or minimal ST-segment deviation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004416\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early in their care, patients with recent cocaine ingestion should receive adequate doses of benzodiazepines, as needed, for sedation and control of blood pressure and heart rate. Some patients require large cumulative doses of benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H12#H12\">",
"     \"Cocaine: Acute intoxication\", section on 'Psychomotor agitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9004423\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with cocaine-associated myocardial ischemia or infarction, we recommend not using beta blockers prior to elimination of the cocaine from the patient&rsquo;s body. This proscription is based principally upon theoretical concerns of coronary artery vasoconstriction and systemic hypertension, which can result from unopposed alpha adrenergic stimulation. In addition, death rates for patients with cocaine-associated MI are low and thus the usual benefit from beta blockers after MI may be lost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21,68\">",
"     21,68",
"    </a>",
"    ]. The use of beta blockers in patients presenting to the emergency room in the setting of acute cocaine intoxication is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H27#H27\">",
"     \"Cocaine: Acute intoxication\", section on 'Management'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Whether a beta blocker should be started after the elimination of cocaine in patients with a documented MI remains unclear. The likelihood of recurrent cocaine use argues against such a strategy. We suggest that patients with left ventricular systolic dysfunction or ventricular arrhythmias be considered for beta blockers at the time of discharge, but only if the risk of recurrent cocaine use is low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link&amp;anchor=H32#H32\">",
"     \"Cocaine abuse and dependence in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Reperfusion and revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with a history of recent cocaine use, in whom an acute non-ST elevation MI (NSTEMI) or ST-segment elevation MI (STEMI) is likely or definitively diagnosed, is similar to that in the broad population of patients with acute MI. This includes the use of an early invasive strategy in some patients with NSTEMI, early reperfusion strategies in patients with STEMI, and the appropriate use of antithrombotic drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with persistent ST-segment elevation, after treatment with nitroglycerine and calcium channel blockers, we agree with the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    Task Force guidelines to proceed with immediate coronary angiography and percutaneous coronary intervention (if indicated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21,65\">",
"     21,65",
"    </a>",
"    ]. Fibrinolytic therapy is an acceptable alternative when timely coronary angiography is not possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two specific management issues merit special attention in patients with cocaine-associated MI: the choice of early reperfusion strategy and the choice of stent type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16774265\">",
"    <span class=\"h3\">",
"     Early reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in any patient with a suspected acute coronary syndrome, early reperfusion is an important part of the management of an acute coronary syndrome associated with cocaine use. In patients with STEMI and recent cocaine use, we suggest coronary angiography and primary percutaneous coronary intervention (if indicated by usual criteria) rather than fibrinolysis for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As the specificity of ST segment elevation on the ECG is lower in young people due to the common finding of benign early repolarization (J-point elevation), the inappropriate use of fibrinolytic therapy becomes more likely.",
"     </li>",
"     <li>",
"      There are reports of a higher rate of intracranial hemorrhage after fibrinolytic therapy in patients who use cocaine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General indications for the use of reperfusion in patients with STEMI and NSTEMI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link&amp;anchor=H32#H32\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H33#H33\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Summary'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16774314\">",
"    <span class=\"h3\">",
"     Stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with a history of cocaine use are likely to be non-compliant with recommendations for long-term dual antiplatelet therapy. In addition, there is an increased rate of stent thrombosis with both bare-metal and drug-eluting stents reported in patients with cocaine-associated myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons the following two strategies should be considered in patients with cocaine-associated myocardial ischemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with acute coronary syndromes the risk of stent thrombosis should be compared to the risk of a conservative management strategy with intensive medical therapy. The choice between the two strategies should be made on the basis of an individual patient's clinical characteristics.",
"     </li>",
"     <li>",
"      Bare-metal stents should be chosen in preference to drug-eluting stents when a decision has been made to place a stent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CESSATION OF COCAINE USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cessation of cocaine use is essential for secondary prevention, although modification of other risk factors, in particular, tobacco smoking, may also play a role. Unfortunately, among patients with cocaine-associated chest pain, approximately 60 percent admit to continued cocaine use in the year after a symptomatic episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/39/39545/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine is among the most commonly used illicit recreational drugs worldwide, and even casual use of cocaine may be associated with acute or chronic cardiovascular toxicity. Acute coronary syndromes (including myocardial ischemia and infarction), aortic dissection and rupture, arrhythmias, myocarditis, and vasculitis are potential toxicities related to cocaine ingestion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major cardiovascular effects of cocaine appear to be caused by the inhibition of norepinephrine reuptake into the synaptic cleft by sympathetic neurons. Since reuptake is the major mechanism by which neurotransmitters are removed from active receptor sites, this inhibition results in potentiation of the response to sympathetic stimulation of innervated organs and to infused catecholamine. Cocaine may also enhance the release of catecholamines from central and peripheral stores. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cardiovascular effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An acute coronary syndrome is the most common cardiac condition associated with cocaine use. The mechanisms of cocaine-associated myocardial ischemia include coronary artery spasm, a prothrombotic state in the coronary circulation, and increases in heart rate and blood pressure which increase myocardial oxygen consumption. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Myocardial ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myocardial infarction (MI) is a well-described complication among patients presenting with cocaine-induced ischemic symptoms, affecting about 6 percent of patients with chest pain and recent cocaine use, and is unrelated to the dose or frequency of use. Most cocaine-associated MIs occur in the absence of high grade atherosclerotic epicardial coronary artery stenoses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Myocardial infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myocarditis is a common autopsy finding among subjects dying from cocaine abuse, affecting as many as 20 to 30 percent of cocaine users through an unclear mechanism(s). If identified early in the disease process, cocaine-induced myocarditis may be fully reversible, particularly in patients who are able to completely abstain from further cocaine use. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Myocarditis and cardiomyopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach to the patient with chest pain following cocaine ingestion is the same as the approach in non-users and includes a complete history and physical examination, electrocardiography (ECG), radiologic studies, and serial serum markers searching for evidence of myocardial infarction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=see_link\">",
"       \"Diagnostic approach to chest pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with cocaine-related unstable angina, non-ST elevation MI, or ST elevation MI (STEMI) are, for the most part, managed in a manner similar to other patients with these diagnoses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , calcium channel blockers, and benzodiazepines are all safe and effective therapies in the early treatment of cocaine-associated chest pain. (See",
"      <a class=\"local\" href=\"#H9004210\">",
"       'Medical therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in any patient with a suspected acute coronary syndrome, early reperfusion is an important part of the management of an acute coronary syndrome associated with cocaine use. In patients with STEMI and recent cocaine use, we suggest coronary angiography and primary percutaneous coronary intervention (if indicated by usual criteria) rather than fibrinolysis because of the decreased specificity of ECG findings and safety concerns (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, fibrinolytic therapy is an acceptable alternative when timely coronary angiography is not possible. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Reperfusion and revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with cocaine-associated myocardial ischemia or infarction, we recommend not using beta blockers prior to elimination of the cocaine from the patient&rsquo;s body (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This is based principally upon theoretical concerns of coronary artery vasoconstriction and systemic hypertension, which can result from unopposed alpha adrenergic stimulation. (See",
"      <a class=\"local\" href=\"#H9004210\">",
"       'Medical therapies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H27#H27\">",
"       \"Cocaine: Acute intoxication\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/1\">",
"      Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/2\">",
"      Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010; 122:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/3\">",
"      Krendel DA, Ditter SM, Frankel MR, Ross WK. Biopsy-proven cerebral vasculitis associated with cocaine abuse. Neurology 1990; 40:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/4\">",
"      Maraj S, Figueredo VM, Lynn Morris D. Cocaine and the heart. Clin Cardiol 2010; 33:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/5\">",
"      Togna G, Tempesta E, Togna AR, et al. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment. Haemostasis 1985; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/6\">",
"      Kugelmass AD, Shannon RP, Yeo EL, Ware JA. Intravenous cocaine induces platelet activation in the conscious dog. Circulation 1995; 91:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/7\">",
"      Heesch CM, Wilhelm CR, Ristich J, et al. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart 2000; 83:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/8\">",
"      Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992; 10:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/9\">",
"      Isner JM, Estes NA 3rd, Thompson PD, et al. Acute cardiac events temporally related to cocaine abuse. N Engl J Med 1986; 315:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/10\">",
"      Lange RA, Willard JE. The cardiovascular effects of cocaine. Heart Dis Stroke 1993; 2:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/11\">",
"      Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine. Ann Emerg Med 1991; 20:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/12\">",
"      Minor RL Jr, Scott BD, Brown DD, Winniford MD. Cocaine-induced myocardial infarction in patients with normal coronary arteries. Ann Intern Med 1991; 115:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/13\">",
"      Mittleman MA, Mintzer D, Maclure M, et al. Triggering of myocardial infarction by cocaine. Circulation 1999; 99:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/14\">",
"      Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med 1995; 333:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/15\">",
"      Bertolet BD, Freund G, Martin CA, et al. Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse population. Clin Cardiol 1990; 13:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/16\">",
"      Lange RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989; 321:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/17\">",
"      Vitullo JC, Karam R, Mekhail N, et al. Cocaine-induced small vessel spasm in isolated rat hearts. Am J Pathol 1989; 135:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/18\">",
"      Kalsner S. Cocaine sensitization of coronary artery contractions: mechanism of drug-induced spasm. J Pharmacol Exp Ther 1993; 264:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/19\">",
"      Afonso L, Mohammad T, Thatai D. Crack whips the heart: a review of the cardiovascular toxicity of cocaine. Am J Cardiol 2007; 100:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/20\">",
"      Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaine-associated chest pain. Cocaine Associated Chest Pain (COCHPA) Study Group. Acad Emerg Med 1994; 1:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/21\">",
"      McCord J, Jneid H, Hollander JE, et al. Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 2008; 117:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/22\">",
"      Carrillo X, Cur&oacute;s A, Muga R, et al. Acute coronary syndrome and cocaine use: 8-year prevalence and inhospital outcomes. Eur Heart J 2011; 32:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/23\">",
"      Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation 2001; 103:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/24\">",
"      Hsue PY, Salinas CL, Bolger AF, et al. Acute aortic dissection related to crack cocaine. Circulation 2002; 105:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/25\">",
"      Eagle KA, Isselbacher EM, DeSanctis RW, International Registry for Aortic Dissection (IRAD) Investigators. Cocaine-related aortic dissection in perspective. Circulation 2002; 105:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/26\">",
"      Satran A, Bart BA, Henry CR, et al. Increased prevalence of coronary artery aneurysms among cocaine users. Circulation 2005; 111:2424.",
"     </a>",
"    </li>",
"    <li>",
"     Waller BF. Chapter 55. Nonatherosclerotic Coronary Heart Disease. In: Hurst's The Heart, 13th, Fuster V, O'Rourke RA, Walsh RA, et al (Eds), McGraw-Hill, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/28\">",
"      Glickel SZ, Maggs PR, Ellis FH Jr. Coronary artery aneurysm. Ann Thorac Surg 1978; 25:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/29\">",
"      Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992; 85:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/30\">",
"      Peng SK, French WJ, Pelikan PC. Direct cocaine cardiotoxicity demonstrated by endomyocardial biopsy. Arch Pathol Lab Med 1989; 113:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/31\">",
"      Virmani R, Robinowitz M, Smialek JE, Smyth DF. Cardiovascular effects of cocaine: an autopsy study of 40 patients. Am Heart J 1988; 115:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/32\">",
"      Hogya PT, Wolfson AB. Chronic cocaine abuse associated with dilated cardiomyopathy. Am J Emerg Med 1990; 8:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/33\">",
"      Isner JM, Chokshi SK. Cardiovascular complications of cocaine. Curr Probl Cardiol 1991; 16:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/34\">",
"      Wiener RS, Lockhart JT, Schwartz RG. Dilated cardiomyopathy and cocaine abuse. Report of two cases. Am J Med 1986; 81:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/35\">",
"      Willens HJ, Chakko SC, Kessler KM. Cardiovascular manifestations of cocaine abuse. A case of recurrent dilated cardiomyopathy. Chest 1994; 106:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/36\">",
"      Fineschi V, Silver MD, Karch SB, et al. Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol 2005; 99:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/37\">",
"      Ren S, Tong W, Lai H, et al. Effect of long-term cocaine use on regional left ventricular function as determined by magnetic resonance imaging. Am J Cardiol 2006; 97:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/38\">",
"      Arora S, Alfayoumi F, Srinivasan V. Transient left ventricular apical ballooning after cocaine use: is catecholamine cardiotoxicity the pathologic link? Mayo Clin Proc 2006; 81:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/39\">",
"      Henzlova MJ, Smith SH, Prchal VM, Helmcke FR. Apparent reversibility of cocaine-induced congestive cardiomyopathy. Am Heart J 1991; 122:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/40\">",
"      Om A, Ellahham S, Ornato JP. Reversibility of cocaine-induced cardiomyopathy. Am Heart J 1992; 124:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/41\">",
"      Chokshi SK, Moore R, Pandian NG, Isner JM. Reversible cardiomyopathy associated with cocaine intoxication. Ann Intern Med 1989; 111:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/42\">",
"      Bauman JL, Grawe JJ, Winecoff AP, Hariman RJ. Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations. J Clin Pharmacol 1994; 34:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/43\">",
"      Om A, Ellenbogen KA, Vetrovec GW. Cocaine-induced bradyarrhythmias. Am Heart J 1992; 124:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/44\">",
"      Schrem SS, Belsky P, Schwartzman D, Slater W. Cocaine-induced torsades de pointes in a patient with the idiopathic long QT syndrome. Am Heart J 1990; 120:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/45\">",
"      Nanji AA, Filipenko JD. Asystole and ventricular fibrillation associated with cocaine intoxication. Chest 1984; 85:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/46\">",
"      Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000; 75:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/47\">",
"      Magnano AR, Talathoti NB, Hallur R, et al. Effect of acute cocaine administration on the QTc interval of habitual users. Am J Cardiol 2006; 97:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/48\">",
"      Hsue PY, McManus D, Selby V, et al. Cardiac arrest in patients who smoke crack cocaine. Am J Cardiol 2007; 99:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/49\">",
"      Haigney MC, Alam S, Tebo S, et al. Intravenous cocaine and QT variability. J Cardiovasc Electrophysiol 2006; 17:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/50\">",
"      Antzelevitch C. Brugada syndrome. Pacing Clin Electrophysiol 2006; 29:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/51\">",
"      Tisdale JE, Shimoyama H, Sabbah HN, Webb CR. The effect of cocaine on Ventricular fibrillation threshold in the normal canine heart. Pharmacotherapy 1996; 16:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/52\">",
"      Petitti DB, Sidney S, Quesenberry C, Bernstein A. Stroke and cocaine or amphetamine use. Epidemiology 1998; 9:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/53\">",
"      Klonoff DC, Andrews BT, Obana WG. Stroke associated with cocaine use. Arch Neurol 1989; 46:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/54\">",
"      Kaufman MJ, Levin JM, Maas LC, et al. Cocaine decreases relative cerebral blood volume in humans: a dynamic susceptibility contrast magnetic resonance imaging study. Psychopharmacology (Berl) 1998; 138:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/55\">",
"      Johnson B, Lamki L, Fang B, et al. Demonstration of dose-dependent global and regional cocaine-induced reductions in brain blood flow using a novel approach to quantitative single photon emission computerized tomography. Neuropsychopharmacology 1998; 18:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/56\">",
"      Konzen JP, Levine SR, Garcia JH. Vasospasm and thrombus formation as possible mechanisms of stroke related to alkaloidal cocaine. Stroke 1995; 26:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/57\">",
"      Mart&iacute;nez N, D&iacute;ez-Tejedor E, Frank A. Vasospasm/thrombus in cerebral ischemia related to cocaine abuse. Stroke 1996; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/58\">",
"      Robinson JE, Heaton RK, O'Malley SS. Neuropsychological functioning in cocaine abusers with and without alcohol dependence. J Int Neuropsychol Soc 1999; 5:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/59\">",
"      Johnson BA, Devous MD Sr, Ruiz P, Ait-Daoud N. Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. Am J Psychiatry 2001; 158:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/60\">",
"      Brickner ME, Willard JE, Eichhorn EJ, et al. Left ventricular hypertrophy associated with chronic cocaine abuse. Circulation 1991; 84:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/61\">",
"      Kolodgie FD, Wilson PS, Cornhill JF, et al. Increased prevalence of aortic fatty streaks in cholesterol-fed rabbits administered intravenous cocaine: the role of vascular endothelium. Toxicol Pathol 1993; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/62\">",
"      Dressler FA, Malekzadeh S, Roberts WC. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. Am J Cardiol 1990; 65:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/63\">",
"      Clinical policy for the initial approach to adults presenting with a chief complaint of chest pain, with no history of trauma. American College of Emergency Physicians. Ann Emerg Med 1995; 25:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/64\">",
"      Hollander JE, Brooks DE, Valentine SM. Assessment of cocaine use in patients with chest pain syndromes. Arch Intern Med 1998; 158:62.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/66\">",
"      McLaurin M, Apple FS, Henry TD, Sharkey SW. Cardiac troponin I and T concentrations in patients with cocaine-associated chest pain. Ann Clin Biochem 1996; 33 ( Pt 3):183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/67\">",
"      Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J 1998; 135:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/68\">",
"      Hollander JE, Hoffman RS, Burstein JL, et al. Cocaine-associated myocardial infarction. Mortality and complications. Cocaine-Associated Myocardial Infarction Study Group. Arch Intern Med 1995; 155:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/69\">",
"      Hollander JE, Wilson LD, Leo PJ, Shih RD. Complications from the use of thrombolytic agents in patients with cocaine associated chest pain. J Emerg Med 1996; 14:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/70\">",
"      Lemos PA. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis? Catheter Cardiovasc Interv 2007; 69:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/71\">",
"      McKee SA, Applegate RJ, Hoyle JR, et al. Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J 2007; 154:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/39/39545/abstract/72\">",
"      Hollander JE, Hoffman RS, Gennis P, et al. Cocaine-associated chest pain: one-year follow-up. Acad Emerg Med 1995; 2:179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4953 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39545=[""].join("\n");
var outline_f38_39_39545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIOVASCULAR EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIOVASCULAR CONDITIONS ASSOCIATED WITH COCAINE USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9004073\">",
"      Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coronary artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Myocarditis and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arrhythmias and conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Miscellaneous cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVALUATION OF COCAINE-INDUCED CHEST PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Serum markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF COCAINE-RELATED MYOCARDIAL ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9004210\">",
"      Medical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9004402\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9004409\">",
"      - Nitroglycerin and calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9004416\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9004423\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reperfusion and revascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16774265\">",
"      - Early reperfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16774314\">",
"      - Stent placement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CESSATION OF COCAINE USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4953|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/41/36509\" title=\"figure 1\">",
"      Risk of MI with cocaine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/35/28217?source=related_link\">",
"      Coronary heart disease and myocardial infarction in young men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/15/34042?source=related_link\">",
"      Diagnostic approach to chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/13/3285?source=related_link\">",
"      Electrocardiographic diagnosis of left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=related_link\">",
"      Nonaneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_39_39546="12 lead WPW";
var content_f38_39_39546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1272px;\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    ECG in Wolff-Parkinson-White",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39546=[""].join("\n");
var outline_f38_39_39546=null;
var title_f38_39_39547="Normal uterine dimensions on ultrasound examination";
var content_f38_39_39547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal uterine dimensions on ultrasound examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nullipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Multipara",
"       </td>",
"       <td class=\"subtitle1\">",
"        Menopausal &le;5 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Menopausal &gt;5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uterine length (cm)",
"       </td>",
"       <td>",
"        7.3 (0.8)",
"       </td>",
"       <td>",
"        8.3 (0.8)",
"       </td>",
"       <td>",
"        9.2 (0.8)",
"       </td>",
"       <td>",
"        6.7 (0.7)",
"       </td>",
"       <td>",
"        5.6 (0.9)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corpus width (cm)",
"       </td>",
"       <td>",
"        4.0 (0.6)",
"       </td>",
"       <td>",
"        4.6 (0.5)",
"       </td>",
"       <td>",
"        5.1 (0.5)",
"       </td>",
"       <td>",
"        3.6 (0.5)",
"       </td>",
"       <td>",
"        3.1 (0.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corpus height (cm)",
"       </td>",
"       <td>",
"        3.2 (0.5)",
"       </td>",
"       <td>",
"        3.9 (0.5)",
"       </td>",
"       <td>",
"        4.3 (0.6)",
"       </td>",
"       <td>",
"        3.1 (0.4)",
"       </td>",
"       <td>",
"        2.5 (0.4)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The mean and standard deviation () for uterine length, width, and height in premenopausal women (nulliparas, primiparas, multiparas) and menopausal women (less than or equal to five years of menopause, and greater than five years of menopause) without uterine or ovarian pathology. These dimensions represent the outer dimensions of the uterus, not the inner dimensions (ie, dimensions of the endometrial cavity).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Merz E, Miric-Tesanic D, Bahlmann F, Weber G, Wellek S. Sonographic size of uterus and ovaries in pre- and post-menopausal women. Ultrasound Obstet Gynecol 1996; 7:38.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39547=[""].join("\n");
var outline_f38_39_39547=null;
var title_f38_39_39548="Comparison of mobility aids";
var content_f38_39_39548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Attributes for selection of particular mobility aids",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Body weight supported",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unilateral/bilateral support",
"       </td>",
"       <td class=\"subtitle1\">",
"        Balance required",
"       </td>",
"       <td class=\"subtitle1\">",
"        Coordination needed",
"       </td>",
"       <td class=\"subtitle1\">",
"        Arm strength needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cane",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Minimal (10 to 15 percent)",
"       </td>",
"       <td class=\"centered\">",
"        Unilateral",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Two-wheel walker",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Moderate (15 to 30 percent)",
"       </td>",
"       <td class=\"centered\">",
"        Bilateral",
"       </td>",
"       <td class=\"centered\">",
"        Moderate",
"       </td>",
"       <td class=\"centered\">",
"        Moderate",
"       </td>",
"       <td class=\"centered\">",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Four-wheel walker",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Moderate (15 to 30 percent)",
"       </td>",
"       <td class=\"centered\">",
"        Bilateral",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Crutches, swing-through motion",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Full (100 percent)",
"       </td>",
"       <td class=\"centered\">",
"        Unilateral",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Excellent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Crutches, alternating motion",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Partial (30 to 50 percent)&nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;Bilateral",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;Good",
"       </td>",
"       <td class=\"centered\">",
"        Good",
"       </td>",
"       <td class=\"centered\">",
"        Good&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Manual wheelchair",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Full (100 percent)",
"       </td>",
"       <td class=\"centered\">",
"        Bilateral",
"       </td>",
"       <td class=\"centered\">",
"        Minimal",
"       </td>",
"       <td class=\"centered\">",
"        Minimal-moderate*",
"       </td>",
"       <td class=\"centered\">",
"        Minimal-good*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Power wheelchair/scooter",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        Full (100 percent)",
"       </td>",
"       <td class=\"centered\">",
"        Bilateral",
"       </td>",
"       <td class=\"centered\">",
"        Minimal-moderate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        Moderate",
"       </td>",
"       <td class=\"centered\">",
"        Minimal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Amount of coordination and arm strength for manual wheelchair depends on if it is self-propelled or propelled by another person.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Good sitting balance is required for a scooter but may not be required for a power wheelchair.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39548=[""].join("\n");
var outline_f38_39_39548=null;
var title_f38_39_39549="Excitation contraction";
var content_f38_39_39549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Major steps of excitation-contraction coupling in mammalian working myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 173px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An inward calcium (Ca2+) current occurs during the action potential and this influx triggers a much greater release of Ca2+ from the sarcoplasmic reticulum. Cytosolic Ca2+ levels rise rapidly and Ca2+ binds to its myofilament receptor on troponin C, activating contractile protein tension generation which results from actin myosin cross bridging. Myocyte relaxation occurs when Ca2+ dissociated from troponin C and the actin-myosin bonds are broken. Ca2+ is taken up by the sarcoplasmic reticulum and is removed via a sodium (Na+)-Ca2+ exchange.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39549=[""].join("\n");
var outline_f38_39_39549=null;
var title_f38_39_39550="HIV with pulmonary symptoms";
var content_f38_39_39550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to HIV-positive patients with pulmonary symptoms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 431px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See text for comment on expectorated versus induced sputum.",
"     <br>",
"      &bull; For example, if bacterial pneumonia, TB, or PCP are suspected based on clinical presentation.",
"      <br>",
"       &Delta; Can include chest computed tomography, exercise oximetry, DLCO, or gallium scan. If patient is critically ill, procede with bronchoscopy and/or other invasive procedure.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39550=[""].join("\n");
var outline_f38_39_39550=null;
var title_f38_39_39551="Glabellar line botulinum toxin injection sites";
var content_f38_39_39551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin injection sites for glabellar lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five central injections represent the primary sites for botulinum toxin injection for glabellar lines (red). Some patients may benefit from two additional injections into the lateral orbicularis oculi muscle (white).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_39_39551=[""].join("\n");
var outline_f38_39_39551=null;
